[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fnq0L20NcHeHYud9EGotL3tPNpl8vZ_LTbMrNisQF2iM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":35,"phaseBuckets":36,"rows":43},"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",[4],465,false,0,193,818634,11,[13,16,19,22,25,28,30,32],{"name":14,"count":15},"Schizophrenia",73,{"name":17,"count":18},"Healthy",55,{"name":20,"count":21},"Anemia",54,{"name":23,"count":24},"Epilepsy",19,{"name":26,"count":27},"Bipolar Disorder",17,{"name":29,"count":27},"Diabetes Mellitus, Type 2",{"name":31,"count":27},"Seizures",{"name":33,"count":34},"Obesity",16,[],[37,38,39,40,41,42],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[44,534,924,1106,1279,1327,1373,1406,1428,1455,1473,1496,1520,1542,1565,1583,1601,1624,1642,1665,1683,1707,1877,1974,2075,2130,2200,2276,2336,2393,2441,2472,2517,2550,2577,2599,2634,2663,2685,2714,2742,2769,2791,2809,2832,2858,2880,2904,2927,2945,2970,2988,3009,3032,3050,3072,3090,3115,3137,3160,3182,3205,3228,3251,3273,3295,3313,3337,3362,3384,3406,3429,3447,3470,3492,3510,3534,3555,3580,3598,3622,3640,3663,3684,3702,3723,3745,3768,3786,3807,3829,3851,3869,3894,3912,3935,3953,3977,3995,4013,4031,4049,4072,4090,4108,4129,4154,4176,4307,4357,4410,4447,4483,4512,4537,4565,4597,4629,4651,4673,4691,4714,4737,4761,4779,4804,4822,4840,4858,4879,4900,4927,4945,4963,4981,4999,5022,5040,5058,5076,5101,5119,5137,5155,5173,5195,5220,5238,5256,5274,5296,5318,5340,5358,5376,5399,5417,5435,5458,5476,5500,5518,5536,5558,5580,5605,5623,5641,5662,5709,5747,5784,5815,5837,5859,5888,5918,5940,5962,5989,6016,6046,6074,6096,6128,6150,6172,6198,6225,6249,6270,6292,6313,6335,6359,6377,6402,6420,6438,6456,6474,6497,6515,6533,6554,6572,6593,6615,6637,6655,6676,6698,6716,6737,6755,6773,6791,6812,6835,6853,6871,6892,6915,6933,6951,6974,6992,7013,7034,7057,7075,7096,7117,7139,7161,7179,7200,7224,7242,7260,7278,7299,7320,7341,7362,7383,7403,7424,7442,7460,7478,7496,7517,7538,7559,7581,7602,7620,7643,7665,7683,7707,7725,7743,7764,7785,7806,7828,7846,7868,7886,7907,7934,7956,7977,7998,8020,8041,8062,8080,8102,8120,8142,8160,8182,8200,8221,8239,8260,8282,8300,8321,8339,8357,8381,8399,8417,8435,8456,8477,8501,8519,8551,8588,8624,8646,8667,8691,8709,8727,8750,8773,8791,8814],{"intervention":45,"totalTrials":46,"cells":47},"epoetin alfa",52,{"EARLY_PHASE1":48,"PHASE1":50,"PHASE2":63,"PHASE3":306,"PHASE4":510,"NA":532},{"trials":49,"activeCount":8},[],{"trials":51,"activeCount":8},[52],{"nctId":53,"briefTitle":54,"status":55,"phases":56,"completion":57,"start":58,"enrollment":59,"conditions":60,"interventions":62},"NCT00641589","A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease","COMPLETED",[38],"2006-11","2006-01",40,[61,20],"Chronic Kidney Disease",[45],{"trials":64,"activeCount":8},[65,76,85,94,102,110,120,130,140,149,159,167,177,189,199,207,215,221,229,238,247,256,263,272,279,290,299],{"nctId":66,"briefTitle":67,"status":68,"phases":69,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":75},"NCT00246298","A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients","TERMINATED",[39],"2006-09","2005-10",31,[20,74],"HIV",[45],{"nctId":77,"briefTitle":78,"status":68,"phases":79,"completion":80,"start":81,"enrollment":11,"conditions":82,"interventions":83},"NCT00240734","Treatment of Anemia in Diabetic Subjects With CKD",[39],"2005-09","2005-03",[20],[84],"Epoetin alfa",{"nctId":86,"briefTitle":87,"status":68,"phases":88,"completion":58,"start":89,"enrollment":90,"conditions":91,"interventions":93},"NCT00236678","Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT",[39],"2004-07",29,[20,92],"Rheumatoid Arthritis",[84],{"nctId":95,"briefTitle":96,"status":68,"phases":97,"completion":71,"start":81,"enrollment":98,"conditions":99,"interventions":101},"NCT00236405","PROCRIT and Short-Term Outcomes in Orthopedic Surgery",[39],6,[20,100],"Surgery, Arthroscopy",[45],{"nctId":103,"briefTitle":104,"status":55,"phases":105,"completion":106,"start":80,"enrollment":107,"conditions":108,"interventions":109},"NCT00212875","A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.",[39],"2007-02",267,[61,20],[45],{"nctId":111,"briefTitle":112,"status":55,"phases":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":119},"NCT00338416","An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks",[39],"2005-01","2003-03",115,[118,20],"Cancer",[84],{"nctId":121,"briefTitle":122,"status":68,"phases":123,"completion":71,"start":124,"enrollment":125,"conditions":126,"interventions":129},"NCT00210795","A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia",[39],"2004-06",12,[20,127,128],"Aged","Hemoglobins",[45],{"nctId":131,"briefTitle":132,"status":55,"phases":133,"completion":81,"start":134,"enrollment":135,"conditions":136,"interventions":138},"NCT00388336","PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy",[39],"2004-02",57,[20,137],"Neoplasms",[139],"Epoetin Alfa",{"nctId":141,"briefTitle":142,"status":55,"phases":143,"completion":144,"enrollment":145,"conditions":146,"interventions":148},"NCT00270010","A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease",[39],"1989-08",72,[20,147],"Acquired Immunodeficiency Syndrome",[45],{"nctId":150,"briefTitle":151,"status":55,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":158},"NCT00337935","A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.",[39],"2009-07","2006-07",157,[157,20],"Renal Failure , Chronic",[139],{"nctId":160,"briefTitle":161,"status":55,"phases":162,"completion":163,"enrollment":164,"conditions":165,"interventions":166},"NCT00266617","A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy",[39],"1990-06",86,[20,137],[45],{"nctId":168,"briefTitle":169,"status":68,"phases":170,"primaryCompletion":171,"completion":172,"start":57,"enrollment":173,"conditions":174,"interventions":175},"NCT00386152","A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy",[39],"2008-03","2008-05",235,[137,20,118],[45,176],"darbepoetin alfa",{"nctId":178,"briefTitle":179,"status":55,"phases":180,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":188},"NCT00270049","Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia",[39],"1994-01","1990-11",195,[20,185,186,118,137,187],"Leukemia, Lymphocytic, Chronic","Leukemia, Lymphocytic","Quality of Life",[45],{"nctId":190,"briefTitle":191,"status":55,"phases":192,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":198},"NCT00338299","Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia",[39],"2004-04","2003-08",51,[20,197],"Chemotherapy",[84],{"nctId":200,"briefTitle":201,"status":55,"phases":202,"completion":80,"start":203,"enrollment":204,"conditions":205,"interventions":206},"NCT00210834","An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.",[39],"2004-05",310,[20],[45],{"nctId":208,"briefTitle":209,"status":55,"phases":210,"completion":71,"start":203,"enrollment":211,"conditions":212,"interventions":214},"NCT00210743","Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.",[39],67,[20,213],"Kidney Diseases",[45],{"nctId":216,"briefTitle":122,"status":68,"phases":217,"completion":80,"start":124,"enrollment":218,"conditions":219,"interventions":220},"NCT00228995",[39],9,[20,127,128],[45],{"nctId":222,"briefTitle":223,"status":55,"phases":224,"completion":225,"enrollment":226,"conditions":227,"interventions":228},"NCT00270270","A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused by the Disease and by Zidovudine (AZT) Therapy",[39],"1989-07",63,[147,20],[45],{"nctId":230,"briefTitle":231,"status":68,"phases":232,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":237},"NCT00306267","A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy",[39],"2007-05","2006-03",61,[20,118,139],[45],{"nctId":239,"briefTitle":240,"status":55,"phases":241,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":246},"NCT00337948","An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks",[39],"2005-02","2003-02",129,[197,20,118],[84],{"nctId":248,"briefTitle":249,"status":250,"phases":251,"completion":252,"enrollment":8,"conditions":253,"interventions":255},"NCT00446602","A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)","WITHDRAWN",[39],"2009-08",[254,20],"Myelodysplastic Syndromes",[84],{"nctId":257,"briefTitle":258,"status":55,"phases":259,"completion":260,"enrollment":145,"conditions":261,"interventions":262},"NCT00269997","A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug",[39],"1990-07",[20,137],[45],{"nctId":264,"briefTitle":265,"status":55,"phases":266,"completion":267,"start":134,"enrollment":268,"conditions":269,"interventions":271},"NCT00210756","Pharmacokinetic\u002F Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.",[39],"2006-02",60,[20,270],"Critical Illness",[45],{"nctId":273,"briefTitle":274,"status":55,"phases":275,"completion":163,"enrollment":276,"conditions":277,"interventions":278},"NCT00269984","A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer",[39],56,[20],[84],{"nctId":280,"briefTitle":281,"status":55,"phases":282,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":289},"NCT00270036","A Study to Determine the Safety of Epoetin Alfa and Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients After Major Orthopedic Surgery.",[39],"1991-10","1991-04",1,[287,288,20],"Blood Transfusion","Orthopedic Procedures",[45],{"nctId":291,"briefTitle":292,"status":55,"phases":293,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":298},"NCT00270283","A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in Patients With Acquired Immunodeficiency Syndrome (AIDS) Who Are Receiving Zidovudine (AZT) Therapy",[39],"1990-04","1988-07",102,[147,20],[45],{"nctId":300,"briefTitle":301,"status":55,"phases":302,"completion":303,"enrollment":268,"conditions":304,"interventions":305},"NCT00269945","A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease",[39],"1989-01",[20,147],[45],{"trials":307,"activeCount":8},[308,318,328,337,344,354,363,369,381,388,396,406,416,425,432,442,451,460,467,477,485,500],{"nctId":309,"briefTitle":310,"status":55,"phases":311,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":317},"NCT00440466","PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients",[40],"2009-03","2007-07",430,[20,316],"Renal Diseases",[45,45,45],{"nctId":319,"briefTitle":320,"status":55,"phases":321,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":327},"NCT00270101","The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma",[40],"1996-09","1995-01",156,[20,326],"Multiple Myeloma",[45],{"nctId":329,"briefTitle":330,"status":68,"phases":331,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":336},"NCT00695396","A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion",[40],"2010-01","2008-06",25,[254,20],[84,84],{"nctId":338,"briefTitle":339,"status":68,"phases":340,"completion":341,"start":134,"conditions":342,"interventions":343},"NCT00083486","Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy",[40],"2004-10",[20],[45],{"nctId":345,"briefTitle":346,"status":55,"phases":347,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":353},"NCT00261521","A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients",[40],"2003-05","2000-02",596,[352,20],"Kidney Failure, Chronic",[45],{"nctId":355,"briefTitle":356,"status":55,"phases":357,"completion":358,"start":359,"enrollment":27,"conditions":360,"interventions":362},"NCT00270140","A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Facilitating the Presurgical Collection of Blood to be Used for Self-donation During Surgery on the Spine, Hip, or Knee.",[40],"1991-08","1989-09",[20,361,288],"Blood Transfusions, Autologous",[45],{"nctId":364,"briefTitle":365,"status":68,"phases":366,"completion":341,"start":134,"conditions":367,"interventions":368},"NCT00083434","Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy",[40],[20,118],[84],{"nctId":370,"briefTitle":371,"status":55,"phases":372,"completion":373,"enrollment":374,"conditions":375,"interventions":380},"NCT00270023","A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.",[39,40],"1991-11",112,[287,376,288,377,378,379],"Blood Transfusion, Autologous","Orthopedic Surgery","Cardiovascular Surgical Procedures","Mammaplasty",[45],{"nctId":382,"briefTitle":383,"status":55,"phases":384,"completion":385,"start":242,"enrollment":195,"conditions":386,"interventions":387},"NCT00210587","An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation",[40],"2005-12",[20,137],[45],{"nctId":389,"briefTitle":390,"status":55,"phases":391,"completion":203,"start":392,"enrollment":393,"conditions":394,"interventions":395},"NCT00341055","A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.",[40],"2003-06",69,[20,118,197],[84],{"nctId":397,"briefTitle":398,"status":55,"phases":399,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":405},"NCT00211146","A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)",[40],"2006-05","1998-04",680,[20,404],"Venous Thrombosis",[45],{"nctId":407,"briefTitle":408,"status":55,"phases":409,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":415},"NCT00211133","A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy",[40],"2006-12","2000-06",939,[20,414,187],"Breast Neoplasms",[45],{"nctId":417,"briefTitle":418,"status":55,"phases":419,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":424},"NCT00270088","A Study to Determine Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients During the Period of Time Around Major Orthopedic Surgery.",[40],"1994-08","1993-04",316,[20,287,288],[45],{"nctId":426,"briefTitle":427,"status":55,"phases":428,"completion":429,"enrollment":27,"conditions":430,"interventions":431},"NCT00270179","A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.",[40],"1988-05",[20],[45],{"nctId":433,"briefTitle":434,"status":55,"phases":435,"completion":436,"start":437,"enrollment":438,"conditions":439,"interventions":441},"NCT00270127","Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy",[40],"1998-09","1996-08",375,[20,118,440],"Neoplasm",[84],{"nctId":443,"briefTitle":444,"status":55,"phases":445,"completion":446,"start":447,"enrollment":448,"conditions":449,"interventions":450},"NCT00270062","A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.",[40],"1991-07","1989-05",77,[20],[45],{"nctId":452,"briefTitle":453,"status":55,"phases":454,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":459},"NCT00091910","Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)",[40],"2006-06","2003-09",1460,[20],[84],{"nctId":461,"briefTitle":462,"status":55,"phases":463,"completion":464,"enrollment":18,"conditions":465,"interventions":466},"NCT00270114","A Study of the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Undergoing Orthopedic Surgery and Who Have Low Hematocrit Levels (the Percent of Red Blood Cells in Whole Blood)",[39,40],"1991-03",[20,287,288],[45],{"nctId":468,"briefTitle":469,"status":55,"phases":470,"completion":471,"start":472,"enrollment":268,"conditions":473,"interventions":476},"NCT00036400","Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery",[40],"2003-12","2001-12",[474,475],"Stomach Neoplasms","Rectal Neoplasms",[45],{"nctId":478,"briefTitle":479,"status":68,"phases":480,"completion":481,"start":124,"enrollment":482,"conditions":483,"interventions":484},"NCT00210730","The Duration Study",[40],"2005-07",2,[20],[45],{"nctId":486,"briefTitle":487,"status":55,"phases":488,"completion":489,"start":490,"enrollment":491,"conditions":492,"interventions":499},"NCT00270166","The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy",[40],"1998-05","1995-02",201,[20,326,493,494,495,496,497,498,440],"Lymphoma","Breast Cancer","Ovarian Cancer","Carcinoma, Small Cell Lung","Esophagus Cancer","Prostate Cancer",[45],{"nctId":501,"briefTitle":502,"status":55,"phases":503,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":509},"NCT00270075","A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery",[39,40],"1992-05","1990-01",80,[287,376,288,377,508],"Cardiovascular Surgical Procedure",[45],{"trials":511,"activeCount":8},[512,523],{"nctId":513,"briefTitle":514,"status":68,"phases":515,"primaryCompletion":516,"completion":516,"start":517,"enrollment":518,"conditions":519,"interventions":521},"NCT00350519","The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and\u002For Pelvic Surgery",[41],"2008-02","2006-08",37,[520],"Hemostasis, Surgical",[84,522],"Standard of Care",{"nctId":524,"briefTitle":525,"status":68,"phases":526,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":531},"NCT00211120","Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)",[41],"2005-08","2002-03",1432,[20],[139],{"trials":533,"activeCount":8},[],{"intervention":535,"totalTrials":536,"cells":537},"topiramate",45,{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":569,"PHASE3":672,"PHASE4":912,"NA":922},{"trials":539,"activeCount":8},[],{"trials":541,"activeCount":8},[542,551,560],{"nctId":543,"briefTitle":544,"status":55,"phases":545,"completion":546,"start":547,"enrollment":276,"conditions":548,"interventions":549},"NCT00986336","A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders",[38],"2002-11","2001-02",[26],[535,535,550,535],"risperidone",{"nctId":552,"briefTitle":553,"status":55,"phases":554,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":559},"NCT00986128","A Pharmacokinetic Study of Lithium Before and During Topiramate Dosing in Bipolar Disorder Patients",[38],"2002-10","2001-03",32,[26],[535,535],{"nctId":561,"briefTitle":562,"status":55,"phases":563,"completion":564,"start":565,"enrollment":34,"conditions":566,"interventions":567},"NCT00233012","A Study of the Pharmacokinetics, Safety and Tolerability of Topiramate in Infants (Age 1-24 Months) With Refractory Partial-onset Seizures",[38],"2007-10","2005-06",[31],[568],"Topiramate",{"trials":570,"activeCount":8},[571,579,587,596,605,613,621,629,637,645,654,663],{"nctId":572,"briefTitle":573,"status":55,"phases":574,"completion":341,"start":134,"enrollment":575,"conditions":576,"interventions":578},"NCT00231647","A Study on Efficacy and Safety of Topiramate OROS Controlled-Release in Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin",[39],113,[33,29,577],"Diabetes Mellitus, Adult-Onset",[535],{"nctId":580,"briefTitle":581,"status":55,"phases":582,"completion":583,"start":447,"enrollment":276,"conditions":584,"interventions":586},"NCT00236860","A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures",[39],"1992-02",[23,585,31],"Epilepsies, Partial",[535],{"nctId":588,"briefTitle":589,"status":55,"phases":590,"completion":517,"start":591,"enrollment":592,"conditions":593,"interventions":595},"NCT00210925","An Efficacy and Safety Study of Topiramate in the Treatment of Alcohol Dependence",[39],"2004-03",371,[594],"Alcoholism",[535],{"nctId":597,"briefTitle":598,"status":55,"phases":599,"completion":600,"start":601,"enrollment":602,"conditions":603,"interventions":604},"NCT00236613","A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity",[39],"2001-07","2000-09",385,[33],[535],{"nctId":606,"briefTitle":607,"status":55,"phases":608,"completion":609,"start":81,"enrollment":125,"conditions":610,"interventions":612},"NCT00210574","A Pilot Study of Topiramate in Childhood Absence Epilepsy",[39],"2006-10",[611],"Epilepsy, Absence",[535],{"nctId":614,"briefTitle":615,"status":55,"phases":616,"completion":617,"start":295,"enrollment":618,"conditions":619,"interventions":620},"NCT00236691","A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.",[39],"1990-12",188,[23,585,31],[535],{"nctId":622,"briefTitle":623,"status":55,"phases":624,"completion":617,"start":625,"enrollment":626,"conditions":627,"interventions":628},"NCT00236730","A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Difficult to Control Epilepsy",[39],"1988-06",178,[23,585,31],[535],{"nctId":630,"briefTitle":631,"status":55,"phases":632,"completion":633,"start":634,"enrollment":268,"conditions":635,"interventions":636},"NCT00236847","A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Epilepsy.",[39],"1993-07","1989-12",[23,585,31],[535],{"nctId":638,"briefTitle":615,"status":55,"phases":639,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":644},"NCT00236873",[39],"1993-05","1989-10",47,[23,585,31],[535],{"nctId":646,"briefTitle":647,"status":55,"phases":648,"completion":649,"start":600,"enrollment":145,"conditions":650,"interventions":653},"NCT00231673","A Study To Evaluate The Effect Of Topiramate On Clinical And Electrophysiological Parameters In Subjects With Diabetic Peripheral Polyneuropathy",[39],"2003-01",[651,29,652],"Diabetic Neuropathies","Polyneuropathies",[568],{"nctId":655,"briefTitle":656,"status":55,"phases":657,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":662},"NCT00231608","A Study of Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity",[39],"2002-01","1998-12",68,[33],[535],{"nctId":664,"briefTitle":665,"status":55,"phases":666,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":671},"NCT00236626","A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 Diabetes",[39],"2002-05","2000-04",38,[33,29,577],[535],{"trials":673,"activeCount":8},[674,682,690,698,707,714,723,735,743,754,763,773,780,789,796,805,813,821,828,836,844,850,858,867,873,880,889,897,905],{"nctId":675,"briefTitle":676,"status":55,"phases":677,"completion":667,"start":678,"enrollment":679,"conditions":680,"interventions":681},"NCT00231530","A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet",[40],"2001-01",541,[33,29,577],[535],{"nctId":683,"briefTitle":684,"status":55,"phases":685,"completion":547,"start":686,"enrollment":687,"conditions":688,"interventions":689},"NCT00236756","A Study of the Efficacy and Safety of Topiramate as an add-on Therapy in the Treatment of Epilepsy Patients With Lennox-Gastaut Syndrome",[40],"1993-08",100,[23,31],[535],{"nctId":691,"briefTitle":692,"status":55,"phases":693,"completion":81,"start":456,"enrollment":694,"conditions":695,"interventions":697},"NCT00210808","A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity",[39,40],407,[33,696],"Binge-Eating Disorder",[535],{"nctId":699,"briefTitle":700,"status":55,"phases":701,"completion":702,"start":703,"enrollment":704,"conditions":705,"interventions":706},"NCT00230698","A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure",[40],"2002-08","1995-11",451,[23,585,31],[535],{"nctId":708,"briefTitle":709,"status":68,"phases":710,"completion":546,"start":711,"enrollment":72,"conditions":712,"interventions":713},"NCT00231634","A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy",[40],"2001-05",[33,29,577],[535],{"nctId":715,"briefTitle":716,"status":55,"phases":717,"completion":134,"start":718,"enrollment":719,"conditions":720,"interventions":722},"NCT00236496","A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.",[40],"2001-10",223,[721],"Essential Tremor",[535],{"nctId":724,"briefTitle":725,"status":55,"phases":726,"completion":727,"start":728,"enrollment":729,"conditions":730,"interventions":734},"NCT00240721","A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder",[40],"2002-09","2000-10",363,[731,732,733],"Bipolar Disorders","Mood Disorders","Affective Disorders, Psychotic",[535],{"nctId":736,"briefTitle":737,"status":55,"phases":738,"completion":739,"start":740,"enrollment":506,"conditions":741,"interventions":742},"NCT00236418","A Study of the Efficacy and Safety of Topiramate in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures",[40],"1996-12","1994-12",[23,31],[535],{"nctId":744,"briefTitle":745,"status":55,"phases":746,"primaryCompletion":747,"completion":748,"start":749,"enrollment":750,"conditions":751,"interventions":753},"NCT00113815","Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures",[40],"2007-06","2007-11","2005-05",118,[752,23,31],"Partial Seizure Disorder",[535,535,535],{"nctId":755,"briefTitle":756,"status":55,"phases":757,"completion":758,"start":556,"enrollment":759,"conditions":760,"interventions":762},"NCT00236665","A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension",[40],"2002-06",531,[33,761],"Hypertension",[535],{"nctId":764,"briefTitle":765,"status":55,"phases":766,"completion":767,"start":134,"enrollment":768,"conditions":769,"interventions":772},"NCT00210821","Comparing the Safety and Effectiveness of Topiramate With the Safety and Effectiveness of Amitriptyline in Preventing Migraine Headaches",[40],"2005-11",347,[770,771],"Migraine","Headache",[535],{"nctId":774,"briefTitle":775,"status":55,"phases":776,"completion":546,"start":600,"enrollment":777,"conditions":778,"interventions":779},"NCT00035230","A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder",[40],338,[26],[568],{"nctId":781,"briefTitle":782,"status":55,"phases":783,"completion":784,"start":658,"enrollment":785,"conditions":786,"interventions":788},"NCT00035802","A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder",[40],"2002-04",13,[26,733,732,787],"Mental Disorders",[568],{"nctId":790,"briefTitle":791,"status":55,"phases":792,"completion":758,"start":728,"enrollment":793,"conditions":794,"interventions":795},"NCT00231660","A Study of the Efficacy and Safety of Topiramate in the Treatment fo Obese, Type 2 Diabetic Patients Treated With Metformin",[40],211,[33,29,577],[535],{"nctId":797,"briefTitle":798,"status":55,"phases":799,"completion":546,"start":556,"enrollment":800,"conditions":801,"interventions":804},"NCT00231595","A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine",[40],768,[770,802,803,771],"Common Migraine","Classic Migraine",[535],{"nctId":806,"briefTitle":807,"status":55,"phases":808,"completion":411,"start":489,"enrollment":809,"conditions":810,"interventions":812},"NCT00236886","Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients",[40],49,[23,585,811,31],"Epilepsy, Generalized",[535],{"nctId":814,"briefTitle":815,"status":55,"phases":816,"completion":728,"start":817,"enrollment":818,"conditions":819,"interventions":820},"NCT00236743","A Study of the Effectiveness and Safety of Topiramate in the Treatment of Children With Epilepsy",[40],"1994-06",90,[23,585,31],[535],{"nctId":822,"briefTitle":823,"status":55,"phases":824,"completion":472,"start":728,"enrollment":793,"conditions":825,"interventions":827},"NCT00253175","A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine",[40],[826,770],"Vascular Headaches",[535],{"nctId":829,"briefTitle":830,"status":55,"phases":831,"completion":758,"start":832,"enrollment":833,"conditions":834,"interventions":835},"NCT00236600","A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program",[40],"2000-08",561,[33],[535],{"nctId":837,"briefTitle":838,"status":55,"phases":839,"completion":840,"start":841,"enrollment":195,"conditions":842,"interventions":843},"NCT00266591","A Study of the Efficacy and Safety of Topiramate Treatment in Patients With Epilepsy",[40],"1997-04","1992-10",[23,31],[535],{"nctId":845,"briefTitle":775,"status":55,"phases":846,"completion":348,"start":678,"enrollment":847,"conditions":848,"interventions":849},"NCT00037674",[40],434,[26],[568],{"nctId":851,"briefTitle":852,"status":55,"phases":853,"completion":854,"start":456,"enrollment":855,"conditions":856,"interventions":857},"NCT00210912","A Study of the Effectiveness and Safety of Topiramate Versus Placebo for Preventing Chronic Migraine Headaches",[40],"2005-04",328,[770],[535],{"nctId":859,"briefTitle":860,"status":55,"phases":861,"completion":456,"start":862,"enrollment":863,"conditions":864,"interventions":866},"NCT00231556","A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy",[40],"1999-07",750,[23,31,585,811,865],"Epilepsy, Tonic-Clonic",[535],{"nctId":868,"briefTitle":798,"status":55,"phases":869,"completion":727,"start":547,"enrollment":870,"conditions":871,"interventions":872},"NCT00236509",[40],763,[770,802,803,771],[535],{"nctId":874,"briefTitle":598,"status":55,"phases":875,"completion":758,"start":876,"enrollment":877,"conditions":878,"interventions":879},"NCT00236639",[40],"2000-07",1293,[33],[535],{"nctId":881,"briefTitle":882,"status":68,"phases":883,"completion":758,"start":711,"enrollment":884,"conditions":885,"interventions":888},"NCT00231621","A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia",[40],179,[33,886,887],"Hyperlipidemia","Hypertriglyceridemia",[535],{"nctId":890,"briefTitle":891,"status":55,"phases":892,"completion":234,"start":893,"enrollment":894,"conditions":895,"interventions":896},"NCT00210860","An Open Label Extension of a Study Comparing Topiramate and Amitriptyline in Migraine Prevention.",[40],"2004-09",142,[770],[535],{"nctId":898,"briefTitle":899,"status":55,"phases":900,"completion":901,"start":902,"enrollment":506,"conditions":903,"interventions":904},"NCT00236704","A Study of the Efficacy and Safety of Topiramate as \"Add on\" Treatment in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures",[40],"1999-12","1994-03",[23,31],[535],{"nctId":906,"briefTitle":907,"status":55,"phases":908,"completion":527,"start":134,"enrollment":909,"conditions":910,"interventions":911},"NCT00210873","An Open Label Extension of a Study of Topiramate in Chronic Migraine.",[40],200,[770],[535],{"trials":913,"activeCount":8},[914],{"nctId":915,"briefTitle":916,"status":55,"phases":917,"completion":747,"start":385,"enrollment":918,"conditions":919,"interventions":921},"NCT00266604","A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy",[41],409,[23,31,585,811,920],"Seizures, Tonic-Clonic",[568],{"trials":923,"activeCount":8},[],{"intervention":925,"totalTrials":926,"cells":927},"Paliperidone ER",22,{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":992,"PHASE3":1002,"PHASE4":1087,"NA":1104},{"trials":929,"activeCount":8},[],{"trials":931,"activeCount":8},[932,940,946,953,960,967,975,981],{"nctId":933,"briefTitle":934,"status":55,"phases":935,"completion":455,"start":58,"enrollment":936,"conditions":937,"interventions":939},"NCT00791622","A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine",[38],110,[14,938],"Schizoaffective Disorder",[925],{"nctId":941,"briefTitle":942,"status":55,"phases":943,"completion":154,"start":234,"enrollment":268,"conditions":944,"interventions":945},"NCT00791713","A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER",[38],[14],[925],{"nctId":947,"briefTitle":948,"status":55,"phases":949,"completion":194,"start":392,"enrollment":950,"conditions":951,"interventions":952},"NCT00796471","A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations",[38],35,[14],[925],{"nctId":954,"briefTitle":955,"status":55,"phases":956,"completion":233,"start":957,"enrollment":145,"conditions":958,"interventions":959},"NCT00790777","A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville",[38],"2007-03",[14],[925],{"nctId":961,"briefTitle":962,"status":55,"phases":963,"completion":517,"start":455,"enrollment":964,"conditions":965,"interventions":966},"NCT00791167","A Study of the Dose Proportionality of Extended Release Paliperidone",[38],58,[14],[925],{"nctId":968,"briefTitle":969,"status":55,"phases":970,"completion":971,"start":194,"enrollment":972,"conditions":973,"interventions":974},"NCT00796185","As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations",[38],"2004-01",62,[14,938],[925],{"nctId":976,"briefTitle":977,"status":55,"phases":978,"completion":233,"start":957,"enrollment":506,"conditions":979,"interventions":980},"NCT00791193","A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR",[38],[14],[925],{"nctId":982,"briefTitle":983,"status":55,"phases":984,"completion":985,"start":986,"enrollment":987,"conditions":988,"interventions":989},"NCT01060228","A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men",[38],"2009-02","2009-01",24,[14,23],[990,991],"paliperidone ER","divalproex sodium ER",{"trials":993,"activeCount":8},[994],{"nctId":995,"briefTitle":996,"status":55,"phases":997,"completion":527,"start":242,"enrollment":998,"conditions":999,"interventions":1001},"NCT00105326","Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia Patients",[39],5,[14,1000],"Insomnia",[990],{"trials":1003,"activeCount":8},[1004,1012,1022,1029,1037,1047,1054,1060,1068,1075,1081],{"nctId":1005,"briefTitle":1006,"status":55,"phases":1007,"primaryCompletion":1008,"completion":1008,"start":400,"enrollment":800,"conditions":1009,"interventions":1010},"NCT00490971","A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder",[40],"2010-04",[26],[1011,925],"Olanzapine",{"nctId":1013,"briefTitle":1014,"status":55,"phases":1015,"primaryCompletion":1016,"completion":748,"start":1017,"enrollment":1018,"conditions":1019,"interventions":1020},"NCT00309699","A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder",[40],"2007-09","2006-04",493,[26,732],[1021,925],"Quetiapine",{"nctId":1023,"briefTitle":1024,"status":55,"phases":1025,"completion":749,"start":193,"enrollment":1026,"conditions":1027,"interventions":1028},"NCT00083668","Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia",[40],619,[14],[925],{"nctId":1030,"briefTitle":1031,"status":55,"phases":1032,"primaryCompletion":333,"completion":333,"start":410,"enrollment":1033,"conditions":1034,"interventions":1036},"NCT00412373","Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.",[40],307,[938,1035],"Psychotic Disorder",[925,925],{"nctId":1038,"briefTitle":1039,"status":55,"phases":1040,"completion":1041,"start":1017,"enrollment":1042,"conditions":1043,"interventions":1046},"NCT00309686","A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder",[40],"2007-08",300,[1044,26,1045],"Affective Psychosis, Bipolar","Mania",[925],{"nctId":1048,"briefTitle":1049,"status":55,"phases":1050,"completion":114,"start":591,"enrollment":1051,"conditions":1052,"interventions":1053},"NCT00078039","Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia",[40],630,[14],[925],{"nctId":1055,"briefTitle":1056,"status":55,"phases":1057,"primaryCompletion":516,"completion":516,"start":57,"enrollment":422,"conditions":1058,"interventions":1059},"NCT00397033","Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.",[40],[938,1035],[925,925],{"nctId":1061,"briefTitle":1062,"status":55,"phases":1063,"completion":749,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1067},"NCT00085748","Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia",[40],"2004-08",114,[14],[990],{"nctId":1069,"briefTitle":1070,"status":55,"phases":1071,"completion":527,"start":591,"enrollment":1072,"conditions":1073,"interventions":1074},"NCT00086320","A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.",[40],111,[14],[925],{"nctId":1076,"briefTitle":1077,"status":55,"phases":1078,"primaryCompletion":312,"completion":312,"start":1041,"enrollment":491,"conditions":1079,"interventions":1080},"NCT00518323","A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients",[40],[14],[925,925,925],{"nctId":1082,"briefTitle":1083,"status":55,"phases":1084,"completion":114,"start":971,"enrollment":125,"conditions":1085,"interventions":1086},"NCT00077714","Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia",[40],[14],[925],{"trials":1088,"activeCount":8},[1089,1097],{"nctId":1090,"briefTitle":1091,"status":55,"phases":1092,"primaryCompletion":1093,"completion":1093,"start":564,"enrollment":491,"conditions":1094,"interventions":1095},"NCT00535132","Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone",[41],"2008-07",[14],[1096,925],"Oral Risperidone",{"nctId":1098,"briefTitle":1099,"status":55,"phases":1100,"primaryCompletion":1101,"completion":1101,"start":1016,"enrollment":491,"conditions":1102,"interventions":1103},"NCT00524043","An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia",[41],"2008-11",[14],[925,925],{"trials":1105,"activeCount":8},[],{"intervention":550,"totalTrials":1107,"cells":1108},20,{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1125,"PHASE3":1127,"PHASE4":1263,"NA":1277},{"trials":1110,"activeCount":8},[],{"trials":1112,"activeCount":8},[1113,1117],{"nctId":543,"briefTitle":544,"status":55,"phases":1114,"completion":546,"start":547,"enrollment":276,"conditions":1115,"interventions":1116},[38],[26],[535,535,550,535],{"nctId":1118,"briefTitle":1119,"status":55,"phases":1120,"completion":1121,"start":392,"enrollment":59,"conditions":1122,"interventions":1124},"NCT00645502","Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.",[38],"2003-07",[14,1123],"Schizoaffective Disorders",[550],{"trials":1126,"activeCount":8},[],{"trials":1128,"activeCount":8},[1129,1139,1146,1154,1161,1169,1179,1187,1194,1200,1208,1218,1225,1234,1241,1249,1255],{"nctId":1130,"briefTitle":1131,"status":55,"phases":1132,"completion":1133,"start":1134,"enrollment":1135,"conditions":1136,"interventions":1138},"NCT00236457","A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder",[40],"2002-12","2000-11",629,[14,1137],"Psychotic Disorders",[550],{"nctId":1140,"briefTitle":1141,"status":55,"phases":1142,"completion":134,"start":1143,"enrollment":687,"conditions":1144,"interventions":1145},"NCT00236587","A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia",[40],"2001-11",[14],[550],{"nctId":1147,"briefTitle":1148,"status":55,"phases":1149,"completion":385,"start":1064,"enrollment":1150,"conditions":1151,"interventions":1152},"NCT00088075","Investigate Risperidone for the Treatment of Schizophrenia in Adolescents",[40],160,[14],[1153],"Risperidone",{"nctId":1155,"briefTitle":1156,"status":55,"phases":1157,"completion":456,"start":472,"enrollment":438,"conditions":1158,"interventions":1160},"NCT00236444","A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders",[40],[1159],"Attention Deficit and Disruptive Behavior Disorders",[550],{"nctId":1162,"briefTitle":1163,"status":55,"phases":1164,"completion":410,"start":1165,"enrollment":1166,"conditions":1167,"interventions":1168},"NCT00246285","A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia",[40],"2001-04",381,[14,1137],[550],{"nctId":1170,"briefTitle":1171,"status":55,"phases":1172,"completion":649,"start":1173,"enrollment":1174,"conditions":1175,"interventions":1178},"NCT00034762","Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease",[40],"2000-12",473,[1176,1177,787],"Dementia","Alzheimer Disease",[550],{"nctId":1180,"briefTitle":1181,"status":55,"phases":1182,"completion":727,"start":556,"enrollment":1183,"conditions":1184,"interventions":1186},"NCT00253162","A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol",[40],439,[731,1185],"Manic Disorder",[550],{"nctId":1188,"briefTitle":1189,"status":55,"phases":1190,"completion":134,"start":901,"enrollment":1191,"conditions":1192,"interventions":1193},"NCT00210691","A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder",[40],273,[14],[1153],{"nctId":1195,"briefTitle":1196,"status":55,"phases":1197,"completion":649,"enrollment":285,"conditions":1198,"interventions":1199},"NCT00236548","Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection",[40],[14,1137],[550],{"nctId":1201,"briefTitle":1202,"status":55,"phases":1203,"completion":1204,"enrollment":1205,"conditions":1206,"interventions":1207},"NCT00253149","A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder",[40],"1999-04",158,[731,1185],[550],{"nctId":1209,"briefTitle":1210,"status":55,"phases":1211,"completion":591,"start":555,"enrollment":1212,"conditions":1213,"interventions":1217},"NCT00044681","A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression",[40],258,[1214,1215,1216],"Depressive Disorder","Depressive Disorder, Major","Depression",[550],{"nctId":1219,"briefTitle":1220,"status":55,"phases":1221,"completion":234,"start":1165,"enrollment":1222,"conditions":1223,"interventions":1224},"NCT00034749","The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia",[40],279,[14],[1153],{"nctId":1226,"briefTitle":1227,"status":55,"phases":1228,"completion":565,"enrollment":1229,"conditions":1230,"interventions":1232},"NCT00086112","Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.",[40],301,[1231],"Anxiety Disorders",[1233],"risperidone oral",{"nctId":1235,"briefTitle":1236,"status":55,"phases":1237,"completion":767,"start":341,"enrollment":1051,"conditions":1238,"interventions":1240},"NCT00095134","Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy",[40],[1239],"Major Depressive Disorder",[550],{"nctId":1242,"briefTitle":1243,"status":55,"phases":1244,"completion":89,"start":658,"enrollment":1245,"conditions":1246,"interventions":1248},"NCT00236470","A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders",[40],232,[1247],"Disruptive Behavior Disorder",[550],{"nctId":1250,"briefTitle":1251,"status":55,"phases":1252,"completion":385,"start":471,"enrollment":785,"conditions":1253,"interventions":1254},"NCT00076115","Study to Determine the Effectiveness of Risperidone in Bipolar Disorder in Children and Adolescents",[40],[26],[1153],{"nctId":1256,"briefTitle":1257,"status":55,"phases":1258,"completion":555,"start":1259,"enrollment":1260,"conditions":1261,"interventions":1262},"NCT00034775","A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.",[40],"2001-08",141,[14,1137],[550],{"trials":1264,"activeCount":8},[1265],{"nctId":1266,"briefTitle":1267,"status":55,"phases":1268,"primaryCompletion":1269,"completion":1269,"start":1270,"enrollment":1271,"conditions":1272,"interventions":1275},"NCT01050582","A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children",[41],"2011-07","2009-10",244,[14,26,1273,1274],"Autistic Disorder","Conduct and Other Disruptive Behavior Disorders",[1153,1276],"Other atypical antipsychotic drugs",{"trials":1278,"activeCount":8},[],{"intervention":1280,"totalTrials":1281,"cells":1282},"Cisapride",4,{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1289,"PHASE4":1291,"NA":1325},{"trials":1284,"activeCount":8},[],{"trials":1286,"activeCount":8},[],{"trials":1288,"activeCount":8},[],{"trials":1290,"activeCount":8},[],{"trials":1292,"activeCount":8},[1293,1301,1309,1316],{"nctId":1294,"briefTitle":1295,"status":68,"phases":1296,"completion":1297,"start":456,"enrollment":98,"conditions":1298,"interventions":1300},"NCT01281553","A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease",[41],"2003-10",[1299],"Gastroesophageal Reflux",[1280],{"nctId":1302,"briefTitle":1303,"status":68,"phases":1304,"completion":1297,"start":1121,"enrollment":1281,"conditions":1305,"interventions":1308},"NCT01286090","An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus",[41],[1306,1307],"Gastroparesis","Diabetes Mellitus",[1280],{"nctId":1310,"briefTitle":1311,"status":68,"phases":1312,"completion":1313,"start":348,"enrollment":1107,"conditions":1314,"interventions":1315},"NCT01281540","An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options",[41],"2003-11",[1306],[1280],{"nctId":1317,"briefTitle":1318,"status":68,"phases":1319,"completion":1121,"start":115,"enrollment":1320,"conditions":1321,"interventions":1324},"NCT01281566","A Study of Cisapride in Premature Infants With Feeding Problems",[41],8,[1322,1323],"Infant, Premature","Infant, Newborn",[1280],{"trials":1326,"activeCount":8},[],{"intervention":1328,"totalTrials":1281,"cells":1329},"galantamine",{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1334,"PHASE3":1336,"PHASE4":1363,"NA":1371},{"trials":1331,"activeCount":8},[],{"trials":1333,"activeCount":8},[],{"trials":1335,"activeCount":8},[],{"trials":1337,"activeCount":8},[1338,1346,1354],{"nctId":1339,"briefTitle":1340,"status":55,"phases":1341,"completion":456,"start":718,"enrollment":1342,"conditions":1343,"interventions":1345},"NCT00035191","A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia",[40],254,[1344],"Dementia, Vascular",[1328],{"nctId":1347,"briefTitle":1348,"status":55,"phases":1349,"completion":528,"start":1350,"enrollment":1351,"conditions":1352,"interventions":1353},"NCT00304629","Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease",[40],"2000-03",241,[1177],[1328],{"nctId":1355,"briefTitle":1356,"status":55,"phases":1357,"completion":1358,"enrollment":1359,"conditions":1360,"interventions":1362},"NCT00309725","A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.",[40],"1999-10",139,[1361],"Alzheimer's Disease",[1328],{"trials":1364,"activeCount":8},[1365],{"nctId":1366,"briefTitle":1367,"status":55,"phases":1368,"completion":348,"enrollment":226,"conditions":1369,"interventions":1370},"NCT00035204","A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease",[41],[1177],[1328],{"trials":1372,"activeCount":8},[],{"intervention":522,"totalTrials":482,"cells":1374},{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1379,"PHASE3":1381,"PHASE4":1398,"NA":1404},{"trials":1376,"activeCount":8},[],{"trials":1378,"activeCount":8},[],{"trials":1380,"activeCount":8},[],{"trials":1382,"activeCount":8},[1383],{"nctId":1384,"briefTitle":1385,"status":55,"phases":1386,"primaryCompletion":1387,"completion":1387,"start":1101,"enrollment":1388,"conditions":1389,"interventions":1394},"NCT00809965","An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome",[40],"2011-09",15526,[1390,1391,1392,1393],"Acute Coronary Syndrome","Myocardial Infarction","Myocardial Ischemia","Unstable Angina",[1395,1396,1397],"Rivaroxaban 2.5 mg","Rivaroxaban 5 mg","Standard of care",{"trials":1399,"activeCount":8},[1400],{"nctId":513,"briefTitle":514,"status":68,"phases":1401,"primaryCompletion":516,"completion":516,"start":517,"enrollment":518,"conditions":1402,"interventions":1403},[41],[520],[84,522],{"trials":1405,"activeCount":8},[],{"intervention":1407,"totalTrials":285,"cells":1408},"levofloxacin; metronidazole",{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1415,"PHASE4":1417,"NA":1426},{"trials":1410,"activeCount":8},[],{"trials":1412,"activeCount":8},[],{"trials":1414,"activeCount":8},[],{"trials":1416,"activeCount":8},[],{"trials":1418,"activeCount":8},[1419],{"nctId":1420,"briefTitle":1421,"status":68,"phases":1422,"completion":893,"start":1121,"enrollment":1359,"conditions":1423,"interventions":1425},"NCT00236912","A Study Comparing Safety and Efficacy of Levofloxacin and Metronidazole Versus Piperacillin\u002FTazobactam in Treating Complicated Appendicitis",[41],[1424],"Appendicitis",[1407],{"trials":1427,"activeCount":8},[],{"intervention":1429,"totalTrials":285,"cells":1430},"Risperidone high dose",{"EARLY_PHASE1":1431,"PHASE1":1433,"PHASE2":1435,"PHASE3":1437,"PHASE4":1439,"NA":1453},{"trials":1432,"activeCount":8},[],{"trials":1434,"activeCount":8},[],{"trials":1436,"activeCount":8},[],{"trials":1438,"activeCount":8},[],{"trials":1440,"activeCount":8},[1441],{"nctId":1442,"briefTitle":1443,"status":55,"phases":1444,"primaryCompletion":1445,"completion":1446,"start":1447,"enrollment":1448,"conditions":1449,"interventions":1451},"NCT00576732","A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder",[41],"2009-09","2010-03","2007-12",96,[1273,1450],"Autism",[1429,1452],"Risperidone low dose",{"trials":1454,"activeCount":8},[],{"intervention":1452,"totalTrials":285,"cells":1456},{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1463,"PHASE4":1465,"NA":1471},{"trials":1458,"activeCount":8},[],{"trials":1460,"activeCount":8},[],{"trials":1462,"activeCount":8},[],{"trials":1464,"activeCount":8},[],{"trials":1466,"activeCount":8},[1467],{"nctId":1442,"briefTitle":1443,"status":55,"phases":1468,"primaryCompletion":1445,"completion":1446,"start":1447,"enrollment":1448,"conditions":1469,"interventions":1470},[41],[1273,1450],[1429,1452],{"trials":1472,"activeCount":8},[],{"intervention":1474,"totalTrials":285,"cells":1475},"tramadol hydrochloride , acetaminophen",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1482,"PHASE4":1484,"NA":1494},{"trials":1477,"activeCount":8},[],{"trials":1479,"activeCount":8},[],{"trials":1481,"activeCount":8},[],{"trials":1483,"activeCount":8},[],{"trials":1485,"activeCount":8},[1486],{"nctId":1487,"briefTitle":1488,"status":68,"phases":1489,"completion":854,"start":81,"enrollment":926,"conditions":1490,"interventions":1493},"NCT00210561","A Study of the Effectiveness and Safety of Tramadol HCl\u002FAcetaminophen Compared to Placebo in Treating Acute Low Back Pain",[41],[1491,1492],"Back Pain","Low Back Pain",[1474],{"trials":1495,"activeCount":8},[],{"intervention":1497,"totalTrials":285,"cells":1498},"tramadol hydrochloride + acetaminophen",{"EARLY_PHASE1":1499,"PHASE1":1501,"PHASE2":1503,"PHASE3":1505,"PHASE4":1507,"NA":1518},{"trials":1500,"activeCount":8},[],{"trials":1502,"activeCount":8},[],{"trials":1504,"activeCount":8},[],{"trials":1506,"activeCount":8},[],{"trials":1508,"activeCount":8},[1509],{"nctId":1510,"briefTitle":1511,"status":55,"phases":1512,"completion":243,"start":546,"enrollment":1513,"conditions":1514,"interventions":1517},"NCT00236483","A Comparison of the Effectiveness and Safety of ULTRACET® (Tramadol Hydrochloride\u002FAcetaminophen) Versus ULTRAM® (Tramadol Hydrochloride) Versus Placebo in Patients With Pain After Oral Surgery",[41],456,[1515,1516],"Surgery, Oral","Pain, Postoperative",[1497],{"trials":1519,"activeCount":8},[],{"intervention":1521,"totalTrials":285,"cells":1522},"risperidone, quetiapine",{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1529,"PHASE4":1531,"NA":1540},{"trials":1524,"activeCount":8},[],{"trials":1526,"activeCount":8},[],{"trials":1528,"activeCount":8},[],{"trials":1530,"activeCount":8},[],{"trials":1532,"activeCount":8},[1533],{"nctId":1534,"briefTitle":1535,"status":55,"phases":1536,"completion":134,"start":392,"enrollment":1537,"conditions":1538,"interventions":1539},"NCT00061802","Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder",[41],225,[14,938],[1521],{"trials":1541,"activeCount":8},[],{"intervention":1543,"totalTrials":285,"cells":1544},"Epoetin alfa 450 IU\u002Fkg once a week",{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1549,"PHASE3":1551,"PHASE4":1553,"NA":1563},{"trials":1546,"activeCount":8},[],{"trials":1548,"activeCount":8},[],{"trials":1550,"activeCount":8},[],{"trials":1552,"activeCount":8},[],{"trials":1554,"activeCount":8},[1555],{"nctId":1556,"briefTitle":1557,"status":55,"phases":1558,"primaryCompletion":1445,"completion":1445,"start":58,"enrollment":1559,"conditions":1560,"interventions":1561},"NCT01394991","A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia",[41],504,[20,137],[1543,1562,1543,1562],"Epoetin alfa 150 IU\u002Fkg 3 times a week",{"trials":1564,"activeCount":8},[],{"intervention":1562,"totalTrials":285,"cells":1566},{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1573,"PHASE4":1575,"NA":1581},{"trials":1568,"activeCount":8},[],{"trials":1570,"activeCount":8},[],{"trials":1572,"activeCount":8},[],{"trials":1574,"activeCount":8},[],{"trials":1576,"activeCount":8},[1577],{"nctId":1556,"briefTitle":1557,"status":55,"phases":1578,"primaryCompletion":1445,"completion":1445,"start":58,"enrollment":1559,"conditions":1579,"interventions":1580},[41],[20,137],[1543,1562,1543,1562],{"trials":1582,"activeCount":8},[],{"intervention":1276,"totalTrials":285,"cells":1584},{"EARLY_PHASE1":1585,"PHASE1":1587,"PHASE2":1589,"PHASE3":1591,"PHASE4":1593,"NA":1599},{"trials":1586,"activeCount":8},[],{"trials":1588,"activeCount":8},[],{"trials":1590,"activeCount":8},[],{"trials":1592,"activeCount":8},[],{"trials":1594,"activeCount":8},[1595],{"nctId":1266,"briefTitle":1267,"status":55,"phases":1596,"primaryCompletion":1269,"completion":1269,"start":1270,"enrollment":1271,"conditions":1597,"interventions":1598},[41],[14,26,1273,1274],[1153,1276],{"trials":1600,"activeCount":8},[],{"intervention":1602,"totalTrials":285,"cells":1603},"Abilify",{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1610,"PHASE4":1612,"NA":1622},{"trials":1605,"activeCount":8},[],{"trials":1607,"activeCount":8},[],{"trials":1609,"activeCount":8},[],{"trials":1611,"activeCount":8},[],{"trials":1613,"activeCount":8},[1614],{"nctId":1615,"briefTitle":1616,"status":55,"phases":1617,"primaryCompletion":986,"completion":986,"start":267,"enrollment":1618,"conditions":1619,"interventions":1620},"NCT00299702","Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia",[41],355,[14,1137],[1602,1621],"Risperidal Consta",{"trials":1623,"activeCount":8},[],{"intervention":1621,"totalTrials":285,"cells":1625},{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1632,"PHASE4":1634,"NA":1640},{"trials":1627,"activeCount":8},[],{"trials":1629,"activeCount":8},[],{"trials":1631,"activeCount":8},[],{"trials":1633,"activeCount":8},[],{"trials":1635,"activeCount":8},[1636],{"nctId":1615,"briefTitle":1616,"status":55,"phases":1637,"primaryCompletion":986,"completion":986,"start":267,"enrollment":1618,"conditions":1638,"interventions":1639},[41],[14,1137],[1602,1621],{"trials":1641,"activeCount":8},[],{"intervention":1643,"totalTrials":285,"cells":1644},"tramadol HCl\u002Facetaminophen",{"EARLY_PHASE1":1645,"PHASE1":1647,"PHASE2":1649,"PHASE3":1651,"PHASE4":1653,"NA":1663},{"trials":1646,"activeCount":8},[],{"trials":1648,"activeCount":8},[],{"trials":1650,"activeCount":8},[],{"trials":1652,"activeCount":8},[],{"trials":1654,"activeCount":8},[1655],{"nctId":1656,"briefTitle":1657,"status":55,"phases":1658,"completion":194,"start":1659,"enrollment":438,"conditions":1660,"interventions":1662},"NCT00297375","A Study Comparing the Effectiveness and Safety of ULTRACET® (Tramadol HCl\u002FAcetaminophen) Versus Placebo for the Treatment of Acute Pain From a Migraine Headache",[41],"2003-04",[770,1661,771],"Head Pain",[1643],{"trials":1664,"activeCount":8},[],{"intervention":1096,"totalTrials":285,"cells":1666},{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1671,"PHASE3":1673,"PHASE4":1675,"NA":1681},{"trials":1668,"activeCount":8},[],{"trials":1670,"activeCount":8},[],{"trials":1672,"activeCount":8},[],{"trials":1674,"activeCount":8},[],{"trials":1676,"activeCount":8},[1677],{"nctId":1090,"briefTitle":1091,"status":55,"phases":1678,"primaryCompletion":1093,"completion":1093,"start":564,"enrollment":491,"conditions":1679,"interventions":1680},[41],[14],[1096,925],{"trials":1682,"activeCount":8},[],{"intervention":1684,"totalTrials":285,"cells":1685},"Pentosan polysulfate sodium 100 mg",{"EARLY_PHASE1":1686,"PHASE1":1688,"PHASE2":1690,"PHASE3":1692,"PHASE4":1694,"NA":1705},{"trials":1687,"activeCount":8},[],{"trials":1689,"activeCount":8},[],{"trials":1691,"activeCount":8},[],{"trials":1693,"activeCount":8},[],{"trials":1695,"activeCount":8},[1696],{"nctId":1697,"briefTitle":1698,"status":68,"phases":1699,"primaryCompletion":1700,"completion":1700,"start":456,"enrollment":1701,"conditions":1702,"interventions":1704},"NCT00086684","Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis",[41],"2011-06",369,[1703],"Interstitial Cystitis",[1684,1684],{"trials":1706,"activeCount":8},[],{"intervention":1708,"totalTrials":1709,"cells":1710},"levofloxacin",18,{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1723,"PHASE3":1725,"PHASE4":1873,"NA":1875},{"trials":1712,"activeCount":8},[],{"trials":1714,"activeCount":8},[1715],{"nctId":1716,"briefTitle":1717,"status":55,"phases":1718,"completion":1017,"start":341,"enrollment":1719,"conditions":1720,"interventions":1721},"NCT00645437","A Study to Evaluate the Pharmacokinetics and Safety of Levofloxacin in Patients With Varying Degrees of Renal Function.",[38],59,[316],[1722],"Levofloxacin",{"trials":1724,"activeCount":8},[],{"trials":1726,"activeCount":8},[1727,1735,1744,1754,1763,1773,1781,1792,1803,1810,1818,1826,1834,1843,1852,1859,1867],{"nctId":1728,"briefTitle":1729,"status":55,"phases":1730,"completion":124,"start":702,"enrollment":1731,"conditions":1732,"interventions":1734},"NCT00034736","A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting",[40],691,[1733],"Pneumonia",[1722],{"nctId":1736,"briefTitle":1737,"status":55,"phases":1738,"completion":1017,"start":341,"enrollment":1739,"conditions":1740,"interventions":1743},"NCT00210886","A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis.",[40],1109,[1741,1742],"Urinary Tract Infections","Pyelonephritis",[1708],{"nctId":1745,"briefTitle":1746,"status":55,"phases":1747,"completion":1748,"start":1749,"enrollment":1750,"conditions":1751,"interventions":1753},"NCT00257062","A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Uncomplicated Infections of the Skin and the Supportive Layers Beneath the Skin",[40],"1994-04","1993-01",361,[1752],"Skin Diseases, Infectious",[1722],{"nctId":1755,"briefTitle":1756,"status":55,"phases":1757,"completion":1143,"start":1758,"enrollment":1759,"conditions":1760,"interventions":1762},"NCT00236808","A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis",[40],"2000-05",383,[1761],"Prostatitis",[1708],{"nctId":1764,"briefTitle":1765,"status":55,"phases":1766,"completion":1767,"start":1768,"enrollment":1769,"conditions":1770,"interventions":1772},"NCT00249197","A Study of the Safety and Effectiveness of Levofloxacin Compared to Ticarcillin\u002FClavulanate Alone or Followed by Amoxicillin\u002FClavulanate in the Treatment of Complicated Skin Infections",[40],"1998-07","1997-01",413,[1771],"Skin Diseases, Bacterial",[1708],{"nctId":1774,"briefTitle":1775,"status":55,"phases":1776,"completion":1121,"start":546,"enrollment":1777,"conditions":1778,"interventions":1780},"NCT00044473","A Study of the Effectiness and Safety of Levofloxacin in Treating Children With a Rapid and Severe Onset of Infection and Inflammation of the Middle Ear That is Difficult to Treat",[40],206,[1779],"Otitis Media",[1708],{"nctId":1782,"briefTitle":1783,"status":55,"phases":1784,"completion":323,"start":1785,"enrollment":1786,"conditions":1787,"interventions":1791},"NCT00258089","A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections",[40],"1993-06",578,[1741,1788,1789,1742,1790],"Bacteriuria","Urologic Diseases","Neurogenic Bladder",[1722],{"nctId":1793,"briefTitle":1794,"status":55,"phases":1795,"completion":1796,"start":1797,"enrollment":1798,"conditions":1799,"interventions":1802},"NCT00257140","A Study of the Safety and Effectiveness of Levofloxacin Compared With Cefaclor in the Treatment of Adults With Chronic Bronchitis Experiencing Rapid Onset of Worsening of Symptoms Caused by Bacteria",[39,40],"1994-07","1931-06",367,[1800,1801],"Bronchitis","Bronchitis, Chronic",[1708],{"nctId":1804,"briefTitle":1805,"status":55,"phases":1806,"completion":758,"start":556,"enrollment":1807,"conditions":1808,"interventions":1809},"NCT00236821","A Study to Compare the Safety and Effectiveness of 2 Doses of Levofloxacin Given for Different Time Periods in Patients With Pneumonia",[40],530,[1733],[1708],{"nctId":1811,"briefTitle":1812,"status":55,"phases":1813,"completion":1814,"start":686,"enrollment":1815,"conditions":1816,"interventions":1817},"NCT00269932","A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Cefuroxime Axetil in the Treatment of Adults With Persistent Bronchitis Experiencing Rapid Onset of Severe Worsening of Symptoms Caused by Bacteria",[40],"1994-05",485,[1801],[1708],{"nctId":1819,"briefTitle":1820,"status":55,"phases":1821,"primaryCompletion":171,"completion":1822,"start":57,"enrollment":1823,"conditions":1824,"interventions":1825},"NCT00402688","An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis",[40],"2008-09",242,[1761],[1708,1708,1708],{"nctId":1827,"briefTitle":1828,"status":55,"phases":1829,"completion":323,"start":1830,"enrollment":1831,"conditions":1832,"interventions":1833},"NCT00257049","A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia",[39,40],"1984-01",604,[1733],[1708],{"nctId":1835,"briefTitle":1836,"status":55,"phases":1837,"completion":1796,"start":686,"enrollment":1838,"conditions":1839,"interventions":1842},"NCT00249210","A Study of the Safety and Effectiveness of Levofloxacin Compared With Amoxicillin\u002FClavulanate Potassium in the Treatment of Adults With Rapid Onset of Severe Inflammation\u002FInfection of the Sinuses",[40],614,[1840,1841],"Sinusitis","Maxillary Sinusitis",[1708],{"nctId":1844,"briefTitle":1845,"status":55,"phases":1846,"completion":1847,"start":446,"enrollment":1848,"conditions":1849,"interventions":1851},"NCT00257036","A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Mild to Moderate Infections of the Skin and the Supportive Layers Beneath the Skin",[39,40],"1993-02",431,[1752,1850],"Cellulitis",[1708],{"nctId":1853,"briefTitle":1854,"status":55,"phases":1855,"completion":193,"start":555,"enrollment":1856,"conditions":1857,"interventions":1858},"NCT00236522","A Comparison of the Safety and Efficacy of Two Different Regimens of Levofloxacin in the Treatment of Acute Bacterial Sinusitis(Sinus Infection) in Adults.",[40],784,[1840],[1708],{"nctId":1860,"briefTitle":1861,"status":55,"phases":1862,"completion":323,"start":1749,"enrollment":1863,"conditions":1864,"interventions":1866},"NCT00258102","A Study of the Safety and Effectiveness of Levofloxacin Compared With Lomefloxacin in the Treatment of Complicated Urinary Tract Infections",[40],603,[1741,1865,1788,1789],"Bacterial Infections",[1722],{"nctId":1868,"briefTitle":1869,"status":55,"phases":1870,"completion":565,"start":1313,"enrollment":1709,"conditions":1871,"interventions":1872},"NCT00236652","A Study Evaluating the Safety and Efficacy of Treating Sinus Infection With Levofloxacin 750 mg for 5 Days.",[40],[1841],[1708],{"trials":1874,"activeCount":8},[],{"trials":1876,"activeCount":8},[],{"intervention":1878,"totalTrials":1879,"cells":1880},"galantamine hydrobromide",10,{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1885,"PHASE3":1896,"PHASE4":1970,"NA":1972},{"trials":1882,"activeCount":8},[],{"trials":1884,"activeCount":8},[],{"trials":1886,"activeCount":8},[1887],{"nctId":1888,"briefTitle":1889,"status":55,"phases":1890,"completion":89,"start":348,"enrollment":1891,"conditions":1892,"interventions":1895},"NCT00416169","A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex\u002FFrontotemporal Dementia",[39],41,[1893,1894],"Frontotemporal Dementia","Pick Complex",[1878],{"trials":1897,"activeCount":8},[1898,1906,1916,1924,1932,1940,1950,1957,1964],{"nctId":1899,"briefTitle":1900,"status":55,"phases":1901,"completion":659,"start":1902,"enrollment":1903,"conditions":1904,"interventions":1905},"NCT00253188","A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease",[40],"1997-02",653,[1177,1176],[1878],{"nctId":1907,"briefTitle":1908,"status":55,"phases":1909,"completion":203,"start":348,"enrollment":1910,"conditions":1911,"interventions":1915},"NCT00240695","A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment",[40],724,[1912,1913,787,1914],"Cognition Disorder","Nervous System Diseases","Brain Diseases",[1878],{"nctId":1917,"briefTitle":1918,"status":55,"phases":1919,"completion":1920,"start":556,"enrollment":1921,"conditions":1922,"interventions":1923},"NCT00253214","Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation",[40],"2002-07",973,[1177,1176],[1878],{"nctId":1925,"briefTitle":1926,"status":55,"phases":1927,"completion":659,"start":1928,"enrollment":1929,"conditions":1930,"interventions":1931},"NCT00253227","A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease",[40],"1997-07",387,[1177,1176],[1878],{"nctId":1933,"briefTitle":1934,"status":55,"phases":1935,"completion":1173,"start":659,"enrollment":1936,"conditions":1937,"interventions":1939},"NCT00261573","A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia",[40],593,[1177,1938],"Vascular Dementia",[1878],{"nctId":1941,"briefTitle":1942,"status":55,"phases":1943,"completion":1944,"start":1945,"enrollment":1946,"conditions":1947,"interventions":1948},"NCT00338117","Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease",[40],"1997-05","1995-08",554,[1361,1176],[1949],"Galantamine hydrobromide",{"nctId":1951,"briefTitle":1952,"status":55,"phases":1953,"completion":471,"start":711,"enrollment":1954,"conditions":1955,"interventions":1956},"NCT00236431","A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment",[40],1063,[1176,1177],[1949],{"nctId":1958,"briefTitle":1900,"status":55,"phases":1959,"completion":1960,"enrollment":1961,"conditions":1962,"interventions":1963},"NCT00253201",[40],"1997-10",636,[1177,1176],[1878],{"nctId":1965,"briefTitle":1952,"status":55,"phases":1966,"completion":1313,"start":711,"enrollment":1967,"conditions":1968,"interventions":1969},"NCT00236574",[40],974,[1176,1177],[1949],{"trials":1971,"activeCount":8},[],{"trials":1973,"activeCount":8},[],{"intervention":1975,"totalTrials":218,"cells":1976},"Trabectedin",{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1993,"PHASE3":2050,"PHASE4":2071,"NA":2073},{"trials":1978,"activeCount":8},[],{"trials":1980,"activeCount":8},[1981],{"nctId":1982,"briefTitle":1983,"status":55,"phases":1984,"completion":564,"start":854,"enrollment":1891,"conditions":1985,"interventions":1990},"NCT00102609","A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma",[38],[1986,1987,1988,1989,137],"Soft Tissue Sarcoma","Sarcoma","Neoplasms, Connective and Soft Tissue","Neoplasms by Histologic Type",[1991,1975,1992],"Doxorubicin","Dexamethasone",{"trials":1994,"activeCount":8},[1995,2003,2016,2026,2036,2044],{"nctId":1996,"briefTitle":1997,"status":55,"phases":1998,"primaryCompletion":332,"completion":332,"start":1999,"enrollment":90,"conditions":2000,"interventions":2002},"NCT00579501","Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid \u002F Round Cell Liposarcoma",[39],"2007-04",[2001],"Liposarcoma,Myxoid",[1975,1992],{"nctId":2004,"briefTitle":2005,"status":55,"phases":2006,"completion":80,"start":555,"enrollment":2007,"conditions":2008,"interventions":2015},"NCT00050414","A Study of Trabectedin in Patients With Advanced Ovarian Cancer",[39],147,[2009,2010,2011,137,2012,2013,2014],"Ovarian Neoplasms","Endocrine Gland Neoplasms","Neoplasms by Site","Ovarian Diseases","Adnexal Diseases","Genital Diseases, Female",[1975,1992],{"nctId":2017,"briefTitle":2018,"status":55,"phases":2019,"completion":89,"start":1920,"enrollment":2020,"conditions":2021,"interventions":2025},"NCT00050440","Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma",[39],50,[2022,2023,2024],"Endometrial Neoplasms","Uterine Neoplasms","Genital Neoplasms, Female Urogenital Neoplasms",[1975,1992],{"nctId":2027,"briefTitle":2028,"status":55,"phases":2029,"primaryCompletion":2030,"completion":2030,"start":2031,"enrollment":2032,"conditions":2033,"interventions":2035},"NCT00786838","A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram",[39],"2009-12","2008-10",76,[2034],"Solid Tumor",[1975],{"nctId":2037,"briefTitle":2038,"status":55,"phases":2039,"primaryCompletion":2040,"completion":2040,"start":747,"enrollment":2041,"conditions":2042,"interventions":2043},"NCT00580112","An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer",[39],"2011-08",127,[414],[1992,1975],{"nctId":2045,"briefTitle":2046,"status":55,"phases":2047,"primaryCompletion":1822,"completion":1101,"start":971,"enrollment":1719,"conditions":2048,"interventions":2049},"NCT00072670","A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer",[39],[498],[1975],{"trials":2051,"activeCount":8},[2052,2061],{"nctId":2053,"briefTitle":2054,"status":55,"phases":2055,"primaryCompletion":2056,"completion":2056,"start":854,"enrollment":2057,"conditions":2058,"interventions":2059},"NCT00113607","An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer",[40],"2010-11",672,[495],[1975,2060,1992],"DOXIL",{"nctId":2062,"briefTitle":2063,"status":55,"phases":2064,"primaryCompletion":2065,"completion":2066,"start":1101,"enrollment":2067,"conditions":2068,"interventions":2069},"NCT00796120","An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)",[40],"2012-08","2014-08",121,[1987],[1975,1991,2070],"Ifosfamide",{"trials":2072,"activeCount":8},[],{"trials":2074,"activeCount":8},[],{"intervention":1992,"totalTrials":1320,"cells":2076},{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2085,"PHASE3":2113,"PHASE4":2126,"NA":2128},{"trials":2078,"activeCount":8},[],{"trials":2080,"activeCount":8},[2081],{"nctId":1982,"briefTitle":1983,"status":55,"phases":2082,"completion":564,"start":854,"enrollment":1891,"conditions":2083,"interventions":2084},[38],[1986,1987,1988,1989,137],[1991,1975,1992],{"trials":2086,"activeCount":8},[2087,2091,2095,2099,2103],{"nctId":1996,"briefTitle":1997,"status":55,"phases":2088,"primaryCompletion":332,"completion":332,"start":1999,"enrollment":90,"conditions":2089,"interventions":2090},[39],[2001],[1975,1992],{"nctId":2004,"briefTitle":2005,"status":55,"phases":2092,"completion":80,"start":555,"enrollment":2007,"conditions":2093,"interventions":2094},[39],[2009,2010,2011,137,2012,2013,2014],[1975,1992],{"nctId":2017,"briefTitle":2018,"status":55,"phases":2096,"completion":89,"start":1920,"enrollment":2020,"conditions":2097,"interventions":2098},[39],[2022,2023,2024],[1975,1992],{"nctId":2037,"briefTitle":2038,"status":55,"phases":2100,"primaryCompletion":2040,"completion":2040,"start":747,"enrollment":2041,"conditions":2101,"interventions":2102},[39],[414],[1992,1975],{"nctId":2104,"briefTitle":2105,"status":55,"phases":2106,"primaryCompletion":172,"completion":172,"start":348,"enrollment":2107,"conditions":2108,"interventions":2111},"NCT00060944","A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer",[39],271,[2109,2110],"Liposarcoma","Leiomyosarcoma",[2112,2112,1992,1992],"Yondelis",{"trials":2114,"activeCount":8},[2115,2119],{"nctId":2053,"briefTitle":2054,"status":55,"phases":2116,"primaryCompletion":2056,"completion":2056,"start":854,"enrollment":2057,"conditions":2117,"interventions":2118},[40],[495],[1975,2060,1992],{"nctId":2120,"briefTitle":2121,"status":55,"phases":2122,"primaryCompletion":564,"completion":1270,"start":114,"enrollment":1537,"conditions":2123,"interventions":2124},"NCT00097981","A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma",[40],[326],[2125,1992,2060],"Thalidomide",{"trials":2127,"activeCount":8},[],{"trials":2129,"activeCount":8},[],{"intervention":2131,"totalTrials":2132,"cells":2133},"paliperidone palmitate",7,{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2138,"PHASE3":2140,"PHASE4":2196,"NA":2198},{"trials":2135,"activeCount":8},[],{"trials":2137,"activeCount":8},[],{"trials":2139,"activeCount":8},[],{"trials":2141,"activeCount":8},[2142,2151,2158,2166,2173,2180,2187],{"nctId":2143,"briefTitle":2144,"status":55,"phases":2145,"completion":234,"start":2146,"enrollment":2147,"conditions":2148,"interventions":2149},"NCT00101634","Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia",[40],"2004-12",518,[14],[2150],"Paliperidone palmitate",{"nctId":2152,"briefTitle":2153,"status":55,"phases":2154,"completion":1999,"start":242,"enrollment":2155,"conditions":2156,"interventions":2157},"NCT00210717","A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia",[40],748,[14],[2131],{"nctId":2159,"briefTitle":2160,"status":55,"phases":2161,"primaryCompletion":106,"completion":516,"start":242,"enrollment":2162,"conditions":2163,"interventions":2164},"NCT00111189","A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.",[40],414,[14],[2165],"Paliperidone Palmitate",{"nctId":2167,"briefTitle":2168,"status":55,"phases":2169,"completion":57,"start":565,"enrollment":2170,"conditions":2171,"interventions":2172},"NCT00119756","A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia",[40],253,[14],[2131],{"nctId":2174,"briefTitle":2175,"status":55,"phases":2176,"completion":203,"start":194,"enrollment":2177,"conditions":2178,"interventions":2179},"NCT00073320","Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia",[40],88,[14],[2165],{"nctId":2181,"briefTitle":2182,"status":55,"phases":2183,"completion":455,"start":854,"enrollment":2184,"conditions":2185,"interventions":2186},"NCT00210548","A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia",[40],366,[14],[2131],{"nctId":2188,"briefTitle":2189,"status":55,"phases":2190,"primaryCompletion":2191,"completion":2191,"start":957,"enrollment":2192,"conditions":2193,"interventions":2194},"NCT00589914","Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia",[40],"2009-06",1221,[14],[2195,2150],"RISPERDAL CONSTA",{"trials":2197,"activeCount":8},[],{"trials":2199,"activeCount":8},[],{"intervention":2201,"totalTrials":2132,"cells":2202},"doripenem",{"EARLY_PHASE1":2203,"PHASE1":2205,"PHASE2":2207,"PHASE3":2221,"PHASE4":2272,"NA":2274},{"trials":2204,"activeCount":8},[],{"trials":2206,"activeCount":8},[],{"trials":2208,"activeCount":8},[2209],{"nctId":2210,"briefTitle":2211,"status":55,"phases":2212,"primaryCompletion":1101,"completion":1101,"start":564,"enrollment":2213,"conditions":2214,"interventions":2218},"NCT00515034","A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia",[39],146,[2215,2216,1733,2217,1865],"Pneumonia, Ventilator-Associated","Pneumonia, Bacterial","Abdominal Abscess",[2219,2219,2220,2220],"Imipenem\u002Fcilastatin","Doripenem",{"trials":2222,"activeCount":8},[2223,2234,2242,2248,2255,2262],{"nctId":2224,"briefTitle":2225,"status":55,"phases":2226,"completion":58,"start":591,"enrollment":2227,"conditions":2228,"interventions":2233},"NCT00210938","Doripenem in the Treatment of Complicated Intra-Abdominal Infections",[40],478,[2229,1424,2230,2231,2232],"Bacterial Infections and Mycoses","Cholecystitis","Pancreatitis","Peritonitis",[2220],{"nctId":2235,"briefTitle":2236,"status":55,"phases":2237,"completion":609,"start":1064,"enrollment":2238,"conditions":2239,"interventions":2241},"NCT00211016","Doripenem in the Treatment of Ventilator-Associated Pneumonia",[40],318,[1733,2240],"Ventilators, Mechanical",[2201],{"nctId":2243,"briefTitle":2225,"status":55,"phases":2244,"completion":234,"start":591,"enrollment":2245,"conditions":2246,"interventions":2247},"NCT00229060",[40],483,[2229,1424,2230,2231,2232],[2201],{"nctId":2249,"briefTitle":2250,"status":55,"phases":2251,"completion":1017,"start":591,"enrollment":2252,"conditions":2253,"interventions":2254},"NCT00210990","Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis",[40],403,[1741,1742],[2201],{"nctId":2256,"briefTitle":2257,"status":55,"phases":2258,"completion":609,"start":203,"enrollment":2259,"conditions":2260,"interventions":2261},"NCT00211003","Doripenem in the Treatment of Hospital-Acquired Pneumonia",[40],240,[1733],[2201],{"nctId":2263,"briefTitle":2264,"status":68,"phases":2265,"primaryCompletion":1700,"completion":1700,"start":2266,"enrollment":2267,"conditions":2268,"interventions":2270},"NCT00589693","To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia",[40],"2008-04",274,[2269],"Ventilator-Associated Pneumonia",[2220,2271],"Imipenem-Cilastatin",{"trials":2273,"activeCount":8},[],{"trials":2275,"activeCount":8},[],{"intervention":2277,"totalTrials":998,"cells":2278},"Tapentadol",{"EARLY_PHASE1":2279,"PHASE1":2281,"PHASE2":2289,"PHASE3":2291,"PHASE4":2332,"NA":2334},{"trials":2280,"activeCount":8},[],{"trials":2282,"activeCount":8},[2283],{"nctId":2284,"briefTitle":2285,"status":55,"phases":2286,"primaryCompletion":2031,"completion":2031,"start":1822,"enrollment":1709,"conditions":2287,"interventions":2288},"NCT01877226","Phase 1 Pharmacokinetic Study of Tapentadol Prolonged-Release 250 Milligram (mg) Formulation in Healthy Participants",[38],[17],[2277],{"trials":2290,"activeCount":8},[],{"trials":2292,"activeCount":8},[2293,2302,2314,2324],{"nctId":2294,"briefTitle":2295,"status":55,"phases":2296,"primaryCompletion":2266,"completion":172,"start":1447,"enrollment":2297,"conditions":2298,"interventions":2299},"NCT00594516","Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain",[40],117,[1492],[2300,2301,2301],"tapentadol (CG5503) Immediate Release IR","tapentadol",{"nctId":2303,"briefTitle":2304,"status":55,"phases":2305,"primaryCompletion":2031,"completion":2031,"start":516,"enrollment":2306,"conditions":2307,"interventions":2312},"NCT00613938","A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.",[40],901,[2308,2309,2310,2311],"Arthralgia","Bunion","Hallux Valgus","Pain",[2277,2277,2313],"oxycodone",{"nctId":2315,"briefTitle":2316,"status":55,"phases":2317,"primaryCompletion":1093,"completion":2318,"start":2319,"enrollment":2320,"conditions":2321,"interventions":2323},"NCT00421928","Tapentadol (CG5503)",[40],"2008-12","2007-01",1030,[2322,2311],"Osteoarthritis, Knee",[2313,2301],{"nctId":2325,"briefTitle":2326,"status":55,"phases":2327,"primaryCompletion":2191,"completion":2191,"start":747,"enrollment":2328,"conditions":2329,"interventions":2331},"NCT00487435","An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain",[40],1166,[2311,2330,1492],"Osteoarthritis",[2277],{"trials":2333,"activeCount":8},[],{"trials":2335,"activeCount":8},[],{"intervention":2337,"totalTrials":1281,"cells":2338},"oxycodone CR",{"EARLY_PHASE1":2339,"PHASE1":2341,"PHASE2":2343,"PHASE3":2357,"PHASE4":2389,"NA":2391},{"trials":2340,"activeCount":8},[],{"trials":2342,"activeCount":8},[],{"trials":2344,"activeCount":8},[2345],{"nctId":2346,"briefTitle":2347,"status":68,"phases":2348,"primaryCompletion":2349,"completion":2349,"start":2350,"enrollment":2351,"conditions":2352,"interventions":2354},"NCT01094262","A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis",[39],"2011-07-01","2010-04-20",196,[2330,2322,2311,2308,2353],"Joint Pain",[2355,2356,2356],"Oxycodone CR","JNJ-42160443",{"trials":2358,"activeCount":8},[2359,2367,2379],{"nctId":2360,"briefTitle":2361,"status":55,"phases":2362,"primaryCompletion":172,"completion":172,"start":106,"enrollment":2363,"conditions":2364,"interventions":2365},"NCT00449176","A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain",[40],981,[1492],[2366,2337],"tapentadol (CG5503) ER",{"nctId":2368,"briefTitle":2369,"status":55,"phases":2370,"primaryCompletion":153,"completion":153,"start":2031,"enrollment":2371,"conditions":2372,"interventions":2375},"NCT00784277","A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease",[40],597,[2373,2374,2330],"Joint Diseases","Arthritis",[2337,2376,2377,2378,2378],"oxycodone IR","Tapentadol ER","Tapentadol IR",{"nctId":2380,"briefTitle":2381,"status":55,"phases":2382,"primaryCompletion":1093,"completion":1093,"start":57,"enrollment":2383,"conditions":2384,"interventions":2387},"NCT00361504","A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain",[40],1123,[2385,2322,2386,2311],"Osteoarthritis, Hip","Lower Back Pain",[2355,2388],"Tapentadol (CG5503) ER",{"trials":2390,"activeCount":8},[],{"trials":2392,"activeCount":8},[],{"intervention":2394,"totalTrials":1281,"cells":2395},"Dapoxetine",{"EARLY_PHASE1":2396,"PHASE1":2398,"PHASE2":2400,"PHASE3":2402,"PHASE4":2437,"NA":2439},{"trials":2397,"activeCount":8},[],{"trials":2399,"activeCount":8},[],{"trials":2401,"activeCount":8},[],{"trials":2403,"activeCount":8},[2404,2412,2421,2428],{"nctId":2405,"briefTitle":2406,"status":55,"phases":2407,"completion":455,"start":81,"enrollment":2408,"conditions":2409,"interventions":2411},"NCT00210704","A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation",[40],1067,[2410],"Erectile Dysfunction",[2394],{"nctId":2413,"briefTitle":2414,"status":55,"phases":2415,"primaryCompletion":2040,"completion":1387,"start":1008,"enrollment":2416,"conditions":2417,"interventions":2419},"NCT01063855","Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction",[40],495,[2410,2418],"Sexual Dysfunction",[2394,2420],"PDE5I",{"nctId":2422,"briefTitle":2406,"status":55,"phases":2423,"completion":609,"start":2146,"enrollment":2424,"conditions":2425,"interventions":2426},"NCT00229073",[40],1116,[2410],[2427],"dapoxetine",{"nctId":2429,"briefTitle":2430,"status":55,"phases":2431,"completion":527,"start":2432,"enrollment":2433,"conditions":2434,"interventions":2436},"NCT00210613","A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation",[40],"2004-11",199,[2418,2435],"Ejaculation",[2394],{"trials":2438,"activeCount":8},[],{"trials":2440,"activeCount":8},[],{"intervention":2060,"totalTrials":2442,"cells":2443},3,{"EARLY_PHASE1":2444,"PHASE1":2446,"PHASE2":2448,"PHASE3":2450,"PHASE4":2468,"NA":2470},{"trials":2445,"activeCount":8},[],{"trials":2447,"activeCount":8},[],{"trials":2449,"activeCount":8},[],{"trials":2451,"activeCount":8},[2452,2456,2464],{"nctId":2053,"briefTitle":2054,"status":55,"phases":2453,"primaryCompletion":2056,"completion":2056,"start":854,"enrollment":2057,"conditions":2454,"interventions":2455},[40],[495],[1975,2060,1992],{"nctId":2457,"briefTitle":2458,"status":55,"phases":2459,"primaryCompletion":2318,"completion":2318,"start":893,"enrollment":2460,"conditions":2461,"interventions":2462},"NCT00091442","A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer",[40],751,[494],[2463,2060],"Docetaxel",{"nctId":2120,"briefTitle":2121,"status":55,"phases":2465,"primaryCompletion":564,"completion":1270,"start":114,"enrollment":1537,"conditions":2466,"interventions":2467},[40],[326],[2125,1992,2060],{"trials":2469,"activeCount":8},[],{"trials":2471,"activeCount":8},[],{"intervention":2473,"totalTrials":2442,"cells":2474},"Tapentadol extended release",{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2490,"PHASE3":2492,"PHASE4":2513,"NA":2515},{"trials":2476,"activeCount":8},[],{"trials":2478,"activeCount":8},[2479],{"nctId":2480,"briefTitle":2481,"status":55,"phases":2482,"primaryCompletion":2483,"completion":2483,"start":2484,"enrollment":2485,"conditions":2486,"interventions":2487},"NCT02019485","A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects",[38],"2010-08","2010-07",64,[17],[2488,2489],"Tapentadol Extended Release","Tapentadol Prolonged-Release Formulation 2",{"trials":2491,"activeCount":8},[],{"trials":2493,"activeCount":8},[2494,2504],{"nctId":2495,"briefTitle":2496,"status":68,"phases":2497,"primaryCompletion":1008,"completion":2498,"start":332,"enrollment":642,"conditions":2499,"interventions":2502},"NCT01063868","A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)",[40],"2010-06",[2500,2501],"Diabetic Neuropathy, Painful","Diabetic Polyneuropathy",[2473,2503],"Oxycodone controlled release",{"nctId":2505,"briefTitle":2506,"status":55,"phases":2507,"primaryCompletion":2508,"completion":2508,"start":2030,"enrollment":2509,"conditions":2510,"interventions":2512},"NCT01041859","A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy",[40],"2011-03",460,[2511],"Diabetic Peripheral Neuropathy",[2473],{"trials":2514,"activeCount":8},[],{"trials":2516,"activeCount":8},[],{"intervention":2518,"totalTrials":2442,"cells":2519},"Risperdal Consta",{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2526,"PHASE4":2546,"NA":2548},{"trials":2521,"activeCount":8},[],{"trials":2523,"activeCount":8},[],{"trials":2525,"activeCount":8},[],{"trials":2527,"activeCount":8},[2528,2535,2542],{"nctId":2529,"briefTitle":2530,"status":55,"phases":2531,"completion":106,"start":203,"enrollment":2532,"conditions":2533,"interventions":2534},"NCT00094926","A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.",[40],275,[26],[2518],{"nctId":2536,"briefTitle":2537,"status":55,"phases":2538,"primaryCompletion":564,"completion":1447,"start":242,"enrollment":2539,"conditions":2540,"interventions":2541},"NCT00132678","A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes",[40],559,[26],[2518],{"nctId":2188,"briefTitle":2189,"status":55,"phases":2543,"primaryCompletion":2191,"completion":2191,"start":957,"enrollment":2192,"conditions":2544,"interventions":2545},[40],[14],[2195,2150],{"trials":2547,"activeCount":8},[],{"trials":2549,"activeCount":8},[],{"intervention":1011,"totalTrials":482,"cells":2551},{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2567,"PHASE4":2573,"NA":2575},{"trials":2553,"activeCount":8},[],{"trials":2555,"activeCount":8},[],{"trials":2557,"activeCount":8},[2558],{"nctId":2559,"briefTitle":2560,"status":55,"phases":2561,"primaryCompletion":2562,"completion":2562,"start":1101,"enrollment":2563,"conditions":2564,"interventions":2565},"NCT00728195","An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia",[39],"2010-02",498,[14],[2566,2566,2566,1011],"JNJ-37822681",{"trials":2568,"activeCount":8},[2569],{"nctId":1005,"briefTitle":1006,"status":55,"phases":2570,"primaryCompletion":1008,"completion":1008,"start":400,"enrollment":800,"conditions":2571,"interventions":2572},[40],[26],[1011,925],{"trials":2574,"activeCount":8},[],{"trials":2576,"activeCount":8},[],{"intervention":2313,"totalTrials":482,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2585,"PHASE4":2595,"NA":2597},{"trials":2580,"activeCount":8},[],{"trials":2582,"activeCount":8},[],{"trials":2584,"activeCount":8},[],{"trials":2586,"activeCount":8},[2587,2591],{"nctId":2303,"briefTitle":2304,"status":55,"phases":2588,"primaryCompletion":2031,"completion":2031,"start":516,"enrollment":2306,"conditions":2589,"interventions":2590},[40],[2308,2309,2310,2311],[2277,2277,2313],{"nctId":2315,"briefTitle":2316,"status":55,"phases":2592,"primaryCompletion":1093,"completion":2318,"start":2319,"enrollment":2320,"conditions":2593,"interventions":2594},[40],[2322,2311],[2313,2301],{"trials":2596,"activeCount":8},[],{"trials":2598,"activeCount":8},[],{"intervention":2600,"totalTrials":482,"cells":2601},"Rivaroxaban",{"EARLY_PHASE1":2602,"PHASE1":2604,"PHASE2":2606,"PHASE3":2616,"PHASE4":2630,"NA":2632},{"trials":2603,"activeCount":8},[],{"trials":2605,"activeCount":8},[],{"trials":2607,"activeCount":8},[2608],{"nctId":2609,"briefTitle":2610,"status":55,"phases":2611,"primaryCompletion":2031,"completion":2031,"start":57,"enrollment":2612,"conditions":2613,"interventions":2614},"NCT00402597","Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)",[39],3490,[1390],[2615,2600],"Rivaroxaban\u002FPlacebo",{"trials":2617,"activeCount":8},[2618],{"nctId":2619,"briefTitle":2620,"status":55,"phases":2621,"primaryCompletion":2622,"completion":2622,"start":410,"enrollment":2623,"conditions":2624,"interventions":2628},"NCT00403767","An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation",[40],"2010-09",14269,[2625,2626,2627],"Atrial Fibrillation","Stroke","Embolism",[2600,2629],"Warfarin",{"trials":2631,"activeCount":8},[],{"trials":2633,"activeCount":8},[],{"intervention":2635,"totalTrials":482,"cells":2636},"Risperidone, oral",{"EARLY_PHASE1":2637,"PHASE1":2639,"PHASE2":2641,"PHASE3":2643,"PHASE4":2659,"NA":2661},{"trials":2638,"activeCount":8},[],{"trials":2640,"activeCount":8},[],{"trials":2642,"activeCount":8},[],{"trials":2644,"activeCount":8},[2645,2652],{"nctId":2646,"briefTitle":2647,"status":55,"phases":2648,"completion":667,"start":1173,"enrollment":107,"conditions":2649,"interventions":2651},"NCT00257075","A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder",[40],[731,2650],"Manic Episode",[2635],{"nctId":2653,"briefTitle":2654,"status":55,"phases":2655,"completion":472,"start":556,"enrollment":2656,"conditions":2657,"interventions":2658},"NCT00249236","A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder",[40],291,[26,2650],[2635],{"trials":2660,"activeCount":8},[],{"trials":2662,"activeCount":8},[],{"intervention":2366,"totalTrials":482,"cells":2664},{"EARLY_PHASE1":2665,"PHASE1":2667,"PHASE2":2669,"PHASE3":2671,"PHASE4":2681,"NA":2683},{"trials":2666,"activeCount":8},[],{"trials":2668,"activeCount":8},[],{"trials":2670,"activeCount":8},[],{"trials":2672,"activeCount":8},[2673,2677],{"nctId":2360,"briefTitle":2361,"status":55,"phases":2674,"primaryCompletion":172,"completion":172,"start":106,"enrollment":2363,"conditions":2675,"interventions":2676},[40],[1492],[2366,2337],{"nctId":2380,"briefTitle":2381,"status":55,"phases":2678,"primaryCompletion":1093,"completion":1093,"start":57,"enrollment":2383,"conditions":2679,"interventions":2680},[40],[2385,2322,2386,2311],[2355,2388],{"trials":2682,"activeCount":8},[],{"trials":2684,"activeCount":8},[],{"intervention":2686,"totalTrials":482,"cells":2687},"Paliperidone ER OROS",{"EARLY_PHASE1":2688,"PHASE1":2690,"PHASE2":2698,"PHASE3":2700,"PHASE4":2710,"NA":2712},{"trials":2689,"activeCount":8},[],{"trials":2691,"activeCount":8},[2692],{"nctId":2693,"briefTitle":2694,"status":55,"phases":2695,"completion":89,"start":591,"enrollment":268,"conditions":2696,"interventions":2697},"NCT00758030","Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.",[38],[14],[2686],{"trials":2699,"activeCount":8},[],{"trials":2701,"activeCount":8},[2702],{"nctId":2703,"briefTitle":2704,"status":55,"phases":2705,"completion":385,"start":971,"enrollment":2706,"conditions":2707,"interventions":2708},"NCT00210769","A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia",[40],203,[14],[2709],"paliperidone ER Oros",{"trials":2711,"activeCount":8},[],{"trials":2713,"activeCount":8},[],{"intervention":2715,"totalTrials":482,"cells":2716},"Risperidone long-acting injectable",{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2721,"PHASE3":2723,"PHASE4":2738,"NA":2740},{"trials":2718,"activeCount":8},[],{"trials":2720,"activeCount":8},[],{"trials":2722,"activeCount":8},[],{"trials":2724,"activeCount":8},[2725,2732],{"nctId":2726,"briefTitle":2727,"status":55,"phases":2728,"completion":70,"start":267,"enrollment":2729,"conditions":2730,"interventions":2731},"NCT00828958","Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.",[40],53,[14],[2715],{"nctId":2733,"briefTitle":2734,"status":55,"phases":2735,"primaryCompletion":957,"completion":957,"start":80,"enrollment":618,"conditions":2736,"interventions":2737},"NCT00843687","A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.",[40],[14],[2715],{"trials":2739,"activeCount":8},[],{"trials":2741,"activeCount":8},[],{"intervention":2743,"totalTrials":482,"cells":2744},"Extended Release OROS® Paliperidone",{"EARLY_PHASE1":2745,"PHASE1":2747,"PHASE2":2749,"PHASE3":2751,"PHASE4":2765,"NA":2767},{"trials":2746,"activeCount":8},[],{"trials":2748,"activeCount":8},[],{"trials":2750,"activeCount":8},[],{"trials":2752,"activeCount":8},[2753,2759],{"nctId":2754,"briefTitle":2755,"status":55,"phases":2756,"completion":517,"start":203,"enrollment":173,"conditions":2757,"interventions":2758},"NCT00645307","A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.",[40],[14],[2743],{"nctId":2760,"briefTitle":2761,"status":55,"phases":2762,"completion":267,"start":591,"enrollment":1174,"conditions":2763,"interventions":2764},"NCT00650793","A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia",[40],[14],[2743],{"trials":2766,"activeCount":8},[],{"trials":2768,"activeCount":8},[],{"intervention":1991,"totalTrials":482,"cells":2770},{"EARLY_PHASE1":2771,"PHASE1":2773,"PHASE2":2779,"PHASE3":2781,"PHASE4":2787,"NA":2789},{"trials":2772,"activeCount":8},[],{"trials":2774,"activeCount":8},[2775],{"nctId":1982,"briefTitle":1983,"status":55,"phases":2776,"completion":564,"start":854,"enrollment":1891,"conditions":2777,"interventions":2778},[38],[1986,1987,1988,1989,137],[1991,1975,1992],{"trials":2780,"activeCount":8},[],{"trials":2782,"activeCount":8},[2783],{"nctId":2062,"briefTitle":2063,"status":55,"phases":2784,"primaryCompletion":2065,"completion":2066,"start":1101,"enrollment":2067,"conditions":2785,"interventions":2786},[40],[1987],[1975,1991,2070],{"trials":2788,"activeCount":8},[],{"trials":2790,"activeCount":8},[],{"intervention":2300,"totalTrials":285,"cells":2792},{"EARLY_PHASE1":2793,"PHASE1":2795,"PHASE2":2797,"PHASE3":2799,"PHASE4":2805,"NA":2807},{"trials":2794,"activeCount":8},[],{"trials":2796,"activeCount":8},[],{"trials":2798,"activeCount":8},[],{"trials":2800,"activeCount":8},[2801],{"nctId":2294,"briefTitle":2295,"status":55,"phases":2802,"primaryCompletion":2266,"completion":172,"start":1447,"enrollment":2297,"conditions":2803,"interventions":2804},[40],[1492],[2300,2301,2301],{"trials":2806,"activeCount":8},[],{"trials":2808,"activeCount":8},[],{"intervention":2810,"totalTrials":285,"cells":2811},"CG5503 IR; tapentadol",{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2816,"PHASE3":2818,"PHASE4":2828,"NA":2830},{"trials":2813,"activeCount":8},[],{"trials":2815,"activeCount":8},[],{"trials":2817,"activeCount":8},[],{"trials":2819,"activeCount":8},[2820],{"nctId":2821,"briefTitle":2822,"status":55,"phases":2823,"primaryCompletion":1041,"completion":1041,"start":609,"enrollment":2824,"conditions":2825,"interventions":2827},"NCT00361582","A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery",[40],669,[2330,2826,2308],"Pain Assessment",[2810],{"trials":2829,"activeCount":8},[],{"trials":2831,"activeCount":8},[],{"intervention":2833,"totalTrials":285,"cells":2834},"Pancrease MT 10.5, or MT 21",{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2839,"PHASE3":2841,"PHASE4":2854,"NA":2856},{"trials":2836,"activeCount":8},[],{"trials":2838,"activeCount":8},[],{"trials":2840,"activeCount":8},[],{"trials":2842,"activeCount":8},[2843],{"nctId":2844,"briefTitle":2845,"status":55,"phases":2846,"primaryCompletion":985,"completion":985,"start":2847,"enrollment":59,"conditions":2848,"interventions":2853},"NCT00662675","A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency",[40],"2008-08",[2849,2850,2851,2852],"Exocrine Pancreatic Insufficiency","Steatorrhea","Malabsorption Syndromes","Cystic Fibrosis",[2833],{"trials":2855,"activeCount":8},[],{"trials":2857,"activeCount":8},[],{"intervention":2859,"totalTrials":285,"cells":2860},"topiramate, propranolol",{"EARLY_PHASE1":2861,"PHASE1":2863,"PHASE2":2865,"PHASE3":2867,"PHASE4":2876,"NA":2878},{"trials":2862,"activeCount":8},[],{"trials":2864,"activeCount":8},[],{"trials":2866,"activeCount":8},[],{"trials":2868,"activeCount":8},[2869],{"nctId":2870,"briefTitle":2871,"status":55,"phases":2872,"completion":1133,"start":1165,"enrollment":2873,"conditions":2874,"interventions":2875},"NCT00236561","A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine",[40],786,[770,802,803,771],[2859],{"trials":2877,"activeCount":8},[],{"trials":2879,"activeCount":8},[],{"intervention":2881,"totalTrials":285,"cells":2882},"CG 5503;tapentadol",{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2889,"PHASE4":2900,"NA":2902},{"trials":2884,"activeCount":8},[],{"trials":2886,"activeCount":8},[],{"trials":2888,"activeCount":8},[],{"trials":2890,"activeCount":8},[2891],{"nctId":2892,"briefTitle":2893,"status":55,"phases":2894,"primaryCompletion":747,"completion":313,"start":154,"enrollment":2895,"conditions":2896,"interventions":2899},"NCT00364546","A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain",[40],877,[2330,2897,2308,2898,1492],"Pain Intensity Assessment","Sciatica",[2881],{"trials":2901,"activeCount":8},[],{"trials":2903,"activeCount":8},[],{"intervention":2905,"totalTrials":285,"cells":2906},"rabeprazole",{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2911,"PHASE3":2913,"PHASE4":2923,"NA":2925},{"trials":2908,"activeCount":8},[],{"trials":2910,"activeCount":8},[],{"trials":2912,"activeCount":8},[],{"trials":2914,"activeCount":8},[2915],{"nctId":2916,"briefTitle":2917,"status":55,"phases":2918,"primaryCompletion":2919,"completion":2919,"start":986,"enrollment":2041,"conditions":2920,"interventions":2922},"NCT00787891","A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients",[40],"2011-01",[2921],"Gastroesophageal Reflux Disease (GERD)",[2905,2905],{"trials":2924,"activeCount":8},[],{"trials":2926,"activeCount":8},[],{"intervention":2503,"totalTrials":285,"cells":2928},{"EARLY_PHASE1":2929,"PHASE1":2931,"PHASE2":2933,"PHASE3":2935,"PHASE4":2941,"NA":2943},{"trials":2930,"activeCount":8},[],{"trials":2932,"activeCount":8},[],{"trials":2934,"activeCount":8},[],{"trials":2936,"activeCount":8},[2937],{"nctId":2495,"briefTitle":2496,"status":68,"phases":2938,"primaryCompletion":1008,"completion":2498,"start":332,"enrollment":642,"conditions":2939,"interventions":2940},[40],[2500,2501],[2473,2503],{"trials":2942,"activeCount":8},[],{"trials":2944,"activeCount":8},[],{"intervention":2946,"totalTrials":285,"cells":2947},"Vincristine, DOXIL",{"EARLY_PHASE1":2948,"PHASE1":2950,"PHASE2":2952,"PHASE3":2954,"PHASE4":2966,"NA":2968},{"trials":2949,"activeCount":8},[],{"trials":2951,"activeCount":8},[],{"trials":2953,"activeCount":8},[],{"trials":2955,"activeCount":8},[2956],{"nctId":2957,"briefTitle":2958,"status":55,"phases":2959,"completion":124,"start":728,"enrollment":2960,"conditions":2961,"interventions":2965},"NCT00344422","Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma",[40],198,[326,2962,2963,2964],"Myeloma","M-Protein","Myeloma Proteins",[2946],{"trials":2967,"activeCount":8},[],{"trials":2969,"activeCount":8},[],{"intervention":1021,"totalTrials":285,"cells":2971},{"EARLY_PHASE1":2972,"PHASE1":2974,"PHASE2":2976,"PHASE3":2978,"PHASE4":2984,"NA":2986},{"trials":2973,"activeCount":8},[],{"trials":2975,"activeCount":8},[],{"trials":2977,"activeCount":8},[],{"trials":2979,"activeCount":8},[2980],{"nctId":1013,"briefTitle":1014,"status":55,"phases":2981,"primaryCompletion":1016,"completion":748,"start":1017,"enrollment":1018,"conditions":2982,"interventions":2983},[40],[26,732],[1021,925],{"trials":2985,"activeCount":8},[],{"trials":2987,"activeCount":8},[],{"intervention":2989,"totalTrials":285,"cells":2990},"Topiramate; Placebo",{"EARLY_PHASE1":2991,"PHASE1":2993,"PHASE2":2995,"PHASE3":2997,"PHASE4":3005,"NA":3007},{"trials":2992,"activeCount":8},[],{"trials":2994,"activeCount":8},[],{"trials":2996,"activeCount":8},[],{"trials":2998,"activeCount":8},[2999],{"nctId":3000,"briefTitle":3001,"status":55,"phases":3002,"completion":57,"start":565,"enrollment":936,"conditions":3003,"interventions":3004},"NCT00210535","A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine Attacks in Children",[40],[770,826],[2989],{"trials":3006,"activeCount":8},[],{"trials":3008,"activeCount":8},[],{"intervention":3010,"totalTrials":285,"cells":3011},"Ketoconazole 2% cream",{"EARLY_PHASE1":3012,"PHASE1":3014,"PHASE2":3016,"PHASE3":3018,"PHASE4":3028,"NA":3030},{"trials":3013,"activeCount":8},[],{"trials":3015,"activeCount":8},[],{"trials":3017,"activeCount":8},[],{"trials":3019,"activeCount":8},[3020],{"nctId":3021,"briefTitle":3022,"status":68,"phases":3023,"primaryCompletion":2031,"completion":2031,"start":313,"enrollment":3024,"conditions":3025,"interventions":3027},"NCT01110330","An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot",[40],583,[3026],"Tinea Pedis",[3010,3010],{"trials":3029,"activeCount":8},[],{"trials":3031,"activeCount":8},[],{"intervention":2629,"totalTrials":285,"cells":3033},{"EARLY_PHASE1":3034,"PHASE1":3036,"PHASE2":3038,"PHASE3":3040,"PHASE4":3046,"NA":3048},{"trials":3035,"activeCount":8},[],{"trials":3037,"activeCount":8},[],{"trials":3039,"activeCount":8},[],{"trials":3041,"activeCount":8},[3042],{"nctId":2619,"briefTitle":2620,"status":55,"phases":3043,"primaryCompletion":2622,"completion":2622,"start":410,"enrollment":2623,"conditions":3044,"interventions":3045},[40],[2625,2626,2627],[2600,2629],{"trials":3047,"activeCount":8},[],{"trials":3049,"activeCount":8},[],{"intervention":3051,"totalTrials":285,"cells":3052},"levofloxacin; amoxicillin\u002Fclavulanate",{"EARLY_PHASE1":3053,"PHASE1":3055,"PHASE2":3057,"PHASE3":3059,"PHASE4":3068,"NA":3070},{"trials":3054,"activeCount":8},[],{"trials":3056,"activeCount":8},[],{"trials":3058,"activeCount":8},[],{"trials":3060,"activeCount":8},[3061],{"nctId":3062,"briefTitle":3063,"status":55,"phases":3064,"completion":749,"start":546,"enrollment":3065,"conditions":3066,"interventions":3067},"NCT00051753","Levofloxacin In The Treatment Of Children With Recurrent And\u002For Persistent Acute Otitis Media",[40],1643,[1779],[3051],{"trials":3069,"activeCount":8},[],{"trials":3071,"activeCount":8},[],{"intervention":2463,"totalTrials":285,"cells":3073},{"EARLY_PHASE1":3074,"PHASE1":3076,"PHASE2":3078,"PHASE3":3080,"PHASE4":3086,"NA":3088},{"trials":3075,"activeCount":8},[],{"trials":3077,"activeCount":8},[],{"trials":3079,"activeCount":8},[],{"trials":3081,"activeCount":8},[3082],{"nctId":2457,"briefTitle":2458,"status":55,"phases":3083,"primaryCompletion":2318,"completion":2318,"start":893,"enrollment":2460,"conditions":3084,"interventions":3085},[40],[494],[2463,2060],{"trials":3087,"activeCount":8},[],{"trials":3089,"activeCount":8},[],{"intervention":3091,"totalTrials":285,"cells":3092},"norelgestromin + ethinyl estradiol; triphasil.",{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3099,"PHASE4":3111,"NA":3113},{"trials":3094,"activeCount":8},[],{"trials":3096,"activeCount":8},[],{"trials":3098,"activeCount":8},[],{"trials":3100,"activeCount":8},[3101],{"nctId":3102,"briefTitle":3103,"status":55,"phases":3104,"completion":3105,"start":1768,"enrollment":3106,"conditions":3107,"interventions":3110},"NCT00236795","A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.",[40],"1999-03",1494,[3108,3109],"Contraception","Female Contraception",[3091],{"trials":3112,"activeCount":8},[],{"trials":3114,"activeCount":8},[],{"intervention":3116,"totalTrials":285,"cells":3117},"risperidone; quetiapine",{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3124,"PHASE4":3133,"NA":3135},{"trials":3119,"activeCount":8},[],{"trials":3121,"activeCount":8},[],{"trials":3123,"activeCount":8},[],{"trials":3125,"activeCount":8},[3126],{"nctId":3127,"briefTitle":3128,"status":55,"phases":3129,"completion":749,"start":341,"enrollment":3130,"conditions":3131,"interventions":3132},"NCT00097032","Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients",[40],30,[26],[3116],{"trials":3134,"activeCount":8},[],{"trials":3136,"activeCount":8},[],{"intervention":3138,"totalTrials":285,"cells":3139},"Tipifarnib;Zarnestra; R115777",{"EARLY_PHASE1":3140,"PHASE1":3142,"PHASE2":3144,"PHASE3":3146,"PHASE4":3156,"NA":3158},{"trials":3141,"activeCount":8},[],{"trials":3143,"activeCount":8},[],{"trials":3145,"activeCount":8},[],{"trials":3147,"activeCount":8},[3148],{"nctId":3149,"briefTitle":3150,"status":55,"phases":3151,"completion":564,"start":971,"enrollment":3152,"conditions":3153,"interventions":3155},"NCT00093990","Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)",[40],457,[3154],"Acute Myeloid Leukemia",[3138],{"trials":3157,"activeCount":8},[],{"trials":3159,"activeCount":8},[],{"intervention":3161,"totalTrials":285,"cells":3162},"Extended-release galantamine hydrobromide",{"EARLY_PHASE1":3163,"PHASE1":3165,"PHASE2":3167,"PHASE3":3169,"PHASE4":3178,"NA":3180},{"trials":3164,"activeCount":8},[],{"trials":3166,"activeCount":8},[],{"trials":3168,"activeCount":8},[],{"trials":3170,"activeCount":8},[3171],{"nctId":3172,"briefTitle":3173,"status":55,"phases":3174,"completion":242,"start":115,"enrollment":3175,"conditions":3176,"interventions":3177},"NCT00077727","A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.",[40],107,[14],[3161],{"trials":3179,"activeCount":8},[],{"trials":3181,"activeCount":8},[],{"intervention":3183,"totalTrials":285,"cells":3184},"Mebendazole",{"EARLY_PHASE1":3185,"PHASE1":3187,"PHASE2":3189,"PHASE3":3191,"PHASE4":3201,"NA":3203},{"trials":3186,"activeCount":8},[],{"trials":3188,"activeCount":8},[],{"trials":3190,"activeCount":8},[],{"trials":3192,"activeCount":8},[3193],{"nctId":3194,"briefTitle":3195,"status":55,"phases":3196,"primaryCompletion":1446,"completion":1446,"start":2562,"enrollment":3197,"conditions":3198,"interventions":3200},"NCT01173562","A Safety Study of Mebendazole in Children 2 to 10 Years of Age",[40],397,[3199],"Healthy Volunteers",[3183],{"trials":3202,"activeCount":8},[],{"trials":3204,"activeCount":8},[],{"intervention":3206,"totalTrials":285,"cells":3207},"CG5503",{"EARLY_PHASE1":3208,"PHASE1":3210,"PHASE2":3212,"PHASE3":3214,"PHASE4":3224,"NA":3226},{"trials":3209,"activeCount":8},[],{"trials":3211,"activeCount":8},[],{"trials":3213,"activeCount":8},[],{"trials":3215,"activeCount":8},[3216],{"nctId":3217,"briefTitle":3218,"status":55,"phases":3219,"primaryCompletion":2847,"completion":2847,"start":1999,"enrollment":3220,"conditions":3221,"interventions":3223},"NCT00455520","A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy",[40],395,[3222],"Diabetic Neuropathy",[3206],{"trials":3225,"activeCount":8},[],{"trials":3227,"activeCount":8},[],{"intervention":3229,"totalTrials":285,"cells":3230},"norelgestromin + ethinyl estradiol",{"EARLY_PHASE1":3231,"PHASE1":3233,"PHASE2":3235,"PHASE3":3237,"PHASE4":3247,"NA":3249},{"trials":3232,"activeCount":8},[],{"trials":3234,"activeCount":8},[],{"trials":3236,"activeCount":8},[],{"trials":3238,"activeCount":8},[3239],{"nctId":3240,"briefTitle":3241,"status":55,"phases":3242,"completion":1358,"start":3243,"enrollment":3244,"conditions":3245,"interventions":3246},"NCT00236769","A Study of Efficacy and Safety With the Transdermal Contraceptive System.",[40],"1997-11",1751,[3108,3109],[3229],{"trials":3248,"activeCount":8},[],{"trials":3250,"activeCount":8},[],{"intervention":3252,"totalTrials":285,"cells":3253},"tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo",{"EARLY_PHASE1":3254,"PHASE1":3256,"PHASE2":3258,"PHASE3":3260,"PHASE4":3269,"NA":3271},{"trials":3255,"activeCount":8},[],{"trials":3257,"activeCount":8},[],{"trials":3259,"activeCount":8},[],{"trials":3261,"activeCount":8},[3262],{"nctId":3263,"briefTitle":3264,"status":55,"phases":3265,"completion":341,"start":471,"enrollment":1863,"conditions":3266,"interventions":3268},"NCT00236535","A Study of the Efficacy and Safety of Tramadol HCl\u002FAcetaminophen, Hydrocodone Bitartrate\u002FAcetaminophen and Placebo in Patients With Pain From an Ankle Sprain With a Partial Torn Ligament",[40],[3267,2311],"Sprains and Strains",[3252],{"trials":3270,"activeCount":8},[],{"trials":3272,"activeCount":8},[],{"intervention":3274,"totalTrials":285,"cells":3275},"Duragesic®",{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3280,"PHASE3":3282,"PHASE4":3291,"NA":3293},{"trials":3277,"activeCount":8},[],{"trials":3279,"activeCount":8},[],{"trials":3281,"activeCount":8},[],{"trials":3283,"activeCount":8},[3284],{"nctId":3285,"briefTitle":3286,"status":55,"phases":3287,"completion":784,"start":349,"enrollment":2433,"conditions":3288,"interventions":3290},"NCT00271466","A Study to Assess the Safety, Dose Conversion, and Dose Individualization of Duragesic® (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Narcotic Pain Relief Therapy",[40],[3289],"Chronic Pain",[3274],{"trials":3292,"activeCount":8},[],{"trials":3294,"activeCount":8},[],{"intervention":2377,"totalTrials":285,"cells":3296},{"EARLY_PHASE1":3297,"PHASE1":3299,"PHASE2":3301,"PHASE3":3303,"PHASE4":3309,"NA":3311},{"trials":3298,"activeCount":8},[],{"trials":3300,"activeCount":8},[],{"trials":3302,"activeCount":8},[],{"trials":3304,"activeCount":8},[3305],{"nctId":2368,"briefTitle":2369,"status":55,"phases":3306,"primaryCompletion":153,"completion":153,"start":2031,"enrollment":2371,"conditions":3307,"interventions":3308},[40],[2373,2374,2330],[2337,2376,2377,2378,2378],{"trials":3310,"activeCount":8},[],{"trials":3312,"activeCount":8},[],{"intervention":3314,"totalTrials":285,"cells":3315},"Prucalopride",{"EARLY_PHASE1":3316,"PHASE1":3318,"PHASE2":3320,"PHASE3":3322,"PHASE4":3333,"NA":3335},{"trials":3317,"activeCount":8},[],{"trials":3319,"activeCount":8},[],{"trials":3321,"activeCount":8},[],{"trials":3323,"activeCount":8},[3324],{"nctId":3325,"briefTitle":3326,"status":55,"phases":3327,"primaryCompletion":2508,"completion":2508,"start":3328,"enrollment":3329,"conditions":3330,"interventions":3332},"NCT01116206","An Efficacy and Safety Study of Prucalopride in Participants With Chronic Constipation",[40],"2010-05",507,[3331],"Constipation",[3314],{"trials":3334,"activeCount":8},[],{"trials":3336,"activeCount":8},[],{"intervention":3338,"totalTrials":285,"cells":3339},"Becaplermin",{"EARLY_PHASE1":3340,"PHASE1":3342,"PHASE2":3344,"PHASE3":3346,"PHASE4":3358,"NA":3360},{"trials":3341,"activeCount":8},[],{"trials":3343,"activeCount":8},[],{"trials":3345,"activeCount":8},[],{"trials":3347,"activeCount":8},[3348],{"nctId":3349,"briefTitle":3350,"status":68,"phases":3351,"completion":134,"start":1173,"enrollment":3352,"conditions":3353,"interventions":3357},"NCT00034788","A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX",[40],84,[3354,3355,3356,651],"Foot Ulcer","Diabetic Foot","Skin Ulcer",[3338],{"trials":3359,"activeCount":8},[],{"trials":3361,"activeCount":8},[],{"intervention":3363,"totalTrials":285,"cells":3364},"galantamine ER",{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3369,"PHASE3":3371,"PHASE4":3380,"NA":3382},{"trials":3366,"activeCount":8},[],{"trials":3368,"activeCount":8},[],{"trials":3370,"activeCount":8},[],{"trials":3372,"activeCount":8},[3373],{"nctId":3374,"briefTitle":3375,"status":55,"phases":3376,"completion":854,"start":203,"enrollment":3377,"conditions":3378,"interventions":3379},"NCT00082602","Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease",[40],83,[1361],[3363],{"trials":3381,"activeCount":8},[],{"trials":3383,"activeCount":8},[],{"intervention":3385,"totalTrials":285,"cells":3386},"norelgestromin + ethinyl estradiol; mercilon",{"EARLY_PHASE1":3387,"PHASE1":3389,"PHASE2":3391,"PHASE3":3393,"PHASE4":3402,"NA":3404},{"trials":3388,"activeCount":8},[],{"trials":3390,"activeCount":8},[],{"trials":3392,"activeCount":8},[],{"trials":3394,"activeCount":8},[3395],{"nctId":3396,"briefTitle":3397,"status":55,"phases":3398,"completion":3105,"start":1960,"enrollment":3399,"conditions":3400,"interventions":3401},"NCT00236782","A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.",[40],1517,[3108],[3385],{"trials":3403,"activeCount":8},[],{"trials":3405,"activeCount":8},[],{"intervention":3407,"totalTrials":285,"cells":3408},"Durogesic®",{"EARLY_PHASE1":3409,"PHASE1":3411,"PHASE2":3413,"PHASE3":3415,"PHASE4":3425,"NA":3427},{"trials":3410,"activeCount":8},[],{"trials":3412,"activeCount":8},[],{"trials":3414,"activeCount":8},[],{"trials":3416,"activeCount":8},[3417],{"nctId":3418,"briefTitle":3419,"status":55,"phases":3420,"completion":3421,"start":3422,"enrollment":1891,"conditions":3423,"interventions":3424},"NCT00271453","A Study to Assess the Safety and Effectiveness of Durogesic (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Long-term Narcotic Pain Relief Therapy",[40],"1998-10","1996-02",[3289],[3407],{"trials":3426,"activeCount":8},[],{"trials":3428,"activeCount":8},[],{"intervention":2420,"totalTrials":285,"cells":3430},{"EARLY_PHASE1":3431,"PHASE1":3433,"PHASE2":3435,"PHASE3":3437,"PHASE4":3443,"NA":3445},{"trials":3432,"activeCount":8},[],{"trials":3434,"activeCount":8},[],{"trials":3436,"activeCount":8},[],{"trials":3438,"activeCount":8},[3439],{"nctId":2413,"briefTitle":2414,"status":55,"phases":3440,"primaryCompletion":2040,"completion":1387,"start":1008,"enrollment":2416,"conditions":3441,"interventions":3442},[40],[2410,2418],[2394,2420],{"trials":3444,"activeCount":8},[],{"trials":3446,"activeCount":8},[],{"intervention":3448,"totalTrials":285,"cells":3449},"levofloxacin, azithromycin, amoxicillin\u002Fclavulanate",{"EARLY_PHASE1":3450,"PHASE1":3452,"PHASE2":3454,"PHASE3":3456,"PHASE4":3466,"NA":3468},{"trials":3451,"activeCount":8},[],{"trials":3453,"activeCount":8},[],{"trials":3455,"activeCount":8},[],{"trials":3457,"activeCount":8},[3458],{"nctId":3459,"briefTitle":3460,"status":55,"phases":3461,"completion":194,"start":1143,"enrollment":3462,"conditions":3463,"interventions":3465},"NCT00042718","A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.",[40],659,[1800,3464],"Chronic Bronchitis",[3448],{"trials":3467,"activeCount":8},[],{"trials":3469,"activeCount":8},[],{"intervention":3471,"totalTrials":285,"cells":3472},"paliperidone ER tablets, quetiapine tablets, placebo - all over encapsulated",{"EARLY_PHASE1":3473,"PHASE1":3475,"PHASE2":3477,"PHASE3":3479,"PHASE4":3488,"NA":3490},{"trials":3474,"activeCount":8},[],{"trials":3476,"activeCount":8},[],{"trials":3478,"activeCount":8},[],{"trials":3480,"activeCount":8},[3481],{"nctId":3482,"briefTitle":3483,"status":55,"phases":3484,"completion":1016,"start":1017,"enrollment":3485,"conditions":3486,"interventions":3487},"NCT00334126","Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia",[40],399,[14],[3471],{"trials":3489,"activeCount":8},[],{"trials":3491,"activeCount":8},[],{"intervention":2271,"totalTrials":285,"cells":3493},{"EARLY_PHASE1":3494,"PHASE1":3496,"PHASE2":3498,"PHASE3":3500,"PHASE4":3506,"NA":3508},{"trials":3495,"activeCount":8},[],{"trials":3497,"activeCount":8},[],{"trials":3499,"activeCount":8},[],{"trials":3501,"activeCount":8},[3502],{"nctId":2263,"briefTitle":2264,"status":68,"phases":3503,"primaryCompletion":1700,"completion":1700,"start":2266,"enrollment":2267,"conditions":3504,"interventions":3505},[40],[2269],[2220,2271],{"trials":3507,"activeCount":8},[],{"trials":3509,"activeCount":8},[],{"intervention":3511,"totalTrials":285,"cells":3512},"Norgestimate-ethinyl estradiol, with or without folic acid",{"EARLY_PHASE1":3513,"PHASE1":3515,"PHASE2":3517,"PHASE3":3519,"PHASE4":3530,"NA":3532},{"trials":3514,"activeCount":8},[],{"trials":3516,"activeCount":8},[],{"trials":3518,"activeCount":8},[],{"trials":3520,"activeCount":8},[3521],{"nctId":3522,"briefTitle":3523,"status":250,"phases":3524,"completion":2146,"enrollment":8,"conditions":3525,"interventions":3529},"NCT00301587","A Study to Evaluate Folate Levels in Women Taking Oral Contraceptives",[40],[3526,3527,3528],"Neural Tube Defects","Congenital, Hereditary, and Neonatal Diseases and Abnormalities","Nervous System Malformations",[3511],{"trials":3531,"activeCount":8},[],{"trials":3533,"activeCount":8},[],{"intervention":3535,"totalTrials":285,"cells":3536},"Paliperidone",{"EARLY_PHASE1":3537,"PHASE1":3539,"PHASE2":3541,"PHASE3":3543,"PHASE4":3551,"NA":3553},{"trials":3538,"activeCount":8},[],{"trials":3540,"activeCount":8},[],{"trials":3542,"activeCount":8},[],{"trials":3544,"activeCount":8},[3545],{"nctId":3546,"briefTitle":3547,"status":55,"phases":3548,"completion":455,"start":134,"enrollment":694,"conditions":3549,"interventions":3550},"NCT00668837","A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.",[40],[14],[3535],{"trials":3552,"activeCount":8},[],{"trials":3554,"activeCount":8},[],{"intervention":3556,"totalTrials":285,"cells":3557},"Rabeprazole sodium 5 mg",{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3562,"PHASE3":3564,"PHASE4":3576,"NA":3578},{"trials":3559,"activeCount":8},[],{"trials":3561,"activeCount":8},[],{"trials":3563,"activeCount":8},[],{"trials":3565,"activeCount":8},[3566],{"nctId":3567,"briefTitle":3568,"status":55,"phases":3569,"primaryCompletion":3570,"completion":3570,"start":3571,"enrollment":3572,"conditions":3573,"interventions":3574},"NCT00992589","Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)",[40],"2011-11","2009-11",344,[1299],[3556,3575],"Rabeprazole sodium 10 mg",{"trials":3577,"activeCount":8},[],{"trials":3579,"activeCount":8},[],{"intervention":3575,"totalTrials":285,"cells":3581},{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3586,"PHASE3":3588,"PHASE4":3594,"NA":3596},{"trials":3583,"activeCount":8},[],{"trials":3585,"activeCount":8},[],{"trials":3587,"activeCount":8},[],{"trials":3589,"activeCount":8},[3590],{"nctId":3567,"briefTitle":3568,"status":55,"phases":3591,"primaryCompletion":3570,"completion":3570,"start":3571,"enrollment":3572,"conditions":3592,"interventions":3593},[40],[1299],[3556,3575],{"trials":3595,"activeCount":8},[],{"trials":3597,"activeCount":8},[],{"intervention":3599,"totalTrials":285,"cells":3600},"Hydromorphone HCl",{"EARLY_PHASE1":3601,"PHASE1":3603,"PHASE2":3605,"PHASE3":3607,"PHASE4":3618,"NA":3620},{"trials":3602,"activeCount":8},[],{"trials":3604,"activeCount":8},[],{"trials":3606,"activeCount":8},[],{"trials":3608,"activeCount":8},[3609],{"nctId":3610,"briefTitle":3611,"status":55,"phases":3612,"primaryCompletion":3613,"completion":3613,"start":2030,"enrollment":3614,"conditions":3615,"interventions":3616},"NCT01205126","An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain",[40],"2011-02",260,[2311],[3599,3617],"Oxycodone HCl CR",{"trials":3619,"activeCount":8},[],{"trials":3621,"activeCount":8},[],{"intervention":3617,"totalTrials":285,"cells":3623},{"EARLY_PHASE1":3624,"PHASE1":3626,"PHASE2":3628,"PHASE3":3630,"PHASE4":3636,"NA":3638},{"trials":3625,"activeCount":8},[],{"trials":3627,"activeCount":8},[],{"trials":3629,"activeCount":8},[],{"trials":3631,"activeCount":8},[3632],{"nctId":3610,"briefTitle":3611,"status":55,"phases":3633,"primaryCompletion":3613,"completion":3613,"start":2030,"enrollment":3614,"conditions":3634,"interventions":3635},[40],[2311],[3599,3617],{"trials":3637,"activeCount":8},[],{"trials":3639,"activeCount":8},[],{"intervention":3641,"totalTrials":285,"cells":3642},"Topiramate; Carbamazepine; Valproate",{"EARLY_PHASE1":3643,"PHASE1":3645,"PHASE2":3647,"PHASE3":3649,"PHASE4":3659,"NA":3661},{"trials":3644,"activeCount":8},[],{"trials":3646,"activeCount":8},[],{"trials":3648,"activeCount":8},[],{"trials":3650,"activeCount":8},[3651],{"nctId":3652,"briefTitle":3653,"status":55,"phases":3654,"completion":1134,"start":3655,"enrollment":3656,"conditions":3657,"interventions":3658},"NCT00236717","A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy",[40],"1997-09",865,[23,31],[3641],{"trials":3660,"activeCount":8},[],{"trials":3662,"activeCount":8},[],{"intervention":3664,"totalTrials":285,"cells":3665},"Risperidone, long-acting injectable",{"EARLY_PHASE1":3666,"PHASE1":3668,"PHASE2":3670,"PHASE3":3672,"PHASE4":3680,"NA":3682},{"trials":3667,"activeCount":8},[],{"trials":3669,"activeCount":8},[],{"trials":3671,"activeCount":8},[],{"trials":3673,"activeCount":8},[3674],{"nctId":3675,"briefTitle":3676,"status":55,"phases":3677,"completion":893,"enrollment":59,"conditions":3678,"interventions":3679},"NCT00297388","A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder",[40],[14,938],[3664],{"trials":3681,"activeCount":8},[],{"trials":3683,"activeCount":8},[],{"intervention":2125,"totalTrials":285,"cells":3685},{"EARLY_PHASE1":3686,"PHASE1":3688,"PHASE2":3690,"PHASE3":3692,"PHASE4":3698,"NA":3700},{"trials":3687,"activeCount":8},[],{"trials":3689,"activeCount":8},[],{"trials":3691,"activeCount":8},[],{"trials":3693,"activeCount":8},[3694],{"nctId":2120,"briefTitle":2121,"status":55,"phases":3695,"primaryCompletion":564,"completion":1270,"start":114,"enrollment":1537,"conditions":3696,"interventions":3697},[40],[326],[2125,1992,2060],{"trials":3699,"activeCount":8},[],{"trials":3701,"activeCount":8},[],{"intervention":3703,"totalTrials":285,"cells":3704},"Paliperidone extended-release",{"EARLY_PHASE1":3705,"PHASE1":3707,"PHASE2":3709,"PHASE3":3711,"PHASE4":3719,"NA":3721},{"trials":3706,"activeCount":8},[],{"trials":3708,"activeCount":8},[],{"trials":3710,"activeCount":8},[],{"trials":3712,"activeCount":8},[3713],{"nctId":3714,"briefTitle":3715,"status":55,"phases":3716,"primaryCompletion":747,"completion":747,"start":267,"enrollment":1174,"conditions":3717,"interventions":3718},"NCT00299715","A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder",[40],[26,732],[3703],{"trials":3720,"activeCount":8},[],{"trials":3722,"activeCount":8},[],{"intervention":3724,"totalTrials":285,"cells":3725},"tramadol, acetaminophen",{"EARLY_PHASE1":3726,"PHASE1":3728,"PHASE2":3730,"PHASE3":3732,"PHASE4":3741,"NA":3743},{"trials":3727,"activeCount":8},[],{"trials":3729,"activeCount":8},[],{"trials":3731,"activeCount":8},[],{"trials":3733,"activeCount":8},[3734],{"nctId":3735,"briefTitle":3736,"status":55,"phases":3737,"completion":749,"start":471,"enrollment":3738,"conditions":3739,"interventions":3740},"NCT00210847","A Study Comparing the Effectiveness and Safety of Tramadol HCl\u002FAcetaminophen Versus Placebo for the Treatment of Painful Neuropathy in Diabetic Patients",[40],313,[651],[3724],{"trials":3742,"activeCount":8},[],{"trials":3744,"activeCount":8},[],{"intervention":3746,"totalTrials":285,"cells":3747},"CAELYX",{"EARLY_PHASE1":3748,"PHASE1":3750,"PHASE2":3752,"PHASE3":3754,"PHASE4":3764,"NA":3766},{"trials":3749,"activeCount":8},[],{"trials":3751,"activeCount":8},[],{"trials":3753,"activeCount":8},[],{"trials":3755,"activeCount":8},[3756],{"nctId":3757,"briefTitle":3758,"status":68,"phases":3759,"completion":668,"start":1944,"enrollment":3760,"conditions":3761,"interventions":3762},"NCT00653952","CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy",[40],220,[2009],[3746,3763],"Paclitaxel HCl",{"trials":3765,"activeCount":8},[],{"trials":3767,"activeCount":8},[],{"intervention":3763,"totalTrials":285,"cells":3769},{"EARLY_PHASE1":3770,"PHASE1":3772,"PHASE2":3774,"PHASE3":3776,"PHASE4":3782,"NA":3784},{"trials":3771,"activeCount":8},[],{"trials":3773,"activeCount":8},[],{"trials":3775,"activeCount":8},[],{"trials":3777,"activeCount":8},[3778],{"nctId":3757,"briefTitle":3758,"status":68,"phases":3779,"completion":668,"start":1944,"enrollment":3760,"conditions":3780,"interventions":3781},[40],[2009],[3746,3763],{"trials":3783,"activeCount":8},[],{"trials":3785,"activeCount":8},[],{"intervention":3787,"totalTrials":285,"cells":3788},"doripenum",{"EARLY_PHASE1":3789,"PHASE1":3791,"PHASE2":3793,"PHASE3":3795,"PHASE4":3803,"NA":3805},{"trials":3790,"activeCount":8},[],{"trials":3792,"activeCount":8},[],{"trials":3794,"activeCount":8},[],{"trials":3796,"activeCount":8},[3797],{"nctId":3798,"briefTitle":2250,"status":55,"phases":3799,"completion":234,"start":471,"enrollment":3800,"conditions":3801,"interventions":3802},"NCT00229021",[40],741,[1741,1742],[3787],{"trials":3804,"activeCount":8},[],{"trials":3806,"activeCount":8},[],{"intervention":3808,"totalTrials":285,"cells":3809},"Oxycodone HCL IR",{"EARLY_PHASE1":3810,"PHASE1":3812,"PHASE2":3814,"PHASE3":3816,"PHASE4":3825,"NA":3827},{"trials":3811,"activeCount":8},[],{"trials":3813,"activeCount":8},[],{"trials":3815,"activeCount":8},[],{"trials":3817,"activeCount":8},[3818],{"nctId":3819,"briefTitle":3820,"status":68,"phases":3821,"primaryCompletion":1447,"completion":1447,"start":609,"enrollment":1798,"conditions":3822,"interventions":3824},"NCT00364533","A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety",[40],[3823],"Arthroplasty",[2378,3808,2378],{"trials":3826,"activeCount":8},[],{"trials":3828,"activeCount":8},[],{"intervention":3830,"totalTrials":285,"cells":3831},"topiramate, phenytoin",{"EARLY_PHASE1":3832,"PHASE1":3834,"PHASE2":3836,"PHASE3":3838,"PHASE4":3847,"NA":3849},{"trials":3833,"activeCount":8},[],{"trials":3835,"activeCount":8},[],{"trials":3837,"activeCount":8},[],{"trials":3839,"activeCount":8},[3840],{"nctId":3841,"briefTitle":3842,"status":55,"phases":3843,"completion":1041,"start":124,"enrollment":3844,"conditions":3845,"interventions":3846},"NCT00210782","A Comparison of the Effectiveness and Safety of Topiramate and Phenytoin in Patients With New Onset Epilepsy Requiring Rapid Initiation of Antiepileptic Drug Treatment",[40],262,[23],[3830],{"trials":3848,"activeCount":8},[],{"trials":3850,"activeCount":8},[],{"intervention":2070,"totalTrials":285,"cells":3852},{"EARLY_PHASE1":3853,"PHASE1":3855,"PHASE2":3857,"PHASE3":3859,"PHASE4":3865,"NA":3867},{"trials":3854,"activeCount":8},[],{"trials":3856,"activeCount":8},[],{"trials":3858,"activeCount":8},[],{"trials":3860,"activeCount":8},[3861],{"nctId":2062,"briefTitle":2063,"status":55,"phases":3862,"primaryCompletion":2065,"completion":2066,"start":1101,"enrollment":2067,"conditions":3863,"interventions":3864},[40],[1987],[1975,1991,2070],{"trials":3866,"activeCount":8},[],{"trials":3868,"activeCount":8},[],{"intervention":3870,"totalTrials":285,"cells":3871},"Gemcitabine with R115777",{"EARLY_PHASE1":3872,"PHASE1":3874,"PHASE2":3876,"PHASE3":3878,"PHASE4":3890,"NA":3892},{"trials":3873,"activeCount":8},[],{"trials":3875,"activeCount":8},[],{"trials":3877,"activeCount":8},[],{"trials":3879,"activeCount":8},[3880],{"nctId":3881,"briefTitle":3882,"status":55,"phases":3883,"completion":1313,"start":3884,"enrollment":3885,"conditions":3886,"interventions":3888},"NCT00005648","Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer",[40],"1999-11",688,[3887],"Pancreatic Neoplasms",[3870,3889],"Gemcitabine with Placebo",{"trials":3891,"activeCount":8},[],{"trials":3893,"activeCount":8},[],{"intervention":3889,"totalTrials":285,"cells":3895},{"EARLY_PHASE1":3896,"PHASE1":3898,"PHASE2":3900,"PHASE3":3902,"PHASE4":3908,"NA":3910},{"trials":3897,"activeCount":8},[],{"trials":3899,"activeCount":8},[],{"trials":3901,"activeCount":8},[],{"trials":3903,"activeCount":8},[3904],{"nctId":3881,"briefTitle":3882,"status":55,"phases":3905,"completion":1313,"start":3884,"enrollment":3885,"conditions":3906,"interventions":3907},[40],[3887],[3870,3889],{"trials":3909,"activeCount":8},[],{"trials":3911,"activeCount":8},[],{"intervention":3913,"totalTrials":285,"cells":3914},"Pegylated liposomal doxorubicin",{"EARLY_PHASE1":3915,"PHASE1":3917,"PHASE2":3919,"PHASE3":3921,"PHASE4":3931,"NA":3933},{"trials":3916,"activeCount":8},[],{"trials":3918,"activeCount":8},[],{"trials":3920,"activeCount":8},[],{"trials":3922,"activeCount":8},[3923],{"nctId":3924,"briefTitle":3925,"status":68,"phases":3926,"primaryCompletion":385,"completion":385,"start":193,"enrollment":972,"conditions":3927,"interventions":3929},"NCT00082095","To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older",[40],[3928],"Metastatic Breast Cancer",[3913,3930],"Capecitabine",{"trials":3932,"activeCount":8},[],{"trials":3934,"activeCount":8},[],{"intervention":3930,"totalTrials":285,"cells":3936},{"EARLY_PHASE1":3937,"PHASE1":3939,"PHASE2":3941,"PHASE3":3943,"PHASE4":3949,"NA":3951},{"trials":3938,"activeCount":8},[],{"trials":3940,"activeCount":8},[],{"trials":3942,"activeCount":8},[],{"trials":3944,"activeCount":8},[3945],{"nctId":3924,"briefTitle":3925,"status":68,"phases":3946,"primaryCompletion":385,"completion":385,"start":193,"enrollment":972,"conditions":3947,"interventions":3948},[40],[3928],[3913,3930],{"trials":3950,"activeCount":8},[],{"trials":3952,"activeCount":8},[],{"intervention":3954,"totalTrials":285,"cells":3955},"Paliperidone palmitate 25 mg eq.",{"EARLY_PHASE1":3956,"PHASE1":3958,"PHASE2":3960,"PHASE3":3962,"PHASE4":3973,"NA":3975},{"trials":3957,"activeCount":8},[],{"trials":3959,"activeCount":8},[],{"trials":3961,"activeCount":8},[],{"trials":3963,"activeCount":8},[3964],{"nctId":3965,"briefTitle":3966,"status":55,"phases":3967,"primaryCompletion":171,"completion":171,"start":957,"enrollment":3968,"conditions":3969,"interventions":3970},"NCT00590577","Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia",[40],652,[14],[3954,3971,3972],"Paliperidone palmitate 150 mg eq.","Paliperidone palmitate 100 mg eq.",{"trials":3974,"activeCount":8},[],{"trials":3976,"activeCount":8},[],{"intervention":3971,"totalTrials":285,"cells":3978},{"EARLY_PHASE1":3979,"PHASE1":3981,"PHASE2":3983,"PHASE3":3985,"PHASE4":3991,"NA":3993},{"trials":3980,"activeCount":8},[],{"trials":3982,"activeCount":8},[],{"trials":3984,"activeCount":8},[],{"trials":3986,"activeCount":8},[3987],{"nctId":3965,"briefTitle":3966,"status":55,"phases":3988,"primaryCompletion":171,"completion":171,"start":957,"enrollment":3968,"conditions":3989,"interventions":3990},[40],[14],[3954,3971,3972],{"trials":3992,"activeCount":8},[],{"trials":3994,"activeCount":8},[],{"intervention":3972,"totalTrials":285,"cells":3996},{"EARLY_PHASE1":3997,"PHASE1":3999,"PHASE2":4001,"PHASE3":4003,"PHASE4":4009,"NA":4011},{"trials":3998,"activeCount":8},[],{"trials":4000,"activeCount":8},[],{"trials":4002,"activeCount":8},[],{"trials":4004,"activeCount":8},[4005],{"nctId":3965,"briefTitle":3966,"status":55,"phases":4006,"primaryCompletion":171,"completion":171,"start":957,"enrollment":3968,"conditions":4007,"interventions":4008},[40],[14],[3954,3971,3972],{"trials":4010,"activeCount":8},[],{"trials":4012,"activeCount":8},[],{"intervention":1395,"totalTrials":285,"cells":4014},{"EARLY_PHASE1":4015,"PHASE1":4017,"PHASE2":4019,"PHASE3":4021,"PHASE4":4027,"NA":4029},{"trials":4016,"activeCount":8},[],{"trials":4018,"activeCount":8},[],{"trials":4020,"activeCount":8},[],{"trials":4022,"activeCount":8},[4023],{"nctId":1384,"briefTitle":1385,"status":55,"phases":4024,"primaryCompletion":1387,"completion":1387,"start":1101,"enrollment":1388,"conditions":4025,"interventions":4026},[40],[1390,1391,1392,1393],[1395,1396,1397],{"trials":4028,"activeCount":8},[],{"trials":4030,"activeCount":8},[],{"intervention":1396,"totalTrials":285,"cells":4032},{"EARLY_PHASE1":4033,"PHASE1":4035,"PHASE2":4037,"PHASE3":4039,"PHASE4":4045,"NA":4047},{"trials":4034,"activeCount":8},[],{"trials":4036,"activeCount":8},[],{"trials":4038,"activeCount":8},[],{"trials":4040,"activeCount":8},[4041],{"nctId":1384,"briefTitle":1385,"status":55,"phases":4042,"primaryCompletion":1387,"completion":1387,"start":1101,"enrollment":1388,"conditions":4043,"interventions":4044},[40],[1390,1391,1392,1393],[1395,1396,1397],{"trials":4046,"activeCount":8},[],{"trials":4048,"activeCount":8},[],{"intervention":4050,"totalTrials":285,"cells":4051},"Epoetin alfa 3 times weekly \u002Fonce weekly",{"EARLY_PHASE1":4052,"PHASE1":4054,"PHASE2":4056,"PHASE3":4058,"PHASE4":4068,"NA":4070},{"trials":4053,"activeCount":8},[],{"trials":4055,"activeCount":8},[],{"trials":4057,"activeCount":8},[],{"trials":4059,"activeCount":8},[4060],{"nctId":4061,"briefTitle":4062,"status":55,"phases":4063,"primaryCompletion":516,"completion":516,"start":70,"enrollment":438,"conditions":4064,"interventions":4065},"NCT00440557","An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease",[40],[20],[4050,4066,4067],"Epoetin alfa once weekly","Epoetin alfa once every two weeks",{"trials":4069,"activeCount":8},[],{"trials":4071,"activeCount":8},[],{"intervention":4066,"totalTrials":285,"cells":4073},{"EARLY_PHASE1":4074,"PHASE1":4076,"PHASE2":4078,"PHASE3":4080,"PHASE4":4086,"NA":4088},{"trials":4075,"activeCount":8},[],{"trials":4077,"activeCount":8},[],{"trials":4079,"activeCount":8},[],{"trials":4081,"activeCount":8},[4082],{"nctId":4061,"briefTitle":4062,"status":55,"phases":4083,"primaryCompletion":516,"completion":516,"start":70,"enrollment":438,"conditions":4084,"interventions":4085},[40],[20],[4050,4066,4067],{"trials":4087,"activeCount":8},[],{"trials":4089,"activeCount":8},[],{"intervention":4067,"totalTrials":285,"cells":4091},{"EARLY_PHASE1":4092,"PHASE1":4094,"PHASE2":4096,"PHASE3":4098,"PHASE4":4104,"NA":4106},{"trials":4093,"activeCount":8},[],{"trials":4095,"activeCount":8},[],{"trials":4097,"activeCount":8},[],{"trials":4099,"activeCount":8},[4100],{"nctId":4061,"briefTitle":4062,"status":55,"phases":4101,"primaryCompletion":516,"completion":516,"start":70,"enrollment":438,"conditions":4102,"interventions":4103},[40],[20],[4050,4066,4067],{"trials":4105,"activeCount":8},[],{"trials":4107,"activeCount":8},[],{"intervention":4109,"totalTrials":285,"cells":4110},"Paliperidone ER OROS®",{"EARLY_PHASE1":4111,"PHASE1":4113,"PHASE2":4115,"PHASE3":4117,"PHASE4":4125,"NA":4127},{"trials":4112,"activeCount":8},[],{"trials":4114,"activeCount":8},[],{"trials":4116,"activeCount":8},[],{"trials":4118,"activeCount":8},[4119],{"nctId":4120,"briefTitle":4121,"status":55,"phases":4122,"completion":767,"start":124,"enrollment":164,"conditions":4123,"interventions":4124},"NCT00752427","24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia",[40],[14],[4109],{"trials":4126,"activeCount":8},[],{"trials":4128,"activeCount":8},[],{"intervention":4130,"totalTrials":285,"cells":4131},"levofloxacin; imipenem\u002Fcilastitin",{"EARLY_PHASE1":4132,"PHASE1":4134,"PHASE2":4136,"PHASE3":4138,"PHASE4":4150,"NA":4152},{"trials":4133,"activeCount":8},[],{"trials":4135,"activeCount":8},[],{"trials":4137,"activeCount":8},[],{"trials":4139,"activeCount":8},[4140],{"nctId":4141,"briefTitle":4142,"status":55,"phases":4143,"completion":4144,"start":4145,"enrollment":4146,"conditions":4147,"interventions":4149},"NCT00236834","A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem\u002FCilastatin in Patients With Pneumonia Acquired During Hospitalization",[40],"2001-06","1997-12",438,[4148],"Nosocomial Pneumonia",[4130],{"trials":4151,"activeCount":8},[],{"trials":4153,"activeCount":8},[],{"intervention":4155,"totalTrials":285,"cells":4156},"CG5503 IR;tapentadol",{"EARLY_PHASE1":4157,"PHASE1":4159,"PHASE2":4161,"PHASE3":4163,"PHASE4":4172,"NA":4174},{"trials":4158,"activeCount":8},[],{"trials":4160,"activeCount":8},[],{"trials":4162,"activeCount":8},[],{"trials":4164,"activeCount":8},[4165],{"nctId":4166,"briefTitle":4167,"status":55,"phases":4168,"primaryCompletion":233,"completion":233,"enrollment":4169,"conditions":4170,"interventions":4171},"NCT00364247","A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo Followed by a Voluntary Open Label Extension for Safety.",[40],602,[2308,2309,2310,2826,2277],[4155],{"trials":4173,"activeCount":8},[],{"trials":4175,"activeCount":8},[],{"intervention":4177,"totalTrials":34,"cells":4178},"Canagliflozin",{"EARLY_PHASE1":4179,"PHASE1":4181,"PHASE2":4283,"PHASE3":4301,"PHASE4":4303,"NA":4305},{"trials":4180,"activeCount":8},[],{"trials":4182,"activeCount":8},[4183,4191,4199,4206,4213,4220,4228,4235,4242,4249,4255,4261,4268,4275],{"nctId":4184,"briefTitle":4185,"status":55,"phases":4186,"primaryCompletion":4187,"completion":4187,"start":4188,"enrollment":506,"conditions":4189,"interventions":4190},"NCT01756404","Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers",[38],"2007-12-05","2007-06-14",[17],[4177],{"nctId":4192,"briefTitle":4193,"status":55,"phases":4194,"primaryCompletion":2040,"completion":2040,"start":1269,"enrollment":4195,"conditions":4196,"interventions":4197},"NCT01395927","A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers",[38],14,[17],[4198,4177],"Rifampin",{"nctId":4200,"briefTitle":4201,"status":55,"phases":4202,"primaryCompletion":171,"completion":171,"start":516,"enrollment":3130,"conditions":4203,"interventions":4204},"NCT01714193","A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers",[38],[17],[4205,4177],"Oral contraceptive",{"nctId":4207,"briefTitle":4208,"status":55,"phases":4209,"primaryCompletion":1822,"completion":1822,"start":333,"enrollment":268,"conditions":4210,"interventions":4211},"NCT01787357","A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)",[38],[17],[4177,4212],"Moxifloxacin",{"nctId":4214,"briefTitle":4215,"status":55,"phases":4216,"primaryCompletion":1101,"completion":1101,"start":171,"enrollment":59,"conditions":4217,"interventions":4219},"NCT01759576","A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function",[38],[4218,17],"Renal Insufficiency",[4177],{"nctId":4221,"briefTitle":4222,"status":55,"phases":4223,"primaryCompletion":4224,"completion":4224,"start":2483,"enrollment":987,"conditions":4225,"interventions":4227},"NCT01186588","A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function",[38],"2011-04",[17,4226],"Hepatic Insufficiency",[4177],{"nctId":4229,"briefTitle":4230,"status":55,"phases":4231,"primaryCompletion":4224,"completion":4224,"start":3613,"enrollment":1709,"conditions":4232,"interventions":4233},"NCT01718652","A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers",[38],[17],[4177,4234],"Cyclosporine",{"nctId":4236,"briefTitle":4237,"status":55,"phases":4238,"completion":1269,"start":2919,"enrollment":4239,"conditions":4240,"interventions":4241},"NCT01273558","A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus",[38],28,[29],[4177],{"nctId":4243,"briefTitle":4244,"status":55,"phases":4245,"primaryCompletion":748,"completion":748,"start":564,"enrollment":1709,"conditions":4246,"interventions":4247},"NCT01756417","A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers",[38],[17],[4248,4177],"Metformin",{"nctId":4250,"briefTitle":4251,"status":55,"phases":4252,"completion":2498,"start":3328,"enrollment":218,"conditions":4253,"interventions":4254},"NCT01157000","A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers",[38],[17],[4177],{"nctId":4256,"briefTitle":4257,"status":55,"phases":4258,"primaryCompletion":1700,"completion":1700,"start":4224,"enrollment":987,"conditions":4259,"interventions":4260},"NCT01343290","The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers",[38],[17],[4177],{"nctId":4262,"briefTitle":4263,"status":55,"phases":4264,"primaryCompletion":1822,"completion":1822,"start":1093,"enrollment":90,"conditions":4265,"interventions":4266},"NCT01733108","A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers",[38],[17],[4267,4177],"Glyburide",{"nctId":4269,"briefTitle":4270,"status":55,"phases":4271,"primaryCompletion":1822,"completion":1822,"start":2847,"enrollment":926,"conditions":4272,"interventions":4273},"NCT01821027","A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy Volunteers",[38],[17],[4274,4177],"Simvastatin",{"nctId":4276,"briefTitle":4277,"status":55,"phases":4278,"primaryCompletion":1445,"completion":1445,"start":2191,"enrollment":1709,"conditions":4279,"interventions":4280},"NCT01714206","A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.",[38],[17],[4281,4282,4177],"Digoxin 0.5 mg","Digoxin 0.25 mg",{"trials":4284,"activeCount":8},[4285,4292],{"nctId":4286,"briefTitle":4287,"status":55,"phases":4288,"primaryCompletion":1822,"completion":1822,"start":172,"enrollment":4289,"conditions":4290,"interventions":4291},"NCT00650806","A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes",[39],376,[33],[4177],{"nctId":4293,"briefTitle":4294,"status":55,"phases":4295,"primaryCompletion":986,"completion":986,"start":2266,"enrollment":704,"conditions":4296,"interventions":4299},"NCT00642278","An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes",[39],[4297,4298],"Diabetes Mellitus, Type II","Diabetes Mellitus, Non Insulin Dependent",[4177,4300],"Sitagliptin",{"trials":4302,"activeCount":8},[],{"trials":4304,"activeCount":8},[],{"trials":4306,"activeCount":8},[],{"intervention":4308,"totalTrials":998,"cells":4309},"JNJ-31001074",{"EARLY_PHASE1":4310,"PHASE1":4312,"PHASE2":4343,"PHASE3":4351,"PHASE4":4353,"NA":4355},{"trials":4311,"activeCount":8},[],{"trials":4313,"activeCount":8},[4314,4321,4330,4336],{"nctId":4315,"briefTitle":4316,"status":55,"phases":4317,"completion":3571,"start":2191,"enrollment":1107,"conditions":4318,"interventions":4320},"NCT00915434","A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers",[38],[17,4319],"Pharmacokinetics",[4308],{"nctId":4322,"briefTitle":4323,"status":55,"phases":4324,"primaryCompletion":2030,"completion":2030,"start":4325,"enrollment":1709,"conditions":4326,"interventions":4329},"NCT00890292","A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)",[38],"2009-05",[4327,4328],"Attention Deficit Hyperactivity Disorder","Attention Deficit Disorders With Hyperactivity",[4308],{"nctId":4331,"briefTitle":4332,"status":55,"phases":4333,"primaryCompletion":3571,"completion":3571,"start":4325,"enrollment":1709,"conditions":4334,"interventions":4335},"NCT00890240","A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)",[38],[4327,4328],[4308],{"nctId":4337,"briefTitle":4338,"status":250,"phases":4339,"completion":2508,"enrollment":8,"conditions":4340,"interventions":4342},"NCT00915668","A Study to Evaluate the Pharmacokinetic Drug Interaction Between Multiple Doses of JNJ-31001074 and a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Women",[38],[4319,4341,17],"Drug Interactions",[4308],{"trials":4344,"activeCount":8},[4345],{"nctId":4346,"briefTitle":4347,"status":55,"phases":4348,"primaryCompletion":1093,"completion":1093,"start":1447,"enrollment":557,"conditions":4349,"interventions":4350},"NCT00566449","A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit\u002FHyperactivity Disorder.",[39],[4327],[4308,4308],{"trials":4352,"activeCount":8},[],{"trials":4354,"activeCount":8},[],{"trials":4356,"activeCount":8},[],{"intervention":2356,"totalTrials":998,"cells":4358},{"EARLY_PHASE1":4359,"PHASE1":4361,"PHASE2":4363,"PHASE3":4404,"PHASE4":4406,"NA":4408},{"trials":4360,"activeCount":8},[],{"trials":4362,"activeCount":8},[],{"trials":4364,"activeCount":8},[4365,4369,4378,4389,4395],{"nctId":2346,"briefTitle":2347,"status":68,"phases":4366,"primaryCompletion":2349,"completion":2349,"start":2350,"enrollment":2351,"conditions":4367,"interventions":4368},[39],[2330,2322,2311,2308,2353],[2355,2356,2356],{"nctId":4370,"briefTitle":4371,"status":68,"phases":4372,"primaryCompletion":1269,"completion":1269,"start":1445,"enrollment":374,"conditions":4373,"interventions":4377},"NCT00964990","A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)",[39],[2311,4374,4375,4376],"Neuralgia, Postherpetic","Neuralgia","Mononeuropathies",[2356],{"nctId":4379,"briefTitle":4380,"status":68,"phases":4381,"primaryCompletion":4382,"completion":4382,"start":4383,"enrollment":72,"conditions":4384,"interventions":4388},"NCT01060254","A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain",[39],"2011-06-24","2010-04-06",[4385,1789,4386,4387],"Cystitis, Interstitial","Urinary Bladder Diseases","Cystitis",[2356],{"nctId":4390,"briefTitle":4391,"status":68,"phases":4392,"primaryCompletion":1700,"completion":1700,"start":3571,"enrollment":448,"conditions":4393,"interventions":4394},"NCT00993018","A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy",[39],[3222],[2356,2356,2356],{"nctId":4396,"briefTitle":4397,"status":68,"phases":4398,"primaryCompletion":4399,"completion":4399,"start":4400,"enrollment":4401,"conditions":4402,"interventions":4403},"NCT00973141","A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain",[39],"2011-06-30","2009-09-16",467,[2330,2385,2322,2311,2308,2353],[2356,2356,2356,2356,2356],{"trials":4405,"activeCount":8},[],{"trials":4407,"activeCount":8},[],{"trials":4409,"activeCount":8},[],{"intervention":4411,"totalTrials":2442,"cells":4412},"JNJ-41443532",{"EARLY_PHASE1":4413,"PHASE1":4415,"PHASE2":4430,"PHASE3":4441,"PHASE4":4443,"NA":4445},{"trials":4414,"activeCount":8},[],{"trials":4416,"activeCount":8},[4417,4423],{"nctId":4418,"briefTitle":4419,"status":55,"phases":4420,"completion":2483,"start":3328,"enrollment":557,"conditions":4421,"interventions":4422},"NCT01105780","JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study",[38],[17],[4411],{"nctId":4424,"briefTitle":4425,"status":55,"phases":4426,"completion":2484,"start":2562,"enrollment":4427,"conditions":4428,"interventions":4429},"NCT01106469","Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of Single and Multiple Ascending Doses of JNJ-41443532 in Healthy Male Participants",[38],74,[17],[4411,4411,4411,4411,4411,4411],{"trials":4431,"activeCount":8},[4432],{"nctId":4433,"briefTitle":4434,"status":55,"phases":4435,"primaryCompletion":1700,"completion":1700,"start":4436,"enrollment":4437,"conditions":4438,"interventions":4439},"NCT01230749","A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus",[39],"2010-12",89,[29],[4411,4440],"Pioglitazone 30 mg",{"trials":4442,"activeCount":8},[],{"trials":4444,"activeCount":8},[],{"trials":4446,"activeCount":8},[],{"intervention":4448,"totalTrials":2442,"cells":4449},"ZARNESTRA, tipifarnib, R115777",{"EARLY_PHASE1":4450,"PHASE1":4452,"PHASE2":4454,"PHASE3":4477,"PHASE4":4479,"NA":4481},{"trials":4451,"activeCount":8},[],{"trials":4453,"activeCount":8},[],{"trials":4455,"activeCount":8},[4456,4463,4471],{"nctId":4457,"briefTitle":4458,"status":55,"phases":4459,"primaryCompletion":71,"completion":4460,"start":727,"enrollment":2067,"conditions":4461,"interventions":4462},"NCT00050141","Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer",[39],"2008-01",[494],[4448],{"nctId":4464,"briefTitle":4465,"status":55,"phases":4466,"completion":400,"start":1920,"enrollment":4467,"conditions":4468,"interventions":4470},"NCT00050154","Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)",[39],82,[4469],"Myelodysplastic Syndrome",[4448],{"nctId":4472,"briefTitle":4473,"status":55,"phases":4474,"completion":767,"start":758,"enrollment":2177,"conditions":4475,"interventions":4476},"NCT00048503","Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older",[39],[3154],[4448],{"trials":4478,"activeCount":8},[],{"trials":4480,"activeCount":8},[],{"trials":4482,"activeCount":8},[],{"intervention":4484,"totalTrials":482,"cells":4485},"PROCRIT",{"EARLY_PHASE1":4486,"PHASE1":4488,"PHASE2":4490,"PHASE3":4506,"PHASE4":4508,"NA":4510},{"trials":4487,"activeCount":8},[],{"trials":4489,"activeCount":8},[],{"trials":4491,"activeCount":8},[4492,4499],{"nctId":4493,"briefTitle":4494,"status":68,"phases":4495,"primaryCompletion":333,"completion":333,"start":527,"enrollment":4496,"conditions":4497,"interventions":4498},"NCT00210626","Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa",[39],192,[20],[4484],{"nctId":4500,"briefTitle":4501,"status":55,"phases":4502,"completion":517,"start":749,"enrollment":4503,"conditions":4504,"interventions":4505},"NCT00210600","Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy",[39],186,[20],[4484],{"trials":4507,"activeCount":8},[],{"trials":4509,"activeCount":8},[],{"trials":4511,"activeCount":8},[],{"intervention":2566,"totalTrials":482,"cells":4513},{"EARLY_PHASE1":4514,"PHASE1":4516,"PHASE2":4518,"PHASE3":4531,"PHASE4":4533,"NA":4535},{"trials":4515,"activeCount":8},[],{"trials":4517,"activeCount":8},[],{"trials":4519,"activeCount":8},[4520,4527],{"nctId":4521,"briefTitle":4522,"status":55,"phases":4523,"primaryCompletion":2318,"completion":2318,"start":1093,"enrollment":4524,"conditions":4525,"interventions":4526},"NCT01812642","A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia",[39],33,[14],[2566],{"nctId":2559,"briefTitle":2560,"status":55,"phases":4528,"primaryCompletion":2562,"completion":2562,"start":1101,"enrollment":2563,"conditions":4529,"interventions":4530},[39],[14],[2566,2566,2566,1011],{"trials":4532,"activeCount":8},[],{"trials":4534,"activeCount":8},[],{"trials":4536,"activeCount":8},[],{"intervention":4248,"totalTrials":482,"cells":4538},{"EARLY_PHASE1":4539,"PHASE1":4541,"PHASE2":4547,"PHASE3":4559,"PHASE4":4561,"NA":4563},{"trials":4540,"activeCount":8},[],{"trials":4542,"activeCount":8},[4543],{"nctId":4243,"briefTitle":4244,"status":55,"phases":4544,"primaryCompletion":748,"completion":748,"start":564,"enrollment":1709,"conditions":4545,"interventions":4546},[38],[17],[4248,4177],{"trials":4548,"activeCount":8},[4549],{"nctId":4550,"briefTitle":4551,"status":55,"phases":4552,"primaryCompletion":1822,"completion":1822,"start":1447,"enrollment":4553,"conditions":4554,"interventions":4557},"NCT00672386","A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes",[39],352,[29,1307,4555,4556],"Endocrine System Diseases","Nutritional and Metabolic Diseases",[4558,4558,4558,4248],"JNJ16269110",{"trials":4560,"activeCount":8},[],{"trials":4562,"activeCount":8},[],{"trials":4564,"activeCount":8},[],{"intervention":4566,"totalTrials":482,"cells":4567},"R256918",{"EARLY_PHASE1":4568,"PHASE1":4570,"PHASE2":4572,"PHASE3":4591,"PHASE4":4593,"NA":4595},{"trials":4569,"activeCount":8},[],{"trials":4571,"activeCount":8},[],{"trials":4573,"activeCount":8},[4574,4584],{"nctId":4575,"briefTitle":4576,"status":55,"phases":4577,"primaryCompletion":2031,"completion":2031,"start":516,"enrollment":4578,"conditions":4579,"interventions":4583},"NCT01041677","A Study of the Safety of R256918 in Obese Patients",[39],71,[33,4556,4580,4581,4582],"Metabolic Diseases","Nutrition Disorders","Overweight",[4566,4566],{"nctId":4585,"briefTitle":4586,"status":55,"phases":4587,"primaryCompletion":333,"completion":333,"start":748,"enrollment":4588,"conditions":4589,"interventions":4590},"NCT00622765","A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients",[39],321,[33,4556,4580,4581,4582],[4566,4566,4566],{"trials":4592,"activeCount":8},[],{"trials":4594,"activeCount":8},[],{"trials":4596,"activeCount":8},[],{"intervention":4598,"totalTrials":482,"cells":4599},"tapentadol HCl",{"EARLY_PHASE1":4600,"PHASE1":4602,"PHASE2":4604,"PHASE3":4623,"PHASE4":4625,"NA":4627},{"trials":4601,"activeCount":8},[],{"trials":4603,"activeCount":8},[],{"trials":4605,"activeCount":8},[4606,4614],{"nctId":4607,"briefTitle":4608,"status":55,"phases":4609,"completion":527,"start":114,"enrollment":4610,"conditions":4611,"interventions":4613},"NCT00806247","A Randomized, Double-Blind, Parallel-Arm, Placebo and Active Controlled Dose-Ranging Study of the Efficacy and Safety of Multiple Doses of Tapentadol IR for Postoperative Pain Following Bunionectomy Surgery",[39],480,[2311,4612],"Postoperative Pain",[4598],{"nctId":4615,"briefTitle":4616,"status":55,"phases":4617,"completion":527,"start":89,"enrollment":4618,"conditions":4619,"interventions":4622},"NCT00745069","Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis",[39],670,[4620,3289,4621],"Osteoarthitis","Knee Pain",[4598],{"trials":4624,"activeCount":8},[],{"trials":4626,"activeCount":8},[],{"trials":4628,"activeCount":8},[],{"intervention":4630,"totalTrials":285,"cells":4631},"R228060",{"EARLY_PHASE1":4632,"PHASE1":4634,"PHASE2":4636,"PHASE3":4645,"PHASE4":4647,"NA":4649},{"trials":4633,"activeCount":8},[],{"trials":4635,"activeCount":8},[],{"trials":4637,"activeCount":8},[4638],{"nctId":4639,"briefTitle":4640,"status":55,"phases":4641,"completion":203,"enrollment":4642,"conditions":4643,"interventions":4644},"NCT00073203","A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder",[39],488,[1239],[4630],{"trials":4646,"activeCount":8},[],{"trials":4648,"activeCount":8},[],{"trials":4650,"activeCount":8},[],{"intervention":4652,"totalTrials":285,"cells":4653},"Escitalopram",{"EARLY_PHASE1":4654,"PHASE1":4656,"PHASE2":4658,"PHASE3":4667,"PHASE4":4669,"NA":4671},{"trials":4655,"activeCount":8},[],{"trials":4657,"activeCount":8},[],{"trials":4659,"activeCount":8},[4660],{"nctId":4661,"briefTitle":4662,"status":55,"phases":4663,"primaryCompletion":2318,"completion":2318,"start":1447,"enrollment":211,"conditions":4664,"interventions":4665},"NCT00566202","A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression",[39],[1239],[4652,4666],"JNJ-18038683",{"trials":4668,"activeCount":8},[],{"trials":4670,"activeCount":8},[],{"trials":4672,"activeCount":8},[],{"intervention":4666,"totalTrials":285,"cells":4674},{"EARLY_PHASE1":4675,"PHASE1":4677,"PHASE2":4679,"PHASE3":4685,"PHASE4":4687,"NA":4689},{"trials":4676,"activeCount":8},[],{"trials":4678,"activeCount":8},[],{"trials":4680,"activeCount":8},[4681],{"nctId":4661,"briefTitle":4662,"status":55,"phases":4682,"primaryCompletion":2318,"completion":2318,"start":1447,"enrollment":211,"conditions":4683,"interventions":4684},[39],[1239],[4652,4666],{"trials":4686,"activeCount":8},[],{"trials":4688,"activeCount":8},[],{"trials":4690,"activeCount":8},[],{"intervention":4692,"totalTrials":285,"cells":4693},"ET743",{"EARLY_PHASE1":4694,"PHASE1":4696,"PHASE2":4698,"PHASE3":4708,"PHASE4":4710,"NA":4712},{"trials":4695,"activeCount":8},[],{"trials":4697,"activeCount":8},[],{"trials":4699,"activeCount":8},[4700],{"nctId":4701,"briefTitle":4702,"status":55,"phases":4703,"completion":410,"start":1133,"enrollment":2729,"conditions":4704,"interventions":4707},"NCT00050427","A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer",[39],[414,137,2011,4705,4706],"Breast Diseases","Skin Diseases",[4692,4692],{"trials":4709,"activeCount":8},[],{"trials":4711,"activeCount":8},[],{"trials":4713,"activeCount":8},[],{"intervention":4715,"totalTrials":285,"cells":4716},"JNJ39758979",{"EARLY_PHASE1":4717,"PHASE1":4719,"PHASE2":4721,"PHASE3":4731,"PHASE4":4733,"NA":4735},{"trials":4718,"activeCount":8},[],{"trials":4720,"activeCount":8},[],{"trials":4722,"activeCount":8},[4723],{"nctId":4724,"briefTitle":4725,"status":55,"phases":4726,"primaryCompletion":2622,"completion":2622,"start":252,"enrollment":4727,"conditions":4728,"interventions":4730},"NCT00946569","A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma",[39],116,[4729],"Asthma",[4715],{"trials":4732,"activeCount":8},[],{"trials":4734,"activeCount":8},[],{"trials":4736,"activeCount":8},[],{"intervention":4738,"totalTrials":285,"cells":4739},"doxorubicin HCL liposome; bevacizumab; carboplatin",{"EARLY_PHASE1":4740,"PHASE1":4742,"PHASE2":4744,"PHASE3":4755,"PHASE4":4757,"NA":4759},{"trials":4741,"activeCount":8},[],{"trials":4743,"activeCount":8},[],{"trials":4745,"activeCount":8},[4746],{"nctId":4747,"briefTitle":4748,"status":55,"phases":4749,"primaryCompletion":4750,"completion":4750,"start":2847,"enrollment":21,"conditions":4751,"interventions":4754},"NCT00698451","A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers",[39],"2010-10",[2009,4752,4753],"Fallopian Tube Neoplasms","Peritoneal Neoplasms",[4738],{"trials":4756,"activeCount":8},[],{"trials":4758,"activeCount":8},[],{"trials":4760,"activeCount":8},[],{"intervention":4558,"totalTrials":285,"cells":4762},{"EARLY_PHASE1":4763,"PHASE1":4765,"PHASE2":4767,"PHASE3":4773,"PHASE4":4775,"NA":4777},{"trials":4764,"activeCount":8},[],{"trials":4766,"activeCount":8},[],{"trials":4768,"activeCount":8},[4769],{"nctId":4550,"briefTitle":4551,"status":55,"phases":4770,"primaryCompletion":1822,"completion":1822,"start":1447,"enrollment":4553,"conditions":4771,"interventions":4772},[39],[29,1307,4555,4556],[4558,4558,4558,4248],{"trials":4774,"activeCount":8},[],{"trials":4776,"activeCount":8},[],{"trials":4778,"activeCount":8},[],{"intervention":4780,"totalTrials":285,"cells":4781},"JNJ-26113100 (50 mg) once daily",{"EARLY_PHASE1":4782,"PHASE1":4784,"PHASE2":4786,"PHASE3":4798,"PHASE4":4800,"NA":4802},{"trials":4783,"activeCount":8},[],{"trials":4785,"activeCount":8},[],{"trials":4787,"activeCount":8},[4788],{"nctId":4789,"briefTitle":4790,"status":68,"phases":4791,"primaryCompletion":312,"completion":312,"start":1999,"enrollment":3352,"conditions":4792,"interventions":4794},"NCT00455429","An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis",[39],[4793],"Atopic Dermatitis",[4780,4795,4796,4797],"JNJ-26113100 (100 mg) once daily","JNJ-26113100 (100 mg) twice daily","JNJ-26113100 (250 mg) twice daily",{"trials":4799,"activeCount":8},[],{"trials":4801,"activeCount":8},[],{"trials":4803,"activeCount":8},[],{"intervention":4795,"totalTrials":285,"cells":4805},{"EARLY_PHASE1":4806,"PHASE1":4808,"PHASE2":4810,"PHASE3":4816,"PHASE4":4818,"NA":4820},{"trials":4807,"activeCount":8},[],{"trials":4809,"activeCount":8},[],{"trials":4811,"activeCount":8},[4812],{"nctId":4789,"briefTitle":4790,"status":68,"phases":4813,"primaryCompletion":312,"completion":312,"start":1999,"enrollment":3352,"conditions":4814,"interventions":4815},[39],[4793],[4780,4795,4796,4797],{"trials":4817,"activeCount":8},[],{"trials":4819,"activeCount":8},[],{"trials":4821,"activeCount":8},[],{"intervention":4796,"totalTrials":285,"cells":4823},{"EARLY_PHASE1":4824,"PHASE1":4826,"PHASE2":4828,"PHASE3":4834,"PHASE4":4836,"NA":4838},{"trials":4825,"activeCount":8},[],{"trials":4827,"activeCount":8},[],{"trials":4829,"activeCount":8},[4830],{"nctId":4789,"briefTitle":4790,"status":68,"phases":4831,"primaryCompletion":312,"completion":312,"start":1999,"enrollment":3352,"conditions":4832,"interventions":4833},[39],[4793],[4780,4795,4796,4797],{"trials":4835,"activeCount":8},[],{"trials":4837,"activeCount":8},[],{"trials":4839,"activeCount":8},[],{"intervention":4797,"totalTrials":285,"cells":4841},{"EARLY_PHASE1":4842,"PHASE1":4844,"PHASE2":4846,"PHASE3":4852,"PHASE4":4854,"NA":4856},{"trials":4843,"activeCount":8},[],{"trials":4845,"activeCount":8},[],{"trials":4847,"activeCount":8},[4848],{"nctId":4789,"briefTitle":4790,"status":68,"phases":4849,"primaryCompletion":312,"completion":312,"start":1999,"enrollment":3352,"conditions":4850,"interventions":4851},[39],[4793],[4780,4795,4796,4797],{"trials":4853,"activeCount":8},[],{"trials":4855,"activeCount":8},[],{"trials":4857,"activeCount":8},[],{"intervention":4859,"totalTrials":285,"cells":4860},"bortezomib; pegylated liposomal doxorubicin",{"EARLY_PHASE1":4861,"PHASE1":4863,"PHASE2":4865,"PHASE3":4873,"PHASE4":4875,"NA":4877},{"trials":4862,"activeCount":8},[],{"trials":4864,"activeCount":8},[],{"trials":4866,"activeCount":8},[4867],{"nctId":4868,"briefTitle":4869,"status":250,"phases":4870,"primaryCompletion":2498,"completion":2498,"start":1093,"enrollment":8,"conditions":4871,"interventions":4872},"NCT00706953","A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib",[39],[326],[4859],{"trials":4874,"activeCount":8},[],{"trials":4876,"activeCount":8},[],{"trials":4878,"activeCount":8},[],{"intervention":4880,"totalTrials":285,"cells":4881},"JNJ 38518168",{"EARLY_PHASE1":4882,"PHASE1":4884,"PHASE2":4886,"PHASE3":4894,"PHASE4":4896,"NA":4898},{"trials":4883,"activeCount":8},[],{"trials":4885,"activeCount":8},[],{"trials":4887,"activeCount":8},[4888],{"nctId":4889,"briefTitle":4890,"status":68,"phases":4891,"primaryCompletion":2056,"completion":2056,"start":2562,"enrollment":164,"conditions":4892,"interventions":4893},"NCT00941707","An Efficacy and Safety Study of JNJ-38518168 in Adult Participants With Rheumatoid Arthritis",[39],[92],[4880],{"trials":4895,"activeCount":8},[],{"trials":4897,"activeCount":8},[],{"trials":4899,"activeCount":8},[],{"intervention":4901,"totalTrials":285,"cells":4902},"JNJ-42160443 3 mg",{"EARLY_PHASE1":4903,"PHASE1":4905,"PHASE2":4907,"PHASE3":4921,"PHASE4":4923,"NA":4925},{"trials":4904,"activeCount":8},[],{"trials":4906,"activeCount":8},[],{"trials":4908,"activeCount":8},[4909],{"nctId":4910,"briefTitle":4911,"status":68,"phases":4912,"primaryCompletion":4913,"completion":4913,"start":1445,"enrollment":4914,"conditions":4915,"interventions":4917},"NCT00973024","A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain",[39],"2011-05",389,[1492,4916],"Low Back Pain, Recurrent",[4901,4918,4919,4920],"JNJ-42160443 1 mg","JNJ-42160443 6 mg\u002F3mg","JNJ-42160443 10 mg",{"trials":4922,"activeCount":8},[],{"trials":4924,"activeCount":8},[],{"trials":4926,"activeCount":8},[],{"intervention":4918,"totalTrials":285,"cells":4928},{"EARLY_PHASE1":4929,"PHASE1":4931,"PHASE2":4933,"PHASE3":4939,"PHASE4":4941,"NA":4943},{"trials":4930,"activeCount":8},[],{"trials":4932,"activeCount":8},[],{"trials":4934,"activeCount":8},[4935],{"nctId":4910,"briefTitle":4911,"status":68,"phases":4936,"primaryCompletion":4913,"completion":4913,"start":1445,"enrollment":4914,"conditions":4937,"interventions":4938},[39],[1492,4916],[4901,4918,4919,4920],{"trials":4940,"activeCount":8},[],{"trials":4942,"activeCount":8},[],{"trials":4944,"activeCount":8},[],{"intervention":4919,"totalTrials":285,"cells":4946},{"EARLY_PHASE1":4947,"PHASE1":4949,"PHASE2":4951,"PHASE3":4957,"PHASE4":4959,"NA":4961},{"trials":4948,"activeCount":8},[],{"trials":4950,"activeCount":8},[],{"trials":4952,"activeCount":8},[4953],{"nctId":4910,"briefTitle":4911,"status":68,"phases":4954,"primaryCompletion":4913,"completion":4913,"start":1445,"enrollment":4914,"conditions":4955,"interventions":4956},[39],[1492,4916],[4901,4918,4919,4920],{"trials":4958,"activeCount":8},[],{"trials":4960,"activeCount":8},[],{"trials":4962,"activeCount":8},[],{"intervention":4920,"totalTrials":285,"cells":4964},{"EARLY_PHASE1":4965,"PHASE1":4967,"PHASE2":4969,"PHASE3":4975,"PHASE4":4977,"NA":4979},{"trials":4966,"activeCount":8},[],{"trials":4968,"activeCount":8},[],{"trials":4970,"activeCount":8},[4971],{"nctId":4910,"briefTitle":4911,"status":68,"phases":4972,"primaryCompletion":4913,"completion":4913,"start":1445,"enrollment":4914,"conditions":4973,"interventions":4974},[39],[1492,4916],[4901,4918,4919,4920],{"trials":4976,"activeCount":8},[],{"trials":4978,"activeCount":8},[],{"trials":4980,"activeCount":8},[],{"intervention":176,"totalTrials":285,"cells":4982},{"EARLY_PHASE1":4983,"PHASE1":4985,"PHASE2":4987,"PHASE3":4993,"PHASE4":4995,"NA":4997},{"trials":4984,"activeCount":8},[],{"trials":4986,"activeCount":8},[],{"trials":4988,"activeCount":8},[4989],{"nctId":168,"briefTitle":169,"status":68,"phases":4990,"primaryCompletion":171,"completion":172,"start":57,"enrollment":173,"conditions":4991,"interventions":4992},[39],[137,20,118],[45,176],{"trials":4994,"activeCount":8},[],{"trials":4996,"activeCount":8},[],{"trials":4998,"activeCount":8},[],{"intervention":5000,"totalTrials":285,"cells":5001},"tipifarnib",{"EARLY_PHASE1":5002,"PHASE1":5004,"PHASE2":5006,"PHASE3":5016,"PHASE4":5018,"NA":5020},{"trials":5003,"activeCount":8},[],{"trials":5005,"activeCount":8},[],{"trials":5007,"activeCount":8},[5008],{"nctId":5009,"briefTitle":5010,"status":55,"phases":5011,"completion":1121,"start":1165,"enrollment":5012,"conditions":5013,"interventions":5015},"NCT00354146","A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.",[39],252,[5014],"Leukemia, Nonlymphocytic, Acute",[5000],{"trials":5017,"activeCount":8},[],{"trials":5019,"activeCount":8},[],{"trials":5021,"activeCount":8},[],{"intervention":4300,"totalTrials":285,"cells":5023},{"EARLY_PHASE1":5024,"PHASE1":5026,"PHASE2":5028,"PHASE3":5034,"PHASE4":5036,"NA":5038},{"trials":5025,"activeCount":8},[],{"trials":5027,"activeCount":8},[],{"trials":5029,"activeCount":8},[5030],{"nctId":4293,"briefTitle":4294,"status":55,"phases":5031,"primaryCompletion":986,"completion":986,"start":2266,"enrollment":704,"conditions":5032,"interventions":5033},[39],[4297,4298],[4177,4300],{"trials":5035,"activeCount":8},[],{"trials":5037,"activeCount":8},[],{"trials":5039,"activeCount":8},[],{"intervention":2219,"totalTrials":285,"cells":5041},{"EARLY_PHASE1":5042,"PHASE1":5044,"PHASE2":5046,"PHASE3":5052,"PHASE4":5054,"NA":5056},{"trials":5043,"activeCount":8},[],{"trials":5045,"activeCount":8},[],{"trials":5047,"activeCount":8},[5048],{"nctId":2210,"briefTitle":2211,"status":55,"phases":5049,"primaryCompletion":1101,"completion":1101,"start":564,"enrollment":2213,"conditions":5050,"interventions":5051},[39],[2215,2216,1733,2217,1865],[2219,2219,2220,2220],{"trials":5053,"activeCount":8},[],{"trials":5055,"activeCount":8},[],{"trials":5057,"activeCount":8},[],{"intervention":2615,"totalTrials":285,"cells":5059},{"EARLY_PHASE1":5060,"PHASE1":5062,"PHASE2":5064,"PHASE3":5070,"PHASE4":5072,"NA":5074},{"trials":5061,"activeCount":8},[],{"trials":5063,"activeCount":8},[],{"trials":5065,"activeCount":8},[5066],{"nctId":2609,"briefTitle":2610,"status":55,"phases":5067,"primaryCompletion":2031,"completion":2031,"start":57,"enrollment":2612,"conditions":5068,"interventions":5069},[39],[1390],[2615,2600],{"trials":5071,"activeCount":8},[],{"trials":5073,"activeCount":8},[],{"trials":5075,"activeCount":8},[],{"intervention":5077,"totalTrials":285,"cells":5078},"Atomoxetine 80 mg\u002Fd",{"EARLY_PHASE1":5079,"PHASE1":5081,"PHASE2":5083,"PHASE3":5095,"PHASE4":5097,"NA":5099},{"trials":5080,"activeCount":8},[],{"trials":5082,"activeCount":8},[],{"trials":5084,"activeCount":8},[5085],{"nctId":5086,"briefTitle":5087,"status":55,"phases":5088,"primaryCompletion":332,"completion":332,"start":4325,"enrollment":314,"conditions":5089,"interventions":5090},"NCT00880217","A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[39],[4327],[5077,5091,5092,5093,5094],"OROS methylphenidate HCl 54 mg\u002Fd","JNJ-31001074 3 mg\u002Fd","JNJ-31001074 1 mg\u002Fd","JNJ-31001074 10 mg\u002Fd",{"trials":5096,"activeCount":8},[],{"trials":5098,"activeCount":8},[],{"trials":5100,"activeCount":8},[],{"intervention":5091,"totalTrials":285,"cells":5102},{"EARLY_PHASE1":5103,"PHASE1":5105,"PHASE2":5107,"PHASE3":5113,"PHASE4":5115,"NA":5117},{"trials":5104,"activeCount":8},[],{"trials":5106,"activeCount":8},[],{"trials":5108,"activeCount":8},[5109],{"nctId":5086,"briefTitle":5087,"status":55,"phases":5110,"primaryCompletion":332,"completion":332,"start":4325,"enrollment":314,"conditions":5111,"interventions":5112},[39],[4327],[5077,5091,5092,5093,5094],{"trials":5114,"activeCount":8},[],{"trials":5116,"activeCount":8},[],{"trials":5118,"activeCount":8},[],{"intervention":5092,"totalTrials":285,"cells":5120},{"EARLY_PHASE1":5121,"PHASE1":5123,"PHASE2":5125,"PHASE3":5131,"PHASE4":5133,"NA":5135},{"trials":5122,"activeCount":8},[],{"trials":5124,"activeCount":8},[],{"trials":5126,"activeCount":8},[5127],{"nctId":5086,"briefTitle":5087,"status":55,"phases":5128,"primaryCompletion":332,"completion":332,"start":4325,"enrollment":314,"conditions":5129,"interventions":5130},[39],[4327],[5077,5091,5092,5093,5094],{"trials":5132,"activeCount":8},[],{"trials":5134,"activeCount":8},[],{"trials":5136,"activeCount":8},[],{"intervention":5093,"totalTrials":285,"cells":5138},{"EARLY_PHASE1":5139,"PHASE1":5141,"PHASE2":5143,"PHASE3":5149,"PHASE4":5151,"NA":5153},{"trials":5140,"activeCount":8},[],{"trials":5142,"activeCount":8},[],{"trials":5144,"activeCount":8},[5145],{"nctId":5086,"briefTitle":5087,"status":55,"phases":5146,"primaryCompletion":332,"completion":332,"start":4325,"enrollment":314,"conditions":5147,"interventions":5148},[39],[4327],[5077,5091,5092,5093,5094],{"trials":5150,"activeCount":8},[],{"trials":5152,"activeCount":8},[],{"trials":5154,"activeCount":8},[],{"intervention":5094,"totalTrials":285,"cells":5156},{"EARLY_PHASE1":5157,"PHASE1":5159,"PHASE2":5161,"PHASE3":5167,"PHASE4":5169,"NA":5171},{"trials":5158,"activeCount":8},[],{"trials":5160,"activeCount":8},[],{"trials":5162,"activeCount":8},[5163],{"nctId":5086,"briefTitle":5087,"status":55,"phases":5164,"primaryCompletion":332,"completion":332,"start":4325,"enrollment":314,"conditions":5165,"interventions":5166},[39],[4327],[5077,5091,5092,5093,5094],{"trials":5168,"activeCount":8},[],{"trials":5170,"activeCount":8},[],{"trials":5172,"activeCount":8},[],{"intervention":5174,"totalTrials":285,"cells":5175},"R209130",{"EARLY_PHASE1":5176,"PHASE1":5178,"PHASE2":5180,"PHASE3":5189,"PHASE4":5191,"NA":5193},{"trials":5177,"activeCount":8},[],{"trials":5179,"activeCount":8},[],{"trials":5181,"activeCount":8},[5182],{"nctId":5183,"briefTitle":5184,"status":55,"phases":5185,"completion":1297,"start":348,"enrollment":5186,"conditions":5187,"interventions":5188},"NCT00063297","Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia",[39],180,[14],[5174],{"trials":5190,"activeCount":8},[],{"trials":5192,"activeCount":8},[],{"trials":5194,"activeCount":8},[],{"intervention":5196,"totalTrials":285,"cells":5197},"JNJ-39588146 5 ng\u002Fkg\u002Fmin",{"EARLY_PHASE1":5198,"PHASE1":5200,"PHASE2":5202,"PHASE3":5214,"PHASE4":5216,"NA":5218},{"trials":5199,"activeCount":8},[],{"trials":5201,"activeCount":8},[],{"trials":5203,"activeCount":8},[5204],{"nctId":5205,"briefTitle":5206,"status":55,"phases":5207,"primaryCompletion":1387,"completion":1387,"start":2498,"enrollment":972,"conditions":5208,"interventions":5210},"NCT01120210","A Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of an Intravenous Solution of JNJ-39588146 or Placebo in Patients With Heart Failure",[39],[5209],"Heart Failure",[5196,5211,5212,5213],"JNJ-39588146 15 ng\u002Fkg\u002Fmin","JNJ-39588146 30 ng\u002Fkg\u002Fmin","JNJ-39588146 5, 15, or 30 ng\u002Fkg\u002Fmin",{"trials":5215,"activeCount":8},[],{"trials":5217,"activeCount":8},[],{"trials":5219,"activeCount":8},[],{"intervention":5211,"totalTrials":285,"cells":5221},{"EARLY_PHASE1":5222,"PHASE1":5224,"PHASE2":5226,"PHASE3":5232,"PHASE4":5234,"NA":5236},{"trials":5223,"activeCount":8},[],{"trials":5225,"activeCount":8},[],{"trials":5227,"activeCount":8},[5228],{"nctId":5205,"briefTitle":5206,"status":55,"phases":5229,"primaryCompletion":1387,"completion":1387,"start":2498,"enrollment":972,"conditions":5230,"interventions":5231},[39],[5209],[5196,5211,5212,5213],{"trials":5233,"activeCount":8},[],{"trials":5235,"activeCount":8},[],{"trials":5237,"activeCount":8},[],{"intervention":5212,"totalTrials":285,"cells":5239},{"EARLY_PHASE1":5240,"PHASE1":5242,"PHASE2":5244,"PHASE3":5250,"PHASE4":5252,"NA":5254},{"trials":5241,"activeCount":8},[],{"trials":5243,"activeCount":8},[],{"trials":5245,"activeCount":8},[5246],{"nctId":5205,"briefTitle":5206,"status":55,"phases":5247,"primaryCompletion":1387,"completion":1387,"start":2498,"enrollment":972,"conditions":5248,"interventions":5249},[39],[5209],[5196,5211,5212,5213],{"trials":5251,"activeCount":8},[],{"trials":5253,"activeCount":8},[],{"trials":5255,"activeCount":8},[],{"intervention":5213,"totalTrials":285,"cells":5257},{"EARLY_PHASE1":5258,"PHASE1":5260,"PHASE2":5262,"PHASE3":5268,"PHASE4":5270,"NA":5272},{"trials":5259,"activeCount":8},[],{"trials":5261,"activeCount":8},[],{"trials":5263,"activeCount":8},[5264],{"nctId":5205,"briefTitle":5206,"status":55,"phases":5265,"primaryCompletion":1387,"completion":1387,"start":2498,"enrollment":972,"conditions":5266,"interventions":5267},[39],[5209],[5196,5211,5212,5213],{"trials":5269,"activeCount":8},[],{"trials":5271,"activeCount":8},[],{"trials":5273,"activeCount":8},[],{"intervention":5275,"totalTrials":285,"cells":5276},"PROCRIT 40,000 IU QW",{"EARLY_PHASE1":5277,"PHASE1":5279,"PHASE2":5281,"PHASE3":5290,"PHASE4":5292,"NA":5294},{"trials":5278,"activeCount":8},[],{"trials":5280,"activeCount":8},[],{"trials":5282,"activeCount":8},[5283],{"nctId":5284,"briefTitle":5285,"status":68,"phases":5286,"primaryCompletion":2847,"completion":2847,"start":455,"enrollment":557,"conditions":5287,"interventions":5289},"NCT00267007","A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy",[39],[5288],"Peripheral Neuropathy, Chemotherapy-induced",[5275],{"trials":5291,"activeCount":8},[],{"trials":5293,"activeCount":8},[],{"trials":5295,"activeCount":8},[],{"intervention":5297,"totalTrials":285,"cells":5298},"JNJ-17299425",{"EARLY_PHASE1":5299,"PHASE1":5301,"PHASE2":5303,"PHASE3":5312,"PHASE4":5314,"NA":5316},{"trials":5300,"activeCount":8},[],{"trials":5302,"activeCount":8},[],{"trials":5304,"activeCount":8},[5305],{"nctId":5306,"briefTitle":5307,"status":68,"phases":5308,"primaryCompletion":2847,"completion":2847,"start":1041,"enrollment":2132,"conditions":5309,"interventions":5311},"NCT01814982","An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain Injury",[39],[5310],"Traumatic Brain Injury",[5297],{"trials":5313,"activeCount":8},[],{"trials":5315,"activeCount":8},[],{"trials":5317,"activeCount":8},[],{"intervention":5319,"totalTrials":285,"cells":5320},"JNJ 40929837",{"EARLY_PHASE1":5321,"PHASE1":5323,"PHASE2":5325,"PHASE3":5334,"PHASE4":5336,"NA":5338},{"trials":5322,"activeCount":8},[],{"trials":5324,"activeCount":8},[],{"trials":5326,"activeCount":8},[5327],{"nctId":5328,"briefTitle":5329,"status":55,"phases":5330,"primaryCompletion":1700,"completion":1700,"start":2056,"enrollment":926,"conditions":5331,"interventions":5332},"NCT01241422","A Study to Evaluate the Effectiveness of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model",[39],[4729],[5319,5333],"Montelukast",{"trials":5335,"activeCount":8},[],{"trials":5337,"activeCount":8},[],{"trials":5339,"activeCount":8},[],{"intervention":5333,"totalTrials":285,"cells":5341},{"EARLY_PHASE1":5342,"PHASE1":5344,"PHASE2":5346,"PHASE3":5352,"PHASE4":5354,"NA":5356},{"trials":5343,"activeCount":8},[],{"trials":5345,"activeCount":8},[],{"trials":5347,"activeCount":8},[5348],{"nctId":5328,"briefTitle":5329,"status":55,"phases":5349,"primaryCompletion":1700,"completion":1700,"start":2056,"enrollment":926,"conditions":5350,"interventions":5351},[39],[4729],[5319,5333],{"trials":5353,"activeCount":8},[],{"trials":5355,"activeCount":8},[],{"trials":5357,"activeCount":8},[],{"intervention":4440,"totalTrials":285,"cells":5359},{"EARLY_PHASE1":5360,"PHASE1":5362,"PHASE2":5364,"PHASE3":5370,"PHASE4":5372,"NA":5374},{"trials":5361,"activeCount":8},[],{"trials":5363,"activeCount":8},[],{"trials":5365,"activeCount":8},[5366],{"nctId":4433,"briefTitle":4434,"status":55,"phases":5367,"primaryCompletion":1700,"completion":1700,"start":4436,"enrollment":4437,"conditions":5368,"interventions":5369},[39],[29],[4411,4440],{"trials":5371,"activeCount":8},[],{"trials":5373,"activeCount":8},[],{"trials":5375,"activeCount":8},[],{"intervention":5377,"totalTrials":285,"cells":5378},"JNJ-18054478",{"EARLY_PHASE1":5379,"PHASE1":5381,"PHASE2":5383,"PHASE3":5393,"PHASE4":5395,"NA":5397},{"trials":5380,"activeCount":8},[],{"trials":5382,"activeCount":8},[],{"trials":5384,"activeCount":8},[5385],{"nctId":5386,"briefTitle":5387,"status":68,"phases":5388,"primaryCompletion":1093,"completion":1093,"start":313,"enrollment":5389,"conditions":5390,"interventions":5391},"NCT00530166","Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.",[39],26,[4729],[5377,5392],"sham comparator",{"trials":5394,"activeCount":8},[],{"trials":5396,"activeCount":8},[],{"trials":5398,"activeCount":8},[],{"intervention":5392,"totalTrials":285,"cells":5400},{"EARLY_PHASE1":5401,"PHASE1":5403,"PHASE2":5405,"PHASE3":5411,"PHASE4":5413,"NA":5415},{"trials":5402,"activeCount":8},[],{"trials":5404,"activeCount":8},[],{"trials":5406,"activeCount":8},[5407],{"nctId":5386,"briefTitle":5387,"status":68,"phases":5408,"primaryCompletion":1093,"completion":1093,"start":313,"enrollment":5389,"conditions":5409,"interventions":5410},[39],[4729],[5377,5392],{"trials":5412,"activeCount":8},[],{"trials":5414,"activeCount":8},[],{"trials":5416,"activeCount":8},[],{"intervention":2112,"totalTrials":285,"cells":5418},{"EARLY_PHASE1":5419,"PHASE1":5421,"PHASE2":5423,"PHASE3":5429,"PHASE4":5431,"NA":5433},{"trials":5420,"activeCount":8},[],{"trials":5422,"activeCount":8},[],{"trials":5424,"activeCount":8},[5425],{"nctId":2104,"briefTitle":2105,"status":55,"phases":5426,"primaryCompletion":172,"completion":172,"start":348,"enrollment":2107,"conditions":5427,"interventions":5428},[39],[2109,2110],[2112,2112,1992,1992],{"trials":5430,"activeCount":8},[],{"trials":5432,"activeCount":8},[],{"trials":5434,"activeCount":8},[],{"intervention":5436,"totalTrials":285,"cells":5437},"JNJ-39220675",{"EARLY_PHASE1":5438,"PHASE1":5440,"PHASE2":5442,"PHASE3":5452,"PHASE4":5454,"NA":5456},{"trials":5439,"activeCount":8},[],{"trials":5441,"activeCount":8},[],{"trials":5443,"activeCount":8},[5444],{"nctId":5445,"briefTitle":5446,"status":55,"phases":5447,"primaryCompletion":985,"completion":985,"start":1101,"enrollment":2729,"conditions":5448,"interventions":5450},"NCT00804687","An Efficacy Study of JNJ-39220675 and Pseudoephedrine in Participants With Allergic Rhinitis",[39],[5449],"Allergic Rhinitis",[5436,5451],"Pseudoephedrine",{"trials":5453,"activeCount":8},[],{"trials":5455,"activeCount":8},[],{"trials":5457,"activeCount":8},[],{"intervention":5451,"totalTrials":285,"cells":5459},{"EARLY_PHASE1":5460,"PHASE1":5462,"PHASE2":5464,"PHASE3":5470,"PHASE4":5472,"NA":5474},{"trials":5461,"activeCount":8},[],{"trials":5463,"activeCount":8},[],{"trials":5465,"activeCount":8},[5466],{"nctId":5445,"briefTitle":5446,"status":55,"phases":5467,"primaryCompletion":985,"completion":985,"start":1101,"enrollment":2729,"conditions":5468,"interventions":5469},[39],[5449],[5436,5451],{"trials":5471,"activeCount":8},[],{"trials":5473,"activeCount":8},[],{"trials":5475,"activeCount":8},[],{"intervention":5477,"totalTrials":285,"cells":5478},"RWJ-445380 100 mg",{"EARLY_PHASE1":5479,"PHASE1":5481,"PHASE2":5483,"PHASE3":5494,"PHASE4":5496,"NA":5498},{"trials":5480,"activeCount":8},[],{"trials":5482,"activeCount":8},[],{"trials":5484,"activeCount":8},[5485],{"nctId":5486,"briefTitle":5487,"status":55,"phases":5488,"primaryCompletion":4460,"completion":4460,"start":410,"enrollment":5489,"conditions":5490,"interventions":5491},"NCT00425321","Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy",[39],259,[92],[5477,5492,5493],"RWJ-445380 200 mg","RWJ-445380 300 mg",{"trials":5495,"activeCount":8},[],{"trials":5497,"activeCount":8},[],{"trials":5499,"activeCount":8},[],{"intervention":5492,"totalTrials":285,"cells":5501},{"EARLY_PHASE1":5502,"PHASE1":5504,"PHASE2":5506,"PHASE3":5512,"PHASE4":5514,"NA":5516},{"trials":5503,"activeCount":8},[],{"trials":5505,"activeCount":8},[],{"trials":5507,"activeCount":8},[5508],{"nctId":5486,"briefTitle":5487,"status":55,"phases":5509,"primaryCompletion":4460,"completion":4460,"start":410,"enrollment":5489,"conditions":5510,"interventions":5511},[39],[92],[5477,5492,5493],{"trials":5513,"activeCount":8},[],{"trials":5515,"activeCount":8},[],{"trials":5517,"activeCount":8},[],{"intervention":5493,"totalTrials":285,"cells":5519},{"EARLY_PHASE1":5520,"PHASE1":5522,"PHASE2":5524,"PHASE3":5530,"PHASE4":5532,"NA":5534},{"trials":5521,"activeCount":8},[],{"trials":5523,"activeCount":8},[],{"trials":5525,"activeCount":8},[5526],{"nctId":5486,"briefTitle":5487,"status":55,"phases":5527,"primaryCompletion":4460,"completion":4460,"start":410,"enrollment":5489,"conditions":5528,"interventions":5529},[39],[92],[5477,5492,5493],{"trials":5531,"activeCount":8},[],{"trials":5533,"activeCount":8},[],{"trials":5535,"activeCount":8},[],{"intervention":5537,"totalTrials":285,"cells":5538},"R092670",{"EARLY_PHASE1":5539,"PHASE1":5541,"PHASE2":5543,"PHASE3":5552,"PHASE4":5554,"NA":5556},{"trials":5540,"activeCount":8},[],{"trials":5542,"activeCount":8},[],{"trials":5544,"activeCount":8},[5545],{"nctId":5546,"briefTitle":5547,"status":55,"phases":5548,"completion":89,"start":1297,"enrollment":5549,"conditions":5550,"interventions":5551},"NCT00074477","Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia",[39],250,[14],[5537],{"trials":5553,"activeCount":8},[],{"trials":5555,"activeCount":8},[],{"trials":5557,"activeCount":8},[],{"intervention":5559,"totalTrials":285,"cells":5560},"JNJ-26489112",{"EARLY_PHASE1":5561,"PHASE1":5563,"PHASE2":5565,"PHASE3":5574,"PHASE4":5576,"NA":5578},{"trials":5562,"activeCount":8},[],{"trials":5564,"activeCount":8},[],{"trials":5566,"activeCount":8},[5567],{"nctId":5568,"briefTitle":5569,"status":55,"phases":5570,"primaryCompletion":1093,"completion":1093,"start":564,"enrollment":125,"conditions":5571,"interventions":5573},"NCT00579384","A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy",[39],[5572],"Photosensitive Epilepsy",[5559],{"trials":5575,"activeCount":8},[],{"trials":5577,"activeCount":8},[],{"trials":5579,"activeCount":8},[],{"intervention":5581,"totalTrials":285,"cells":5582},"JNJ-39758979 30 mg\u002Fd",{"EARLY_PHASE1":5583,"PHASE1":5585,"PHASE2":5587,"PHASE3":5599,"PHASE4":5601,"NA":5603},{"trials":5584,"activeCount":8},[],{"trials":5586,"activeCount":8},[],{"trials":5588,"activeCount":8},[5589],{"nctId":5590,"briefTitle":5591,"status":250,"phases":5592,"primaryCompletion":5593,"completion":5593,"start":5594,"enrollment":8,"conditions":5595,"interventions":5596},"NCT01493882","Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma",[39],"2015-06","2012-03",[4729],[5581,5597,5598],"JNJ-39758979 100 mg\u002Fd","JNJ-39758979 300 mg\u002Fd",{"trials":5600,"activeCount":8},[],{"trials":5602,"activeCount":8},[],{"trials":5604,"activeCount":8},[],{"intervention":5597,"totalTrials":285,"cells":5606},{"EARLY_PHASE1":5607,"PHASE1":5609,"PHASE2":5611,"PHASE3":5617,"PHASE4":5619,"NA":5621},{"trials":5608,"activeCount":8},[],{"trials":5610,"activeCount":8},[],{"trials":5612,"activeCount":8},[5613],{"nctId":5590,"briefTitle":5591,"status":250,"phases":5614,"primaryCompletion":5593,"completion":5593,"start":5594,"enrollment":8,"conditions":5615,"interventions":5616},[39],[4729],[5581,5597,5598],{"trials":5618,"activeCount":8},[],{"trials":5620,"activeCount":8},[],{"trials":5622,"activeCount":8},[],{"intervention":5598,"totalTrials":285,"cells":5624},{"EARLY_PHASE1":5625,"PHASE1":5627,"PHASE2":5629,"PHASE3":5635,"PHASE4":5637,"NA":5639},{"trials":5626,"activeCount":8},[],{"trials":5628,"activeCount":8},[],{"trials":5630,"activeCount":8},[5631],{"nctId":5590,"briefTitle":5591,"status":250,"phases":5632,"primaryCompletion":5593,"completion":5593,"start":5594,"enrollment":8,"conditions":5633,"interventions":5634},[39],[4729],[5581,5597,5598],{"trials":5636,"activeCount":8},[],{"trials":5638,"activeCount":8},[],{"trials":5640,"activeCount":8},[],{"intervention":5642,"totalTrials":285,"cells":5643},"JNJ-17166864",{"EARLY_PHASE1":5644,"PHASE1":5646,"PHASE2":5648,"PHASE3":5656,"PHASE4":5658,"NA":5660},{"trials":5645,"activeCount":8},[],{"trials":5647,"activeCount":8},[],{"trials":5649,"activeCount":8},[5650],{"nctId":5651,"briefTitle":5652,"status":55,"phases":5653,"primaryCompletion":516,"completion":516,"start":4460,"enrollment":4427,"conditions":5654,"interventions":5655},"NCT00604123","A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adults",[39],[5449],[5642],{"trials":5657,"activeCount":8},[],{"trials":5659,"activeCount":8},[],{"trials":5661,"activeCount":8},[],{"intervention":5663,"totalTrials":998,"cells":5664},"ER OROS Paliperidone",{"EARLY_PHASE1":5665,"PHASE1":5667,"PHASE2":5701,"PHASE3":5703,"PHASE4":5705,"NA":5707},{"trials":5666,"activeCount":8},[],{"trials":5668,"activeCount":8},[5669,5675,5682,5688,5695],{"nctId":5670,"briefTitle":5671,"status":55,"phases":5672,"completion":2146,"start":89,"enrollment":506,"conditions":5673,"interventions":5674},"NCT00892489","A Bioequivalence Study of 15 mg ER OROS Paliperidone",[38],[14],[5663],{"nctId":5676,"briefTitle":5677,"status":55,"phases":5678,"completion":242,"start":193,"enrollment":642,"conditions":5679,"interventions":5681},"NCT00791401","A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function",[38],[14,5680],"Renal Impairment",[5663],{"nctId":5683,"briefTitle":5684,"status":55,"phases":5685,"completion":341,"start":89,"enrollment":2020,"conditions":5686,"interventions":5687},"NCT00796835","A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone",[38],[14],[5663],{"nctId":5689,"briefTitle":5690,"status":55,"phases":5691,"completion":2432,"start":341,"enrollment":3130,"conditions":5692,"interventions":5693},"NCT00892541","A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone",[38],[14],[5694],"ER OROS paliperidone",{"nctId":5696,"briefTitle":5697,"status":55,"phases":5698,"completion":203,"start":591,"enrollment":1107,"conditions":5699,"interventions":5700},"NCT00892320","A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers",[38],[14],[5694],{"trials":5702,"activeCount":8},[],{"trials":5704,"activeCount":8},[],{"trials":5706,"activeCount":8},[],{"trials":5708,"activeCount":8},[],{"intervention":5710,"totalTrials":2442,"cells":5711},"JNJ-40411813",{"EARLY_PHASE1":5712,"PHASE1":5714,"PHASE2":5739,"PHASE3":5741,"PHASE4":5743,"NA":5745},{"trials":5713,"activeCount":8},[],{"trials":5715,"activeCount":8},[5716,5723,5729],{"nctId":5717,"briefTitle":5718,"status":55,"phases":5719,"primaryCompletion":3328,"completion":3328,"start":332,"enrollment":1709,"conditions":5720,"interventions":5721},"NCT01951053","A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients",[38],[17],[5710,5722],"Citalopram",{"nctId":5724,"briefTitle":5725,"status":55,"phases":5726,"primaryCompletion":2508,"completion":2508,"start":2056,"enrollment":785,"conditions":5727,"interventions":5728},"NCT01358006","A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers",[38],[17],[5710,5710],{"nctId":5730,"briefTitle":5731,"status":55,"phases":5732,"completion":2484,"start":2562,"enrollment":59,"conditions":5733,"interventions":5736},"NCT01101659","Ketamine Challenge Study With JNJ-40411813",[38],[5734,5735,14],"Perceptual Disorders","Confusion",[5710,5737,5738],"normal saline","ketamine",{"trials":5740,"activeCount":8},[],{"trials":5742,"activeCount":8},[],{"trials":5744,"activeCount":8},[],{"trials":5746,"activeCount":8},[],{"intervention":5748,"totalTrials":2442,"cells":5749},"tapentadol (CG5503) ER 50-mg TRF",{"EARLY_PHASE1":5750,"PHASE1":5752,"PHASE2":5776,"PHASE3":5778,"PHASE4":5780,"NA":5782},{"trials":5751,"activeCount":8},[],{"trials":5753,"activeCount":8},[5754,5764,5770],{"nctId":5755,"briefTitle":5756,"status":55,"phases":5757,"completion":4913,"start":3613,"enrollment":46,"conditions":5758,"interventions":5760},"NCT01309425","A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers",[38],[5759],"Healthy Volunteer",[5761,5748,5762,5763],"tapentadol (CG5503) ER two 100-mg TRF","tapentadol (CG5503) ER 25-mg TRF","tapentadol (CG5503) ER 100-mg TRF",{"nctId":5765,"briefTitle":5766,"status":55,"phases":5767,"completion":3613,"start":4436,"enrollment":3130,"conditions":5768,"interventions":5769},"NCT01273506","A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet",[38],[5759],[5762,5748],{"nctId":5771,"briefTitle":5772,"status":55,"phases":5773,"completion":2508,"start":4436,"enrollment":3130,"conditions":5774,"interventions":5775},"NCT01273532","A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet",[38],[5759],[5763,5748],{"trials":5777,"activeCount":8},[],{"trials":5779,"activeCount":8},[],{"trials":5781,"activeCount":8},[],{"trials":5783,"activeCount":8},[],{"intervention":5785,"totalTrials":482,"cells":5786},"Canagliflozin 100 mg",{"EARLY_PHASE1":5787,"PHASE1":5789,"PHASE2":5807,"PHASE3":5809,"PHASE4":5811,"NA":5813},{"trials":5788,"activeCount":8},[],{"trials":5790,"activeCount":8},[5791,5800],{"nctId":5792,"briefTitle":5793,"status":55,"phases":5794,"primaryCompletion":4224,"completion":4224,"start":2919,"enrollment":5795,"conditions":5796,"interventions":5797},"NCT01281579","A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers",[38],27,[17],[5785,5798,5799],"Canagliflozin 50 mg","Canagliflozin 300 mg",{"nctId":5801,"briefTitle":5802,"status":55,"phases":5803,"completion":2484,"start":1446,"enrollment":5804,"conditions":5805,"interventions":5806},"NCT01128985","A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus",[38],39,[29],[5798,5785,5799],{"trials":5808,"activeCount":8},[],{"trials":5810,"activeCount":8},[],{"trials":5812,"activeCount":8},[],{"trials":5814,"activeCount":8},[],{"intervention":5798,"totalTrials":482,"cells":5816},{"EARLY_PHASE1":5817,"PHASE1":5819,"PHASE2":5829,"PHASE3":5831,"PHASE4":5833,"NA":5835},{"trials":5818,"activeCount":8},[],{"trials":5820,"activeCount":8},[5821,5825],{"nctId":5792,"briefTitle":5793,"status":55,"phases":5822,"primaryCompletion":4224,"completion":4224,"start":2919,"enrollment":5795,"conditions":5823,"interventions":5824},[38],[17],[5785,5798,5799],{"nctId":5801,"briefTitle":5802,"status":55,"phases":5826,"completion":2484,"start":1446,"enrollment":5804,"conditions":5827,"interventions":5828},[38],[29],[5798,5785,5799],{"trials":5830,"activeCount":8},[],{"trials":5832,"activeCount":8},[],{"trials":5834,"activeCount":8},[],{"trials":5836,"activeCount":8},[],{"intervention":5799,"totalTrials":482,"cells":5838},{"EARLY_PHASE1":5839,"PHASE1":5841,"PHASE2":5851,"PHASE3":5853,"PHASE4":5855,"NA":5857},{"trials":5840,"activeCount":8},[],{"trials":5842,"activeCount":8},[5843,5847],{"nctId":5792,"briefTitle":5793,"status":55,"phases":5844,"primaryCompletion":4224,"completion":4224,"start":2919,"enrollment":5795,"conditions":5845,"interventions":5846},[38],[17],[5785,5798,5799],{"nctId":5801,"briefTitle":5802,"status":55,"phases":5848,"completion":2484,"start":1446,"enrollment":5804,"conditions":5849,"interventions":5850},[38],[29],[5798,5785,5799],{"trials":5852,"activeCount":8},[],{"trials":5854,"activeCount":8},[],{"trials":5856,"activeCount":8},[],{"trials":5858,"activeCount":8},[],{"intervention":5860,"totalTrials":482,"cells":5861},"JNJ-26481585",{"EARLY_PHASE1":5862,"PHASE1":5864,"PHASE2":5880,"PHASE3":5882,"PHASE4":5884,"NA":5886},{"trials":5863,"activeCount":8},[],{"trials":5865,"activeCount":8},[5866,5873],{"nctId":5867,"briefTitle":5868,"status":68,"phases":5869,"primaryCompletion":1387,"completion":1387,"start":2318,"enrollment":1879,"conditions":5870,"interventions":5872},"NCT00676728","A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome",[38],[5871,254],"Advanced or Refractory Leukemia",[5860],{"nctId":5874,"briefTitle":5875,"status":55,"phases":5876,"primaryCompletion":1387,"completion":1387,"start":1041,"enrollment":5877,"conditions":5878,"interventions":5879},"NCT00677105","A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.",[38],92,[493,137],[5860],{"trials":5881,"activeCount":8},[],{"trials":5883,"activeCount":8},[],{"trials":5885,"activeCount":8},[],{"trials":5887,"activeCount":8},[],{"intervention":5889,"totalTrials":482,"cells":5890},"Rabeprazole sodium",{"EARLY_PHASE1":5891,"PHASE1":5893,"PHASE2":5910,"PHASE3":5912,"PHASE4":5914,"NA":5916},{"trials":5892,"activeCount":8},[],{"trials":5894,"activeCount":8},[5895,5902],{"nctId":5896,"briefTitle":5897,"status":55,"phases":5898,"completion":1445,"start":171,"enrollment":72,"conditions":5899,"interventions":5901},"NCT00747695","A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive",[38],[5900],"GERD",[5889],{"nctId":5903,"briefTitle":5904,"status":55,"phases":5905,"primaryCompletion":1822,"completion":1822,"start":2847,"enrollment":5906,"conditions":5907,"interventions":5908},"NCT01101646","A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers",[38],36,[1299],[5909,5909,5909],"rabeprazole sodium",{"trials":5911,"activeCount":8},[],{"trials":5913,"activeCount":8},[],{"trials":5915,"activeCount":8},[],{"trials":5917,"activeCount":8},[],{"intervention":5762,"totalTrials":482,"cells":5919},{"EARLY_PHASE1":5920,"PHASE1":5922,"PHASE2":5932,"PHASE3":5934,"PHASE4":5936,"NA":5938},{"trials":5921,"activeCount":8},[],{"trials":5923,"activeCount":8},[5924,5928],{"nctId":5755,"briefTitle":5756,"status":55,"phases":5925,"completion":4913,"start":3613,"enrollment":46,"conditions":5926,"interventions":5927},[38],[5759],[5761,5748,5762,5763],{"nctId":5765,"briefTitle":5766,"status":55,"phases":5929,"completion":3613,"start":4436,"enrollment":3130,"conditions":5930,"interventions":5931},[38],[5759],[5762,5748],{"trials":5933,"activeCount":8},[],{"trials":5935,"activeCount":8},[],{"trials":5937,"activeCount":8},[],{"trials":5939,"activeCount":8},[],{"intervention":5763,"totalTrials":482,"cells":5941},{"EARLY_PHASE1":5942,"PHASE1":5944,"PHASE2":5954,"PHASE3":5956,"PHASE4":5958,"NA":5960},{"trials":5943,"activeCount":8},[],{"trials":5945,"activeCount":8},[5946,5950],{"nctId":5755,"briefTitle":5756,"status":55,"phases":5947,"completion":4913,"start":3613,"enrollment":46,"conditions":5948,"interventions":5949},[38],[5759],[5761,5748,5762,5763],{"nctId":5771,"briefTitle":5772,"status":55,"phases":5951,"completion":2508,"start":4436,"enrollment":3130,"conditions":5952,"interventions":5953},[38],[5759],[5763,5748],{"trials":5955,"activeCount":8},[],{"trials":5957,"activeCount":8},[],{"trials":5959,"activeCount":8},[],{"trials":5961,"activeCount":8},[],{"intervention":5963,"totalTrials":482,"cells":5964},"JNJ-39393406",{"EARLY_PHASE1":5965,"PHASE1":5967,"PHASE2":5981,"PHASE3":5983,"PHASE4":5985,"NA":5987},{"trials":5966,"activeCount":8},[],{"trials":5968,"activeCount":8},[5969,5975],{"nctId":5970,"briefTitle":5971,"status":55,"phases":5972,"primaryCompletion":2191,"completion":2191,"start":986,"enrollment":2177,"conditions":5973,"interventions":5974},"NCT02023255","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39393406 in Healthy Participants",[38],[17],[5963],{"nctId":5976,"briefTitle":5977,"status":55,"phases":5978,"primaryCompletion":2056,"completion":2056,"start":2622,"enrollment":125,"conditions":5979,"interventions":5980},"NCT01556217","A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers",[38],[3199],[5963],{"trials":5982,"activeCount":8},[],{"trials":5984,"activeCount":8},[],{"trials":5986,"activeCount":8},[],{"trials":5988,"activeCount":8},[],{"intervention":5990,"totalTrials":482,"cells":5991},"Norgestimate; Ethinyl Estradiol; Folic acid",{"EARLY_PHASE1":5992,"PHASE1":5994,"PHASE2":6008,"PHASE3":6010,"PHASE4":6012,"NA":6014},{"trials":5993,"activeCount":8},[],{"trials":5995,"activeCount":8},[5996,6002],{"nctId":5997,"briefTitle":5998,"status":55,"phases":5999,"completion":242,"start":114,"enrollment":642,"conditions":6000,"interventions":6001},"NCT00709332","A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM)\u002FEthinyl Estradiol (EE) in Healthy Women.",[38],[4341,3108,4319],[5990],{"nctId":6003,"briefTitle":6004,"status":55,"phases":6005,"completion":481,"start":749,"enrollment":642,"conditions":6006,"interventions":6007},"NCT00709982","A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM) \u002FEthinyl Estradiol (EE) in Healthy Women.",[38],[4341,17,4319],[5990],{"trials":6009,"activeCount":8},[],{"trials":6011,"activeCount":8},[],{"trials":6013,"activeCount":8},[],{"trials":6015,"activeCount":8},[],{"intervention":6017,"totalTrials":482,"cells":6018},"JNJ-38431055",{"EARLY_PHASE1":6019,"PHASE1":6021,"PHASE2":6038,"PHASE3":6040,"PHASE4":6042,"NA":6044},{"trials":6020,"activeCount":8},[],{"trials":6022,"activeCount":8},[6023,6030],{"nctId":6024,"briefTitle":6025,"status":55,"phases":6026,"primaryCompletion":6027,"completion":6027,"start":1101,"enrollment":518,"conditions":6028,"interventions":6029},"NCT00910923","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-38431055 in Healthy Male Volunteers",[38],"2009-04",[29],[6017],{"nctId":6031,"briefTitle":6032,"status":55,"phases":6033,"completion":2562,"start":2030,"enrollment":1709,"conditions":6034,"interventions":6035},"NCT01054118","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin",[38],[29],[6017,6036,6037],"Sitagliptin 100 mg","JNJ-38431055 + Sitagliptin 100 mg",{"trials":6039,"activeCount":8},[],{"trials":6041,"activeCount":8},[],{"trials":6043,"activeCount":8},[],{"trials":6045,"activeCount":8},[],{"intervention":6047,"totalTrials":482,"cells":6048},"A",{"EARLY_PHASE1":6049,"PHASE1":6051,"PHASE2":6066,"PHASE3":6068,"PHASE4":6070,"NA":6072},{"trials":6050,"activeCount":8},[],{"trials":6052,"activeCount":8},[6053,6060],{"nctId":6054,"briefTitle":6055,"status":55,"phases":6056,"primaryCompletion":3570,"completion":3570,"start":1387,"enrollment":2485,"conditions":6057,"interventions":6058},"NCT01454622","A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg\u002F1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers",[38],[17],[6047,6059],"B",{"nctId":6061,"briefTitle":6062,"status":55,"phases":6063,"primaryCompletion":3570,"completion":3570,"start":1387,"enrollment":2485,"conditions":6064,"interventions":6065},"NCT01518712","A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg\u002F850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers",[38],[17],[6047,6059],{"trials":6067,"activeCount":8},[],{"trials":6069,"activeCount":8},[],{"trials":6071,"activeCount":8},[],{"trials":6073,"activeCount":8},[],{"intervention":6059,"totalTrials":482,"cells":6075},{"EARLY_PHASE1":6076,"PHASE1":6078,"PHASE2":6088,"PHASE3":6090,"PHASE4":6092,"NA":6094},{"trials":6077,"activeCount":8},[],{"trials":6079,"activeCount":8},[6080,6084],{"nctId":6054,"briefTitle":6055,"status":55,"phases":6081,"primaryCompletion":3570,"completion":3570,"start":1387,"enrollment":2485,"conditions":6082,"interventions":6083},[38],[17],[6047,6059],{"nctId":6061,"briefTitle":6062,"status":55,"phases":6085,"primaryCompletion":3570,"completion":3570,"start":1387,"enrollment":2485,"conditions":6086,"interventions":6087},[38],[17],[6047,6059],{"trials":6089,"activeCount":8},[],{"trials":6091,"activeCount":8},[],{"trials":6093,"activeCount":8},[],{"trials":6095,"activeCount":8},[],{"intervention":6097,"totalTrials":482,"cells":6098},"Rabeprazole sodium: Treatment A",{"EARLY_PHASE1":6099,"PHASE1":6101,"PHASE2":6120,"PHASE3":6122,"PHASE4":6124,"NA":6126},{"trials":6100,"activeCount":8},[],{"trials":6102,"activeCount":8},[6103,6112],{"nctId":6104,"briefTitle":6105,"status":55,"phases":6106,"primaryCompletion":4436,"completion":4436,"start":4750,"enrollment":6107,"conditions":6108,"interventions":6109},"NCT01241409","A Bioequivalence Study of 2 Formulations of Rabeprazole Sodium and Evaluation of the Effect of Food on Rabeprazole Sodium in Healthy Adult Volunteers",[38],78,[17],[6097,6110,6111],"Rabeprazole sodium: Treatment B","Rabeprazole sodium: Treatment C",{"nctId":6113,"briefTitle":6114,"status":55,"phases":6115,"primaryCompletion":2056,"completion":2056,"start":2483,"enrollment":950,"conditions":6116,"interventions":6117},"NCT01186497","A Relative Bioavailability Study of Rabeprazole Sodium Administered With Different Dosing Vehicles in Healthy Adult Volunteers",[38],[17],[6118,6111,6119,6097,6110],"Rabeprazole sodium: Treatment E","Rabeprazole sodium: Treatment D",{"trials":6121,"activeCount":8},[],{"trials":6123,"activeCount":8},[],{"trials":6125,"activeCount":8},[],{"trials":6127,"activeCount":8},[],{"intervention":6110,"totalTrials":482,"cells":6129},{"EARLY_PHASE1":6130,"PHASE1":6132,"PHASE2":6142,"PHASE3":6144,"PHASE4":6146,"NA":6148},{"trials":6131,"activeCount":8},[],{"trials":6133,"activeCount":8},[6134,6138],{"nctId":6104,"briefTitle":6105,"status":55,"phases":6135,"primaryCompletion":4436,"completion":4436,"start":4750,"enrollment":6107,"conditions":6136,"interventions":6137},[38],[17],[6097,6110,6111],{"nctId":6113,"briefTitle":6114,"status":55,"phases":6139,"primaryCompletion":2056,"completion":2056,"start":2483,"enrollment":950,"conditions":6140,"interventions":6141},[38],[17],[6118,6111,6119,6097,6110],{"trials":6143,"activeCount":8},[],{"trials":6145,"activeCount":8},[],{"trials":6147,"activeCount":8},[],{"trials":6149,"activeCount":8},[],{"intervention":6111,"totalTrials":482,"cells":6151},{"EARLY_PHASE1":6152,"PHASE1":6154,"PHASE2":6164,"PHASE3":6166,"PHASE4":6168,"NA":6170},{"trials":6153,"activeCount":8},[],{"trials":6155,"activeCount":8},[6156,6160],{"nctId":6104,"briefTitle":6105,"status":55,"phases":6157,"primaryCompletion":4436,"completion":4436,"start":4750,"enrollment":6107,"conditions":6158,"interventions":6159},[38],[17],[6097,6110,6111],{"nctId":6113,"briefTitle":6114,"status":55,"phases":6161,"primaryCompletion":2056,"completion":2056,"start":2483,"enrollment":950,"conditions":6162,"interventions":6163},[38],[17],[6118,6111,6119,6097,6110],{"trials":6165,"activeCount":8},[],{"trials":6167,"activeCount":8},[],{"trials":6169,"activeCount":8},[],{"trials":6171,"activeCount":8},[],{"intervention":6036,"totalTrials":482,"cells":6173},{"EARLY_PHASE1":6174,"PHASE1":6176,"PHASE2":6190,"PHASE3":6192,"PHASE4":6194,"NA":6196},{"trials":6175,"activeCount":8},[],{"trials":6177,"activeCount":8},[6178,6186],{"nctId":6179,"briefTitle":6180,"status":55,"phases":6181,"primaryCompletion":153,"completion":153,"start":6027,"enrollment":334,"conditions":6182,"interventions":6183},"NCT00871507","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus",[38],[29],[6184,6036,6185],"JNJ-38431055 Dose 1","JNJ-38431055 Dose 2",{"nctId":6031,"briefTitle":6032,"status":55,"phases":6187,"completion":2562,"start":2030,"enrollment":1709,"conditions":6188,"interventions":6189},[38],[29],[6017,6036,6037],{"trials":6191,"activeCount":8},[],{"trials":6193,"activeCount":8},[],{"trials":6195,"activeCount":8},[],{"trials":6197,"activeCount":8},[],{"intervention":6199,"totalTrials":482,"cells":6200},"ULTRAM ER",{"EARLY_PHASE1":6201,"PHASE1":6203,"PHASE2":6217,"PHASE3":6219,"PHASE4":6221,"NA":6223},{"trials":6202,"activeCount":8},[],{"trials":6204,"activeCount":8},[6205,6211],{"nctId":6206,"briefTitle":6207,"status":55,"phases":6208,"primaryCompletion":1822,"completion":1822,"start":564,"enrollment":669,"conditions":6209,"interventions":6210},"NCT01586507","A Study of ULTRAM ER at Two Dose Levels in Adolescents With Pain",[38],[2311],[6199,6199],{"nctId":6212,"briefTitle":6213,"status":55,"phases":6214,"primaryCompletion":2191,"completion":2191,"start":564,"enrollment":518,"conditions":6215,"interventions":6216},"NCT01586494","A Pharmacokinetic, Tolerability, and Safety Study of ULTRAM ER in Children With Pain",[38],[2311],[6199,6199],{"trials":6218,"activeCount":8},[],{"trials":6220,"activeCount":8},[],{"trials":6222,"activeCount":8},[],{"trials":6224,"activeCount":8},[],{"intervention":5738,"totalTrials":482,"cells":6226},{"EARLY_PHASE1":6227,"PHASE1":6229,"PHASE2":6241,"PHASE3":6243,"PHASE4":6245,"NA":6247},{"trials":6228,"activeCount":8},[],{"trials":6230,"activeCount":8},[6231,6235],{"nctId":5730,"briefTitle":5731,"status":55,"phases":6232,"completion":2484,"start":2562,"enrollment":59,"conditions":6233,"interventions":6234},[38],[5734,5735,14],[5710,5737,5738],{"nctId":6236,"briefTitle":6237,"status":55,"phases":6238,"completion":3328,"start":1270,"enrollment":987,"conditions":6239,"interventions":6240},"NCT01165294","The Effect of Ketamine on Attentiveness",[38],[14],[5738],{"trials":6242,"activeCount":8},[],{"trials":6244,"activeCount":8},[],{"trials":6246,"activeCount":8},[],{"trials":6248,"activeCount":8},[],{"intervention":6250,"totalTrials":285,"cells":6251},"extended-release (ER) OROS paliperidone",{"EARLY_PHASE1":6252,"PHASE1":6254,"PHASE2":6262,"PHASE3":6264,"PHASE4":6266,"NA":6268},{"trials":6253,"activeCount":8},[],{"trials":6255,"activeCount":8},[6256],{"nctId":6257,"briefTitle":6258,"status":55,"phases":6259,"completion":392,"start":115,"enrollment":575,"conditions":6260,"interventions":6261},"NCT00791232","A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia",[38],[14],[6250],{"trials":6263,"activeCount":8},[],{"trials":6265,"activeCount":8},[],{"trials":6267,"activeCount":8},[],{"trials":6269,"activeCount":8},[],{"intervention":6271,"totalTrials":285,"cells":6272},"ER OROS paliperidone, paliperidone ER",{"EARLY_PHASE1":6273,"PHASE1":6275,"PHASE2":6284,"PHASE3":6286,"PHASE4":6288,"NA":6290},{"trials":6274,"activeCount":8},[],{"trials":6276,"activeCount":8},[6277],{"nctId":6278,"briefTitle":6279,"status":55,"phases":6280,"completion":517,"start":58,"enrollment":334,"conditions":6281,"interventions":6283},"NCT00796081","A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder",[38],[14,938,6282],"Schizophreniform Disorders",[6271],{"trials":6285,"activeCount":8},[],{"trials":6287,"activeCount":8},[],{"trials":6289,"activeCount":8},[],{"trials":6291,"activeCount":8},[],{"intervention":6293,"totalTrials":285,"cells":6294},"Drug combination\u002F 26489112",{"EARLY_PHASE1":6295,"PHASE1":6297,"PHASE2":6305,"PHASE3":6307,"PHASE4":6309,"NA":6311},{"trials":6296,"activeCount":8},[],{"trials":6298,"activeCount":8},[6299],{"nctId":6300,"briefTitle":6301,"status":55,"phases":6302,"completion":2483,"start":2498,"enrollment":1107,"conditions":6303,"interventions":6304},"NCT01147887","A Pharmacokinetic and Drug Interaction Study of JNJ-26489112 in Healthy Volunteers",[38],[17],[6293],{"trials":6306,"activeCount":8},[],{"trials":6308,"activeCount":8},[],{"trials":6310,"activeCount":8},[],{"trials":6312,"activeCount":8},[],{"intervention":6314,"totalTrials":285,"cells":6315},"A:JNJ-39758979\u002FPlacebo #1",{"EARLY_PHASE1":6316,"PHASE1":6318,"PHASE2":6327,"PHASE3":6329,"PHASE4":6331,"NA":6333},{"trials":6317,"activeCount":8},[],{"trials":6319,"activeCount":8},[6320],{"nctId":6321,"briefTitle":6322,"status":55,"phases":6323,"completion":3328,"start":2562,"enrollment":987,"conditions":6324,"interventions":6326},"NCT01068223","A Study To Investigate The Effect of JNJ-39758979 on Histamine Induced Itch in Healthy Male Volunteers",[38],[6325],"Histamine Induced Itch",[6314],{"trials":6328,"activeCount":8},[],{"trials":6330,"activeCount":8},[],{"trials":6332,"activeCount":8},[],{"trials":6334,"activeCount":8},[],{"intervention":6336,"totalTrials":285,"cells":6337},"JNJ-40346527\u002FPlacebo",{"EARLY_PHASE1":6338,"PHASE1":6340,"PHASE2":6351,"PHASE3":6353,"PHASE4":6355,"NA":6357},{"trials":6339,"activeCount":8},[],{"trials":6341,"activeCount":8},[6342],{"nctId":6343,"briefTitle":6344,"status":55,"phases":6345,"completion":2919,"start":332,"enrollment":6346,"conditions":6347,"interventions":6349},"NCT01054014","A Single and Multiple Dose Study to Explore the Safety Of JNJ-40346527 In Healthy Volunteers",[38],120,[6348],"Health",[6336,6336,6350],"JNJ-40346527",{"trials":6352,"activeCount":8},[],{"trials":6354,"activeCount":8},[],{"trials":6356,"activeCount":8},[],{"trials":6358,"activeCount":8},[],{"intervention":6350,"totalTrials":285,"cells":6360},{"EARLY_PHASE1":6361,"PHASE1":6363,"PHASE2":6369,"PHASE3":6371,"PHASE4":6373,"NA":6375},{"trials":6362,"activeCount":8},[],{"trials":6364,"activeCount":8},[6365],{"nctId":6343,"briefTitle":6344,"status":55,"phases":6366,"completion":2919,"start":332,"enrollment":6346,"conditions":6367,"interventions":6368},[38],[6348],[6336,6336,6350],{"trials":6370,"activeCount":8},[],{"trials":6372,"activeCount":8},[],{"trials":6374,"activeCount":8},[],{"trials":6376,"activeCount":8},[],{"intervention":6378,"totalTrials":285,"cells":6379},"JNJ 39393406 30 mg solid X",{"EARLY_PHASE1":6380,"PHASE1":6382,"PHASE2":6394,"PHASE3":6396,"PHASE4":6398,"NA":6400},{"trials":6381,"activeCount":8},[],{"trials":6383,"activeCount":8},[6384],{"nctId":6385,"briefTitle":6386,"status":55,"phases":6387,"primaryCompletion":252,"completion":252,"start":4325,"enrollment":1107,"conditions":6388,"interventions":6389},"NCT01986491","A Study of Solid Formulations of JNJ-39393406 in Healthy Male Participants",[38],[17],[6378,6390,6391,6392,6393],"JNJ 39393406 30 mg solid Y","JNJ 39393406 120 mg solid X","JNJ 39393406 120 mg solid Y","JNJ 39393406 30 mg solution",{"trials":6395,"activeCount":8},[],{"trials":6397,"activeCount":8},[],{"trials":6399,"activeCount":8},[],{"trials":6401,"activeCount":8},[],{"intervention":6390,"totalTrials":285,"cells":6403},{"EARLY_PHASE1":6404,"PHASE1":6406,"PHASE2":6412,"PHASE3":6414,"PHASE4":6416,"NA":6418},{"trials":6405,"activeCount":8},[],{"trials":6407,"activeCount":8},[6408],{"nctId":6385,"briefTitle":6386,"status":55,"phases":6409,"primaryCompletion":252,"completion":252,"start":4325,"enrollment":1107,"conditions":6410,"interventions":6411},[38],[17],[6378,6390,6391,6392,6393],{"trials":6413,"activeCount":8},[],{"trials":6415,"activeCount":8},[],{"trials":6417,"activeCount":8},[],{"trials":6419,"activeCount":8},[],{"intervention":6391,"totalTrials":285,"cells":6421},{"EARLY_PHASE1":6422,"PHASE1":6424,"PHASE2":6430,"PHASE3":6432,"PHASE4":6434,"NA":6436},{"trials":6423,"activeCount":8},[],{"trials":6425,"activeCount":8},[6426],{"nctId":6385,"briefTitle":6386,"status":55,"phases":6427,"primaryCompletion":252,"completion":252,"start":4325,"enrollment":1107,"conditions":6428,"interventions":6429},[38],[17],[6378,6390,6391,6392,6393],{"trials":6431,"activeCount":8},[],{"trials":6433,"activeCount":8},[],{"trials":6435,"activeCount":8},[],{"trials":6437,"activeCount":8},[],{"intervention":6392,"totalTrials":285,"cells":6439},{"EARLY_PHASE1":6440,"PHASE1":6442,"PHASE2":6448,"PHASE3":6450,"PHASE4":6452,"NA":6454},{"trials":6441,"activeCount":8},[],{"trials":6443,"activeCount":8},[6444],{"nctId":6385,"briefTitle":6386,"status":55,"phases":6445,"primaryCompletion":252,"completion":252,"start":4325,"enrollment":1107,"conditions":6446,"interventions":6447},[38],[17],[6378,6390,6391,6392,6393],{"trials":6449,"activeCount":8},[],{"trials":6451,"activeCount":8},[],{"trials":6453,"activeCount":8},[],{"trials":6455,"activeCount":8},[],{"intervention":6393,"totalTrials":285,"cells":6457},{"EARLY_PHASE1":6458,"PHASE1":6460,"PHASE2":6466,"PHASE3":6468,"PHASE4":6470,"NA":6472},{"trials":6459,"activeCount":8},[],{"trials":6461,"activeCount":8},[6462],{"nctId":6385,"briefTitle":6386,"status":55,"phases":6463,"primaryCompletion":252,"completion":252,"start":4325,"enrollment":1107,"conditions":6464,"interventions":6465},[38],[17],[6378,6390,6391,6392,6393],{"trials":6467,"activeCount":8},[],{"trials":6469,"activeCount":8},[],{"trials":6471,"activeCount":8},[],{"trials":6473,"activeCount":8},[],{"intervention":6475,"totalTrials":285,"cells":6476},"Canagliflozin, 50 mg",{"EARLY_PHASE1":6477,"PHASE1":6479,"PHASE2":6489,"PHASE3":6491,"PHASE4":6493,"NA":6495},{"trials":6478,"activeCount":8},[],{"trials":6480,"activeCount":8},[6481],{"nctId":6482,"briefTitle":6483,"status":55,"phases":6484,"primaryCompletion":2040,"completion":2040,"start":4913,"enrollment":987,"conditions":6485,"interventions":6486},"NCT01340677","A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers",[38],[17],[6475,6487,6488],"Canagliflozin, 300 mg","Canagliflozin, 100 mg",{"trials":6490,"activeCount":8},[],{"trials":6492,"activeCount":8},[],{"trials":6494,"activeCount":8},[],{"trials":6496,"activeCount":8},[],{"intervention":6487,"totalTrials":285,"cells":6498},{"EARLY_PHASE1":6499,"PHASE1":6501,"PHASE2":6507,"PHASE3":6509,"PHASE4":6511,"NA":6513},{"trials":6500,"activeCount":8},[],{"trials":6502,"activeCount":8},[6503],{"nctId":6482,"briefTitle":6483,"status":55,"phases":6504,"primaryCompletion":2040,"completion":2040,"start":4913,"enrollment":987,"conditions":6505,"interventions":6506},[38],[17],[6475,6487,6488],{"trials":6508,"activeCount":8},[],{"trials":6510,"activeCount":8},[],{"trials":6512,"activeCount":8},[],{"trials":6514,"activeCount":8},[],{"intervention":6488,"totalTrials":285,"cells":6516},{"EARLY_PHASE1":6517,"PHASE1":6519,"PHASE2":6525,"PHASE3":6527,"PHASE4":6529,"NA":6531},{"trials":6518,"activeCount":8},[],{"trials":6520,"activeCount":8},[6521],{"nctId":6482,"briefTitle":6483,"status":55,"phases":6522,"primaryCompletion":2040,"completion":2040,"start":4913,"enrollment":987,"conditions":6523,"interventions":6524},[38],[17],[6475,6487,6488],{"trials":6526,"activeCount":8},[],{"trials":6528,"activeCount":8},[],{"trials":6530,"activeCount":8},[],{"trials":6532,"activeCount":8},[],{"intervention":6534,"totalTrials":285,"cells":6535},"EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE",{"EARLY_PHASE1":6536,"PHASE1":6538,"PHASE2":6546,"PHASE3":6548,"PHASE4":6550,"NA":6552},{"trials":6537,"activeCount":8},[],{"trials":6539,"activeCount":8},[6540],{"nctId":6541,"briefTitle":6542,"status":55,"phases":6543,"completion":893,"start":193,"enrollment":2729,"conditions":6544,"interventions":6545},"NCT00258076","A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch)",[38],[3108,3109],[6534],{"trials":6547,"activeCount":8},[],{"trials":6549,"activeCount":8},[],{"trials":6551,"activeCount":8},[],{"trials":6553,"activeCount":8},[],{"intervention":4198,"totalTrials":285,"cells":6555},{"EARLY_PHASE1":6556,"PHASE1":6558,"PHASE2":6564,"PHASE3":6566,"PHASE4":6568,"NA":6570},{"trials":6557,"activeCount":8},[],{"trials":6559,"activeCount":8},[6560],{"nctId":4192,"briefTitle":4193,"status":55,"phases":6561,"primaryCompletion":2040,"completion":2040,"start":1269,"enrollment":4195,"conditions":6562,"interventions":6563},[38],[17],[4198,4177],{"trials":6565,"activeCount":8},[],{"trials":6567,"activeCount":8},[],{"trials":6569,"activeCount":8},[],{"trials":6571,"activeCount":8},[],{"intervention":6573,"totalTrials":285,"cells":6574},"14C-paliperidone",{"EARLY_PHASE1":6575,"PHASE1":6577,"PHASE2":6585,"PHASE3":6587,"PHASE4":6589,"NA":6591},{"trials":6576,"activeCount":8},[],{"trials":6578,"activeCount":8},[6579],{"nctId":6580,"briefTitle":6581,"status":55,"phases":6582,"completion":1121,"start":1121,"enrollment":998,"conditions":6583,"interventions":6584},"NCT00796029","A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose",[38],[14],[6573],{"trials":6586,"activeCount":8},[],{"trials":6588,"activeCount":8},[],{"trials":6590,"activeCount":8},[],{"trials":6592,"activeCount":8},[],{"intervention":6594,"totalTrials":285,"cells":6595},"Norgestimate\u002FEhinyl Estradiol; Folic acid.",{"EARLY_PHASE1":6596,"PHASE1":6598,"PHASE2":6607,"PHASE3":6609,"PHASE4":6611,"NA":6613},{"trials":6597,"activeCount":8},[],{"trials":6599,"activeCount":8},[6600],{"nctId":6601,"briefTitle":6602,"status":55,"phases":6603,"completion":527,"start":749,"enrollment":2729,"conditions":6604,"interventions":6606},"NCT00709189","Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)\u002FEthinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.",[38],[3109,3108,6605,4319],"Therapeutic Equivalency",[6594],{"trials":6608,"activeCount":8},[],{"trials":6610,"activeCount":8},[],{"trials":6612,"activeCount":8},[],{"trials":6614,"activeCount":8},[],{"intervention":6616,"totalTrials":285,"cells":6617},"Canagliflozin (JNJ-28431754) 200 mg",{"EARLY_PHASE1":6618,"PHASE1":6620,"PHASE2":6629,"PHASE3":6631,"PHASE4":6633,"NA":6635},{"trials":6619,"activeCount":8},[],{"trials":6621,"activeCount":8},[6622],{"nctId":6623,"briefTitle":6624,"status":55,"phases":6625,"primaryCompletion":1822,"completion":1822,"start":2847,"enrollment":34,"conditions":6626,"interventions":6627},"NCT01748526","A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers",[38],[17],[6616,6628],"Canagliflozin (JNJ-28431754) 300 mg",{"trials":6630,"activeCount":8},[],{"trials":6632,"activeCount":8},[],{"trials":6634,"activeCount":8},[],{"trials":6636,"activeCount":8},[],{"intervention":6628,"totalTrials":285,"cells":6638},{"EARLY_PHASE1":6639,"PHASE1":6641,"PHASE2":6647,"PHASE3":6649,"PHASE4":6651,"NA":6653},{"trials":6640,"activeCount":8},[],{"trials":6642,"activeCount":8},[6643],{"nctId":6623,"briefTitle":6624,"status":55,"phases":6644,"primaryCompletion":1822,"completion":1822,"start":2847,"enrollment":34,"conditions":6645,"interventions":6646},[38],[17],[6616,6628],{"trials":6648,"activeCount":8},[],{"trials":6650,"activeCount":8},[],{"trials":6652,"activeCount":8},[],{"trials":6654,"activeCount":8},[],{"intervention":6656,"totalTrials":285,"cells":6657},"JNJ-39823277",{"EARLY_PHASE1":6658,"PHASE1":6660,"PHASE2":6668,"PHASE3":6670,"PHASE4":6672,"NA":6674},{"trials":6659,"activeCount":8},[],{"trials":6661,"activeCount":8},[6662],{"nctId":6663,"briefTitle":6664,"status":55,"phases":6665,"primaryCompletion":2191,"completion":2191,"start":4325,"enrollment":557,"conditions":6666,"interventions":6667},"NCT02103985","A Study of Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy Participants",[38],[17],[6656],{"trials":6669,"activeCount":8},[],{"trials":6671,"activeCount":8},[],{"trials":6673,"activeCount":8},[],{"trials":6675,"activeCount":8},[],{"intervention":6677,"totalTrials":285,"cells":6678},"[11C] JNJ-42491293",{"EARLY_PHASE1":6679,"PHASE1":6681,"PHASE2":6690,"PHASE3":6692,"PHASE4":6694,"NA":6696},{"trials":6680,"activeCount":8},[],{"trials":6682,"activeCount":8},[6683],{"nctId":6684,"briefTitle":6685,"status":55,"phases":6686,"primaryCompletion":1269,"completion":1269,"start":4436,"enrollment":1107,"conditions":6687,"interventions":6688},"NCT01359852","A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers",[38],[17],[6677,6689,6689,6677],"[11C] JNJ-42491293 + JNJ-40411813",{"trials":6691,"activeCount":8},[],{"trials":6693,"activeCount":8},[],{"trials":6695,"activeCount":8},[],{"trials":6697,"activeCount":8},[],{"intervention":6689,"totalTrials":285,"cells":6699},{"EARLY_PHASE1":6700,"PHASE1":6702,"PHASE2":6708,"PHASE3":6710,"PHASE4":6712,"NA":6714},{"trials":6701,"activeCount":8},[],{"trials":6703,"activeCount":8},[6704],{"nctId":6684,"briefTitle":6685,"status":55,"phases":6705,"primaryCompletion":1269,"completion":1269,"start":4436,"enrollment":1107,"conditions":6706,"interventions":6707},[38],[17],[6677,6689,6689,6677],{"trials":6709,"activeCount":8},[],{"trials":6711,"activeCount":8},[],{"trials":6713,"activeCount":8},[],{"trials":6715,"activeCount":8},[],{"intervention":6717,"totalTrials":285,"cells":6718},"JNJ-26854165",{"EARLY_PHASE1":6719,"PHASE1":6721,"PHASE2":6729,"PHASE3":6731,"PHASE4":6733,"NA":6735},{"trials":6720,"activeCount":8},[],{"trials":6722,"activeCount":8},[6723],{"nctId":6724,"briefTitle":6725,"status":55,"phases":6726,"completion":2562,"start":57,"enrollment":4578,"conditions":6727,"interventions":6728},"NCT00676910","A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.",[38],[137],[6717],{"trials":6730,"activeCount":8},[],{"trials":6732,"activeCount":8},[],{"trials":6734,"activeCount":8},[],{"trials":6736,"activeCount":8},[],{"intervention":4205,"totalTrials":285,"cells":6738},{"EARLY_PHASE1":6739,"PHASE1":6741,"PHASE2":6747,"PHASE3":6749,"PHASE4":6751,"NA":6753},{"trials":6740,"activeCount":8},[],{"trials":6742,"activeCount":8},[6743],{"nctId":4200,"briefTitle":4201,"status":55,"phases":6744,"primaryCompletion":171,"completion":171,"start":516,"enrollment":3130,"conditions":6745,"interventions":6746},[38],[17],[4205,4177],{"trials":6748,"activeCount":8},[],{"trials":6750,"activeCount":8},[],{"trials":6752,"activeCount":8},[],{"trials":6754,"activeCount":8},[],{"intervention":4212,"totalTrials":285,"cells":6756},{"EARLY_PHASE1":6757,"PHASE1":6759,"PHASE2":6765,"PHASE3":6767,"PHASE4":6769,"NA":6771},{"trials":6758,"activeCount":8},[],{"trials":6760,"activeCount":8},[6761],{"nctId":4207,"briefTitle":4208,"status":55,"phases":6762,"primaryCompletion":1822,"completion":1822,"start":333,"enrollment":268,"conditions":6763,"interventions":6764},[38],[17],[4177,4212],{"trials":6766,"activeCount":8},[],{"trials":6768,"activeCount":8},[],{"trials":6770,"activeCount":8},[],{"trials":6772,"activeCount":8},[],{"intervention":5722,"totalTrials":285,"cells":6774},{"EARLY_PHASE1":6775,"PHASE1":6777,"PHASE2":6783,"PHASE3":6785,"PHASE4":6787,"NA":6789},{"trials":6776,"activeCount":8},[],{"trials":6778,"activeCount":8},[6779],{"nctId":5717,"briefTitle":5718,"status":55,"phases":6780,"primaryCompletion":3328,"completion":3328,"start":332,"enrollment":1709,"conditions":6781,"interventions":6782},[38],[17],[5710,5722],{"trials":6784,"activeCount":8},[],{"trials":6786,"activeCount":8},[],{"trials":6788,"activeCount":8},[],{"trials":6790,"activeCount":8},[],{"intervention":6792,"totalTrials":285,"cells":6793},"Canagliflozin 300 mg once daily and HCTZ 25 mg once daily",{"EARLY_PHASE1":6794,"PHASE1":6796,"PHASE2":6804,"PHASE3":6806,"PHASE4":6808,"NA":6810},{"trials":6795,"activeCount":8},[],{"trials":6797,"activeCount":8},[6798],{"nctId":6799,"briefTitle":6800,"status":55,"phases":6801,"primaryCompletion":1269,"completion":1269,"start":2508,"enrollment":3130,"conditions":6802,"interventions":6803},"NCT01294631","A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers",[38],[17],[6792],{"trials":6805,"activeCount":8},[],{"trials":6807,"activeCount":8},[],{"trials":6809,"activeCount":8},[],{"trials":6811,"activeCount":8},[],{"intervention":6813,"totalTrials":285,"cells":6814},"Canagliflozin 300 mg once daily and 150 mg twice daily",{"EARLY_PHASE1":6815,"PHASE1":6817,"PHASE2":6827,"PHASE3":6829,"PHASE4":6831,"NA":6833},{"trials":6816,"activeCount":8},[],{"trials":6818,"activeCount":8},[6819],{"nctId":6820,"briefTitle":6821,"status":55,"phases":6822,"completion":4913,"start":2919,"enrollment":6823,"conditions":6824,"interventions":6825},"NCT01286103","A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers",[38],34,[17],[6813,6826],"Canagliflozin 100 mg once daily and 50 mg twice daily",{"trials":6828,"activeCount":8},[],{"trials":6830,"activeCount":8},[],{"trials":6832,"activeCount":8},[],{"trials":6834,"activeCount":8},[],{"intervention":6826,"totalTrials":285,"cells":6836},{"EARLY_PHASE1":6837,"PHASE1":6839,"PHASE2":6845,"PHASE3":6847,"PHASE4":6849,"NA":6851},{"trials":6838,"activeCount":8},[],{"trials":6840,"activeCount":8},[6841],{"nctId":6820,"briefTitle":6821,"status":55,"phases":6842,"completion":4913,"start":2919,"enrollment":6823,"conditions":6843,"interventions":6844},[38],[17],[6813,6826],{"trials":6846,"activeCount":8},[],{"trials":6848,"activeCount":8},[],{"trials":6850,"activeCount":8},[],{"trials":6852,"activeCount":8},[],{"intervention":5761,"totalTrials":285,"cells":6854},{"EARLY_PHASE1":6855,"PHASE1":6857,"PHASE2":6863,"PHASE3":6865,"PHASE4":6867,"NA":6869},{"trials":6856,"activeCount":8},[],{"trials":6858,"activeCount":8},[6859],{"nctId":5755,"briefTitle":5756,"status":55,"phases":6860,"completion":4913,"start":3613,"enrollment":46,"conditions":6861,"interventions":6862},[38],[5759],[5761,5748,5762,5763],{"trials":6864,"activeCount":8},[],{"trials":6866,"activeCount":8},[],{"trials":6868,"activeCount":8},[],{"trials":6870,"activeCount":8},[],{"intervention":6872,"totalTrials":285,"cells":6873},"JNJ-31001074; ketoconazole",{"EARLY_PHASE1":6874,"PHASE1":6876,"PHASE2":6884,"PHASE3":6886,"PHASE4":6888,"NA":6890},{"trials":6875,"activeCount":8},[],{"trials":6877,"activeCount":8},[6878],{"nctId":6879,"briefTitle":6880,"status":55,"phases":6881,"completion":2030,"start":3571,"enrollment":4195,"conditions":6882,"interventions":6883},"NCT00915746","A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers",[38],[17,4319,4341],[6872],{"trials":6885,"activeCount":8},[],{"trials":6887,"activeCount":8},[],{"trials":6889,"activeCount":8},[],{"trials":6891,"activeCount":8},[],{"intervention":6893,"totalTrials":285,"cells":6894},"Canagliflozin 300mg\u002FPlacebo",{"EARLY_PHASE1":6895,"PHASE1":6897,"PHASE2":6907,"PHASE3":6909,"PHASE4":6911,"NA":6913},{"trials":6896,"activeCount":8},[],{"trials":6898,"activeCount":8},[6899],{"nctId":6900,"briefTitle":6901,"status":55,"phases":6902,"primaryCompletion":3570,"completion":3570,"start":1700,"enrollment":518,"conditions":6903,"interventions":6904},"NCT01381887","A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus",[38],[29],[6893,6905,6906],"Canagliflozin 300mg\u002FCanagliflozin 150mg","Canagliflozin 300mg",{"trials":6908,"activeCount":8},[],{"trials":6910,"activeCount":8},[],{"trials":6912,"activeCount":8},[],{"trials":6914,"activeCount":8},[],{"intervention":6905,"totalTrials":285,"cells":6916},{"EARLY_PHASE1":6917,"PHASE1":6919,"PHASE2":6925,"PHASE3":6927,"PHASE4":6929,"NA":6931},{"trials":6918,"activeCount":8},[],{"trials":6920,"activeCount":8},[6921],{"nctId":6900,"briefTitle":6901,"status":55,"phases":6922,"primaryCompletion":3570,"completion":3570,"start":1700,"enrollment":518,"conditions":6923,"interventions":6924},[38],[29],[6893,6905,6906],{"trials":6926,"activeCount":8},[],{"trials":6928,"activeCount":8},[],{"trials":6930,"activeCount":8},[],{"trials":6932,"activeCount":8},[],{"intervention":6906,"totalTrials":285,"cells":6934},{"EARLY_PHASE1":6935,"PHASE1":6937,"PHASE2":6943,"PHASE3":6945,"PHASE4":6947,"NA":6949},{"trials":6936,"activeCount":8},[],{"trials":6938,"activeCount":8},[6939],{"nctId":6900,"briefTitle":6901,"status":55,"phases":6940,"primaryCompletion":3570,"completion":3570,"start":1700,"enrollment":518,"conditions":6941,"interventions":6942},[38],[29],[6893,6905,6906],{"trials":6944,"activeCount":8},[],{"trials":6946,"activeCount":8},[],{"trials":6948,"activeCount":8},[],{"trials":6950,"activeCount":8},[],{"intervention":6952,"totalTrials":285,"cells":6953},"JNJ-39758979 \u002F MTX",{"EARLY_PHASE1":6954,"PHASE1":6956,"PHASE2":6966,"PHASE3":6968,"PHASE4":6970,"NA":6972},{"trials":6955,"activeCount":8},[],{"trials":6957,"activeCount":8},[6958],{"nctId":6959,"briefTitle":6960,"status":55,"phases":6961,"completion":6962,"start":2040,"enrollment":6963,"conditions":6964,"interventions":6965},"NCT01442545","A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants",[38],"2011-12",21,[92],[6952],{"trials":6967,"activeCount":8},[],{"trials":6969,"activeCount":8},[],{"trials":6971,"activeCount":8},[],{"trials":6973,"activeCount":8},[],{"intervention":4234,"totalTrials":285,"cells":6975},{"EARLY_PHASE1":6976,"PHASE1":6978,"PHASE2":6984,"PHASE3":6986,"PHASE4":6988,"NA":6990},{"trials":6977,"activeCount":8},[],{"trials":6979,"activeCount":8},[6980],{"nctId":4229,"briefTitle":4230,"status":55,"phases":6981,"primaryCompletion":4224,"completion":4224,"start":3613,"enrollment":1709,"conditions":6982,"interventions":6983},[38],[17],[4177,4234],{"trials":6985,"activeCount":8},[],{"trials":6987,"activeCount":8},[],{"trials":6989,"activeCount":8},[],{"trials":6991,"activeCount":8},[],{"intervention":6993,"totalTrials":285,"cells":6994},"JNJ-39439335, Placebo",{"EARLY_PHASE1":6995,"PHASE1":6997,"PHASE2":7005,"PHASE3":7007,"PHASE4":7009,"NA":7011},{"trials":6996,"activeCount":8},[],{"trials":6998,"activeCount":8},[6999],{"nctId":7000,"briefTitle":7001,"status":55,"phases":7002,"completion":2498,"start":2191,"enrollment":125,"conditions":7003,"interventions":7004},"NCT01006304","An Exploratory Study to Assess the Effects of JNJ-39439335 on the Relief of Pain Using a Thermal-Grill Experimental Model",[38],[2311],[6993],{"trials":7006,"activeCount":8},[],{"trials":7008,"activeCount":8},[],{"trials":7010,"activeCount":8},[],{"trials":7012,"activeCount":8},[],{"intervention":7014,"totalTrials":285,"cells":7015},"Canagliflozin\u002FPlacebo Placebo\u002FCanagliflozin",{"EARLY_PHASE1":7016,"PHASE1":7018,"PHASE2":7026,"PHASE3":7028,"PHASE4":7030,"NA":7032},{"trials":7017,"activeCount":8},[],{"trials":7019,"activeCount":8},[7020],{"nctId":7021,"briefTitle":7022,"status":55,"phases":7023,"completion":1387,"start":2056,"enrollment":5389,"conditions":7024,"interventions":7025},"NCT01173549","A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers",[38],[17],[7014],{"trials":7027,"activeCount":8},[],{"trials":7029,"activeCount":8},[],{"trials":7031,"activeCount":8},[],{"trials":7033,"activeCount":8},[],{"intervention":7035,"totalTrials":285,"cells":7036},"Paliperidone palmitate Treatment A",{"EARLY_PHASE1":7037,"PHASE1":7039,"PHASE2":7049,"PHASE3":7051,"PHASE4":7053,"NA":7055},{"trials":7038,"activeCount":8},[],{"trials":7040,"activeCount":8},[7041],{"nctId":7042,"briefTitle":7043,"status":55,"phases":7044,"primaryCompletion":2191,"completion":2191,"start":1016,"enrollment":7045,"conditions":7046,"interventions":7047},"NCT01150448","A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia",[38],212,[14],[7035,7048],"Paliperidone palmitate Treatment B",{"trials":7050,"activeCount":8},[],{"trials":7052,"activeCount":8},[],{"trials":7054,"activeCount":8},[],{"trials":7056,"activeCount":8},[],{"intervention":7048,"totalTrials":285,"cells":7058},{"EARLY_PHASE1":7059,"PHASE1":7061,"PHASE2":7067,"PHASE3":7069,"PHASE4":7071,"NA":7073},{"trials":7060,"activeCount":8},[],{"trials":7062,"activeCount":8},[7063],{"nctId":7042,"briefTitle":7043,"status":55,"phases":7064,"primaryCompletion":2191,"completion":2191,"start":1016,"enrollment":7045,"conditions":7065,"interventions":7066},[38],[14],[7035,7048],{"trials":7068,"activeCount":8},[],{"trials":7070,"activeCount":8},[],{"trials":7072,"activeCount":8},[],{"trials":7074,"activeCount":8},[],{"intervention":7076,"totalTrials":285,"cells":7077},"Canagliflozin\u002FMetformin",{"EARLY_PHASE1":7078,"PHASE1":7080,"PHASE2":7088,"PHASE3":7090,"PHASE4":7092,"NA":7094},{"trials":7079,"activeCount":8},[],{"trials":7081,"activeCount":8},[7082],{"nctId":7083,"briefTitle":7084,"status":55,"phases":7085,"completion":3613,"start":4436,"enrollment":1709,"conditions":7086,"interventions":7087},"NCT01273571","A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult Volunteers",[38],[17],[7076],{"trials":7089,"activeCount":8},[],{"trials":7091,"activeCount":8},[],{"trials":7093,"activeCount":8},[],{"trials":7095,"activeCount":8},[],{"intervention":7097,"totalTrials":285,"cells":7098},"levofloxacin oral solution",{"EARLY_PHASE1":7099,"PHASE1":7101,"PHASE2":7109,"PHASE3":7111,"PHASE4":7113,"NA":7115},{"trials":7100,"activeCount":8},[],{"trials":7102,"activeCount":8},[7103],{"nctId":7104,"briefTitle":7105,"status":55,"phases":7106,"completion":1133,"start":555,"enrollment":987,"conditions":7107,"interventions":7108},"NCT00601432","A Study to Evaluate the Effect of Food on Levofloxacin Pharmacokinetics From an Oral Solution Formulation",[38],[17],[7097],{"trials":7110,"activeCount":8},[],{"trials":7112,"activeCount":8},[],{"trials":7114,"activeCount":8},[],{"trials":7116,"activeCount":8},[],{"intervention":7118,"totalTrials":285,"cells":7119},"14C-JNJ26489112",{"EARLY_PHASE1":7120,"PHASE1":7122,"PHASE2":7131,"PHASE3":7133,"PHASE4":7135,"NA":7137},{"trials":7121,"activeCount":8},[],{"trials":7123,"activeCount":8},[7124],{"nctId":7125,"briefTitle":7126,"status":55,"phases":7127,"primaryCompletion":1446,"completion":1446,"start":332,"enrollment":1879,"conditions":7128,"interventions":7130},"NCT01949610","A Study to Evaluate Absorption, Metabolism, and Excretion of 14C-JNJ26489112 in Healthy Male Participants",[38],[7129],"Healthy Participants",[7118],{"trials":7132,"activeCount":8},[],{"trials":7134,"activeCount":8},[],{"trials":7136,"activeCount":8},[],{"trials":7138,"activeCount":8},[],{"intervention":7140,"totalTrials":285,"cells":7141},"Tapentadol ER 250-mg TRF",{"EARLY_PHASE1":7142,"PHASE1":7144,"PHASE2":7153,"PHASE3":7155,"PHASE4":7157,"NA":7159},{"trials":7143,"activeCount":8},[],{"trials":7145,"activeCount":8},[7146],{"nctId":7147,"briefTitle":7148,"status":55,"phases":7149,"primaryCompletion":2483,"completion":2483,"start":2484,"enrollment":226,"conditions":7150,"interventions":7151},"NCT01981278","A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants",[38],[17],[7140,7152],"Tapentadol ER 250-mg PR2",{"trials":7154,"activeCount":8},[],{"trials":7156,"activeCount":8},[],{"trials":7158,"activeCount":8},[],{"trials":7160,"activeCount":8},[],{"intervention":7152,"totalTrials":285,"cells":7162},{"EARLY_PHASE1":7163,"PHASE1":7165,"PHASE2":7171,"PHASE3":7173,"PHASE4":7175,"NA":7177},{"trials":7164,"activeCount":8},[],{"trials":7166,"activeCount":8},[7167],{"nctId":7147,"briefTitle":7148,"status":55,"phases":7168,"primaryCompletion":2483,"completion":2483,"start":2484,"enrollment":226,"conditions":7169,"interventions":7170},[38],[17],[7140,7152],{"trials":7172,"activeCount":8},[],{"trials":7174,"activeCount":8},[],{"trials":7176,"activeCount":8},[],{"trials":7178,"activeCount":8},[],{"intervention":7180,"totalTrials":285,"cells":7181},"JNJ 28431754",{"EARLY_PHASE1":7182,"PHASE1":7184,"PHASE2":7192,"PHASE3":7194,"PHASE4":7196,"NA":7198},{"trials":7183,"activeCount":8},[],{"trials":7185,"activeCount":8},[7186],{"nctId":7187,"briefTitle":7188,"status":55,"phases":7189,"primaryCompletion":1447,"completion":1447,"start":747,"enrollment":4727,"conditions":7190,"interventions":7191},"NCT00963768","A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus",[38],[29],[7180],{"trials":7193,"activeCount":8},[],{"trials":7195,"activeCount":8},[],{"trials":7197,"activeCount":8},[],{"trials":7199,"activeCount":8},[],{"intervention":7201,"totalTrials":285,"cells":7202},"JNJ-40411813: Formulation A",{"EARLY_PHASE1":7203,"PHASE1":7205,"PHASE2":7216,"PHASE3":7218,"PHASE4":7220,"NA":7222},{"trials":7204,"activeCount":8},[],{"trials":7206,"activeCount":8},[7207],{"nctId":7208,"briefTitle":7209,"status":55,"phases":7210,"primaryCompletion":3328,"completion":3328,"start":2562,"enrollment":5906,"conditions":7211,"interventions":7212},"NCT01932320","A Study to Evaluate the Relative Bioavailability, Food Effect and Effect of Ketoconazole on the Rate and Extent of Absorption of Solid Dosage Formulation(s) of JNJ-40411813",[38],[17],[7201,7213,7214,7215],"JNJ-40411813: Formulation B","JNJ-40411813: Formulation C","Ketoconazole",{"trials":7217,"activeCount":8},[],{"trials":7219,"activeCount":8},[],{"trials":7221,"activeCount":8},[],{"trials":7223,"activeCount":8},[],{"intervention":7213,"totalTrials":285,"cells":7225},{"EARLY_PHASE1":7226,"PHASE1":7228,"PHASE2":7234,"PHASE3":7236,"PHASE4":7238,"NA":7240},{"trials":7227,"activeCount":8},[],{"trials":7229,"activeCount":8},[7230],{"nctId":7208,"briefTitle":7209,"status":55,"phases":7231,"primaryCompletion":3328,"completion":3328,"start":2562,"enrollment":5906,"conditions":7232,"interventions":7233},[38],[17],[7201,7213,7214,7215],{"trials":7235,"activeCount":8},[],{"trials":7237,"activeCount":8},[],{"trials":7239,"activeCount":8},[],{"trials":7241,"activeCount":8},[],{"intervention":7214,"totalTrials":285,"cells":7243},{"EARLY_PHASE1":7244,"PHASE1":7246,"PHASE2":7252,"PHASE3":7254,"PHASE4":7256,"NA":7258},{"trials":7245,"activeCount":8},[],{"trials":7247,"activeCount":8},[7248],{"nctId":7208,"briefTitle":7209,"status":55,"phases":7249,"primaryCompletion":3328,"completion":3328,"start":2562,"enrollment":5906,"conditions":7250,"interventions":7251},[38],[17],[7201,7213,7214,7215],{"trials":7253,"activeCount":8},[],{"trials":7255,"activeCount":8},[],{"trials":7257,"activeCount":8},[],{"trials":7259,"activeCount":8},[],{"intervention":7215,"totalTrials":285,"cells":7261},{"EARLY_PHASE1":7262,"PHASE1":7264,"PHASE2":7270,"PHASE3":7272,"PHASE4":7274,"NA":7276},{"trials":7263,"activeCount":8},[],{"trials":7265,"activeCount":8},[7266],{"nctId":7208,"briefTitle":7209,"status":55,"phases":7267,"primaryCompletion":3328,"completion":3328,"start":2562,"enrollment":5906,"conditions":7268,"interventions":7269},[38],[17],[7201,7213,7214,7215],{"trials":7271,"activeCount":8},[],{"trials":7273,"activeCount":8},[],{"trials":7275,"activeCount":8},[],{"trials":7277,"activeCount":8},[],{"intervention":7279,"totalTrials":285,"cells":7280},"Folic acid",{"EARLY_PHASE1":7281,"PHASE1":7283,"PHASE2":7291,"PHASE3":7293,"PHASE4":7295,"NA":7297},{"trials":7282,"activeCount":8},[],{"trials":7284,"activeCount":8},[7285],{"nctId":7286,"briefTitle":7287,"status":55,"phases":7288,"completion":2146,"start":341,"enrollment":125,"conditions":7289,"interventions":7290},"NCT00709267","Bioavailability Study of Folic Acid in Healthy Women",[38],[17,4319],[7279],{"trials":7292,"activeCount":8},[],{"trials":7294,"activeCount":8},[],{"trials":7296,"activeCount":8},[],{"trials":7298,"activeCount":8},[],{"intervention":7300,"totalTrials":285,"cells":7301},"EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).",{"EARLY_PHASE1":7302,"PHASE1":7304,"PHASE2":7312,"PHASE3":7314,"PHASE4":7316,"NA":7318},{"trials":7303,"activeCount":8},[],{"trials":7305,"activeCount":8},[7306],{"nctId":7307,"briefTitle":7308,"status":55,"phases":7309,"completion":115,"start":702,"enrollment":6823,"conditions":7310,"interventions":7311},"NCT00254865","A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers",[38],[3108,3109],[7300],{"trials":7313,"activeCount":8},[],{"trials":7315,"activeCount":8},[],{"trials":7317,"activeCount":8},[],{"trials":7319,"activeCount":8},[],{"intervention":7321,"totalTrials":285,"cells":7322},"Topiramate oral liquid formulation;Topiramate Sprinkle formulation",{"EARLY_PHASE1":7323,"PHASE1":7325,"PHASE2":7333,"PHASE3":7335,"PHASE4":7337,"NA":7339},{"trials":7324,"activeCount":8},[],{"trials":7326,"activeCount":8},[7327],{"nctId":7328,"briefTitle":7329,"status":55,"phases":7330,"completion":2146,"start":2432,"enrollment":59,"conditions":7331,"interventions":7332},"NCT00701493","A Phase 1 Bioavailability Study of Topiramate Oral Liquid Formulation Compared to the Marketed Sprinkle Capsule Formulation in Healthy Adults",[38],[23],[7321],{"trials":7334,"activeCount":8},[],{"trials":7336,"activeCount":8},[],{"trials":7338,"activeCount":8},[],{"trials":7340,"activeCount":8},[],{"intervention":7342,"totalTrials":285,"cells":7343},"Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations",{"EARLY_PHASE1":7344,"PHASE1":7346,"PHASE2":7354,"PHASE3":7356,"PHASE4":7358,"NA":7360},{"trials":7345,"activeCount":8},[],{"trials":7347,"activeCount":8},[7348],{"nctId":7349,"briefTitle":7350,"status":55,"phases":7351,"completion":546,"start":555,"enrollment":145,"conditions":7352,"interventions":7353},"NCT00602589","A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects",[38],[17],[7342],{"trials":7355,"activeCount":8},[],{"trials":7357,"activeCount":8},[],{"trials":7359,"activeCount":8},[],{"trials":7361,"activeCount":8},[],{"intervention":7363,"totalTrials":285,"cells":7364},"IR OROS paliperidone and ER OROS paliperidone",{"EARLY_PHASE1":7365,"PHASE1":7367,"PHASE2":7375,"PHASE3":7377,"PHASE4":7379,"NA":7381},{"trials":7366,"activeCount":8},[],{"trials":7368,"activeCount":8},[7369],{"nctId":7370,"briefTitle":7371,"status":55,"phases":7372,"completion":1064,"start":203,"enrollment":1107,"conditions":7373,"interventions":7374},"NCT00796276","A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone",[38],[14],[7363],{"trials":7376,"activeCount":8},[],{"trials":7378,"activeCount":8},[],{"trials":7380,"activeCount":8},[],{"trials":7382,"activeCount":8},[],{"intervention":7384,"totalTrials":285,"cells":7385},"ER Paliperidone",{"EARLY_PHASE1":7386,"PHASE1":7388,"PHASE2":7395,"PHASE3":7397,"PHASE4":7399,"NA":7401},{"trials":7387,"activeCount":8},[],{"trials":7389,"activeCount":8},[7390],{"nctId":7391,"briefTitle":948,"status":55,"phases":7392,"completion":1313,"start":456,"enrollment":950,"conditions":7393,"interventions":7394},"NCT00796640",[38],[14],[7384],{"trials":7396,"activeCount":8},[],{"trials":7398,"activeCount":8},[],{"trials":7400,"activeCount":8},[],{"trials":7402,"activeCount":8},[],{"intervention":7404,"totalTrials":285,"cells":7405},"14C-JNJ-39823277",{"EARLY_PHASE1":7406,"PHASE1":7408,"PHASE2":7416,"PHASE3":7418,"PHASE4":7420,"NA":7422},{"trials":7407,"activeCount":8},[],{"trials":7409,"activeCount":8},[7410],{"nctId":7411,"briefTitle":7412,"status":55,"phases":7413,"primaryCompletion":4325,"completion":4325,"start":6027,"enrollment":98,"conditions":7414,"interventions":7415},"NCT02049697","A Study to Evaluate of the Absorption, Metabolism, and Excretion of 14C-JNJ-39823277 in Healthy Male Participants",[38],[17],[7404],{"trials":7417,"activeCount":8},[],{"trials":7419,"activeCount":8},[],{"trials":7421,"activeCount":8},[],{"trials":7423,"activeCount":8},[],{"intervention":6118,"totalTrials":285,"cells":7425},{"EARLY_PHASE1":7426,"PHASE1":7428,"PHASE2":7434,"PHASE3":7436,"PHASE4":7438,"NA":7440},{"trials":7427,"activeCount":8},[],{"trials":7429,"activeCount":8},[7430],{"nctId":6113,"briefTitle":6114,"status":55,"phases":7431,"primaryCompletion":2056,"completion":2056,"start":2483,"enrollment":950,"conditions":7432,"interventions":7433},[38],[17],[6118,6111,6119,6097,6110],{"trials":7435,"activeCount":8},[],{"trials":7437,"activeCount":8},[],{"trials":7439,"activeCount":8},[],{"trials":7441,"activeCount":8},[],{"intervention":6119,"totalTrials":285,"cells":7443},{"EARLY_PHASE1":7444,"PHASE1":7446,"PHASE2":7452,"PHASE3":7454,"PHASE4":7456,"NA":7458},{"trials":7445,"activeCount":8},[],{"trials":7447,"activeCount":8},[7448],{"nctId":6113,"briefTitle":6114,"status":55,"phases":7449,"primaryCompletion":2056,"completion":2056,"start":2483,"enrollment":950,"conditions":7450,"interventions":7451},[38],[17],[6118,6111,6119,6097,6110],{"trials":7453,"activeCount":8},[],{"trials":7455,"activeCount":8},[],{"trials":7457,"activeCount":8},[],{"trials":7459,"activeCount":8},[],{"intervention":6184,"totalTrials":285,"cells":7461},{"EARLY_PHASE1":7462,"PHASE1":7464,"PHASE2":7470,"PHASE3":7472,"PHASE4":7474,"NA":7476},{"trials":7463,"activeCount":8},[],{"trials":7465,"activeCount":8},[7466],{"nctId":6179,"briefTitle":6180,"status":55,"phases":7467,"primaryCompletion":153,"completion":153,"start":6027,"enrollment":334,"conditions":7468,"interventions":7469},[38],[29],[6184,6036,6185],{"trials":7471,"activeCount":8},[],{"trials":7473,"activeCount":8},[],{"trials":7475,"activeCount":8},[],{"trials":7477,"activeCount":8},[],{"intervention":6185,"totalTrials":285,"cells":7479},{"EARLY_PHASE1":7480,"PHASE1":7482,"PHASE2":7488,"PHASE3":7490,"PHASE4":7492,"NA":7494},{"trials":7481,"activeCount":8},[],{"trials":7483,"activeCount":8},[7484],{"nctId":6179,"briefTitle":6180,"status":55,"phases":7485,"primaryCompletion":153,"completion":153,"start":6027,"enrollment":334,"conditions":7486,"interventions":7487},[38],[29],[6184,6036,6185],{"trials":7489,"activeCount":8},[],{"trials":7491,"activeCount":8},[],{"trials":7493,"activeCount":8},[],{"trials":7495,"activeCount":8},[],{"intervention":7497,"totalTrials":285,"cells":7498},"Canagliflozin\u002FWarfarin",{"EARLY_PHASE1":7499,"PHASE1":7501,"PHASE2":7509,"PHASE3":7511,"PHASE4":7513,"NA":7515},{"trials":7500,"activeCount":8},[],{"trials":7502,"activeCount":8},[7503],{"nctId":7504,"briefTitle":7505,"status":55,"phases":7506,"primaryCompletion":4436,"completion":4436,"start":2622,"enrollment":4195,"conditions":7507,"interventions":7508},"NCT01195324","A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers",[38],[17],[7497,7497],{"trials":7510,"activeCount":8},[],{"trials":7512,"activeCount":8},[],{"trials":7514,"activeCount":8},[],{"trials":7516,"activeCount":8},[],{"intervention":7518,"totalTrials":285,"cells":7519},"paliperidone palmitate 100 mg",{"EARLY_PHASE1":7520,"PHASE1":7522,"PHASE2":7530,"PHASE3":7532,"PHASE4":7534,"NA":7536},{"trials":7521,"activeCount":8},[],{"trials":7523,"activeCount":8},[7524],{"nctId":7525,"briefTitle":7526,"status":55,"phases":7527,"completion":234,"start":481,"enrollment":809,"conditions":7528,"interventions":7529},"NCT01110317","A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate",[38],[14],[7518],{"trials":7531,"activeCount":8},[],{"trials":7533,"activeCount":8},[],{"trials":7535,"activeCount":8},[],{"trials":7537,"activeCount":8},[],{"intervention":7539,"totalTrials":285,"cells":7540},"risperidone IR and LAI formulation",{"EARLY_PHASE1":7541,"PHASE1":7543,"PHASE2":7551,"PHASE3":7553,"PHASE4":7555,"NA":7557},{"trials":7542,"activeCount":8},[],{"trials":7544,"activeCount":8},[7545],{"nctId":7546,"briefTitle":7547,"status":55,"phases":7548,"primaryCompletion":2191,"completion":2191,"start":2318,"enrollment":987,"conditions":7549,"interventions":7550},"NCT00821600","Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia",[38],[1137,14],[7539],{"trials":7552,"activeCount":8},[],{"trials":7554,"activeCount":8},[],{"trials":7556,"activeCount":8},[],{"trials":7558,"activeCount":8},[],{"intervention":7560,"totalTrials":285,"cells":7561},"Norgestimate; Ethinyl Estradiol; Folic acid.",{"EARLY_PHASE1":7562,"PHASE1":7564,"PHASE2":7573,"PHASE3":7575,"PHASE4":7577,"NA":7579},{"trials":7563,"activeCount":8},[],{"trials":7565,"activeCount":8},[7566],{"nctId":7567,"briefTitle":7568,"status":55,"phases":7569,"completion":527,"start":854,"enrollment":21,"conditions":7570,"interventions":7572},"NCT00709644","Bioequivalence Study of the Oral Contraceptive (OC) Tablet Containing Norgestimate (NGM)\u002FEthinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.",[38],[4319,6605,7571],"Contraceptives, Oral",[7560],{"trials":7574,"activeCount":8},[],{"trials":7576,"activeCount":8},[],{"trials":7578,"activeCount":8},[],{"trials":7580,"activeCount":8},[],{"intervention":7582,"totalTrials":285,"cells":7583},"paliperidone ER; Carbamazepine",{"EARLY_PHASE1":7584,"PHASE1":7586,"PHASE2":7594,"PHASE3":7596,"PHASE4":7598,"NA":7600},{"trials":7585,"activeCount":8},[],{"trials":7587,"activeCount":8},[7588],{"nctId":7589,"briefTitle":7590,"status":55,"phases":7591,"completion":957,"start":70,"enrollment":2485,"conditions":7592,"interventions":7593},"NCT00892125","A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder",[38],[14,26],[7582],{"trials":7595,"activeCount":8},[],{"trials":7597,"activeCount":8},[],{"trials":7599,"activeCount":8},[],{"trials":7601,"activeCount":8},[],{"intervention":6037,"totalTrials":285,"cells":7603},{"EARLY_PHASE1":7604,"PHASE1":7606,"PHASE2":7612,"PHASE3":7614,"PHASE4":7616,"NA":7618},{"trials":7605,"activeCount":8},[],{"trials":7607,"activeCount":8},[7608],{"nctId":6031,"briefTitle":6032,"status":55,"phases":7609,"completion":2562,"start":2030,"enrollment":1709,"conditions":7610,"interventions":7611},[38],[29],[6017,6036,6037],{"trials":7613,"activeCount":8},[],{"trials":7615,"activeCount":8},[],{"trials":7617,"activeCount":8},[],{"trials":7619,"activeCount":8},[],{"intervention":7621,"totalTrials":285,"cells":7622},"Topiramate; flunarizine",{"EARLY_PHASE1":7623,"PHASE1":7625,"PHASE2":7635,"PHASE3":7637,"PHASE4":7639,"NA":7641},{"trials":7624,"activeCount":8},[],{"trials":7626,"activeCount":8},[7627],{"nctId":7628,"briefTitle":7629,"status":55,"phases":7630,"completion":591,"start":115,"enrollment":7631,"conditions":7632,"interventions":7634},"NCT00752466","A Drug Interaction Study of the Pharmacokinetics of Topiramate and FLUNARIZINE When Given Together or Separately",[38],75,[7633,770],"Human Volunteers",[7621],{"trials":7636,"activeCount":8},[],{"trials":7638,"activeCount":8},[],{"trials":7640,"activeCount":8},[],{"trials":7642,"activeCount":8},[],{"intervention":7644,"totalTrials":285,"cells":7645},"Tapentadol ER Tamper-resistant Formulation",{"EARLY_PHASE1":7646,"PHASE1":7648,"PHASE2":7657,"PHASE3":7659,"PHASE4":7661,"NA":7663},{"trials":7647,"activeCount":8},[],{"trials":7649,"activeCount":8},[7650],{"nctId":7651,"briefTitle":7652,"status":55,"phases":7653,"primaryCompletion":2483,"completion":2483,"start":2484,"enrollment":2485,"conditions":7654,"interventions":7655},"NCT01900587","A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet",[38],[17],[7644,7656],"Tapentadol ER Prolonged-Release 2",{"trials":7658,"activeCount":8},[],{"trials":7660,"activeCount":8},[],{"trials":7662,"activeCount":8},[],{"trials":7664,"activeCount":8},[],{"intervention":7656,"totalTrials":285,"cells":7666},{"EARLY_PHASE1":7667,"PHASE1":7669,"PHASE2":7675,"PHASE3":7677,"PHASE4":7679,"NA":7681},{"trials":7668,"activeCount":8},[],{"trials":7670,"activeCount":8},[7671],{"nctId":7651,"briefTitle":7652,"status":55,"phases":7672,"primaryCompletion":2483,"completion":2483,"start":2484,"enrollment":2485,"conditions":7673,"interventions":7674},[38],[17],[7644,7656],{"trials":7676,"activeCount":8},[],{"trials":7678,"activeCount":8},[],{"trials":7680,"activeCount":8},[],{"trials":7682,"activeCount":8},[],{"intervention":7684,"totalTrials":285,"cells":7685},"JNJ38224342",{"EARLY_PHASE1":7686,"PHASE1":7688,"PHASE2":7699,"PHASE3":7701,"PHASE4":7703,"NA":7705},{"trials":7687,"activeCount":8},[],{"trials":7689,"activeCount":8},[7690],{"nctId":7691,"briefTitle":7692,"status":55,"phases":7693,"completion":2508,"start":2562,"enrollment":7694,"conditions":7695,"interventions":7697},"NCT01054352","A Single and Multiple Dose Study to Explore the Safety of JNJ-38224342 in Healthy Patients and Patients With Seasonal Allergies",[38],182,[7696],"Seasonal Allergic Rhinitis",[7684,7698,7698,7698],"JNJ38224342\u002Fplacebo",{"trials":7700,"activeCount":8},[],{"trials":7702,"activeCount":8},[],{"trials":7704,"activeCount":8},[],{"trials":7706,"activeCount":8},[],{"intervention":7698,"totalTrials":285,"cells":7708},{"EARLY_PHASE1":7709,"PHASE1":7711,"PHASE2":7717,"PHASE3":7719,"PHASE4":7721,"NA":7723},{"trials":7710,"activeCount":8},[],{"trials":7712,"activeCount":8},[7713],{"nctId":7691,"briefTitle":7692,"status":55,"phases":7714,"completion":2508,"start":2562,"enrollment":7694,"conditions":7715,"interventions":7716},[38],[7696],[7684,7698,7698,7698],{"trials":7718,"activeCount":8},[],{"trials":7720,"activeCount":8},[],{"trials":7722,"activeCount":8},[],{"trials":7724,"activeCount":8},[],{"intervention":2489,"totalTrials":285,"cells":7726},{"EARLY_PHASE1":7727,"PHASE1":7729,"PHASE2":7735,"PHASE3":7737,"PHASE4":7739,"NA":7741},{"trials":7728,"activeCount":8},[],{"trials":7730,"activeCount":8},[7731],{"nctId":2480,"briefTitle":2481,"status":55,"phases":7732,"primaryCompletion":2483,"completion":2483,"start":2484,"enrollment":2485,"conditions":7733,"interventions":7734},[38],[17],[2488,2489],{"trials":7736,"activeCount":8},[],{"trials":7738,"activeCount":8},[],{"trials":7740,"activeCount":8},[],{"trials":7742,"activeCount":8},[],{"intervention":7744,"totalTrials":285,"cells":7745},"Methylphenidate HCl",{"EARLY_PHASE1":7746,"PHASE1":7748,"PHASE2":7756,"PHASE3":7758,"PHASE4":7760,"NA":7762},{"trials":7747,"activeCount":8},[],{"trials":7749,"activeCount":8},[7750],{"nctId":7751,"briefTitle":7752,"status":55,"phases":7753,"primaryCompletion":4750,"completion":2056,"start":2622,"enrollment":1879,"conditions":7754,"interventions":7755},"NCT01202734","A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers",[38],[17],[7744],{"trials":7757,"activeCount":8},[],{"trials":7759,"activeCount":8},[],{"trials":7761,"activeCount":8},[],{"trials":7763,"activeCount":8},[],{"intervention":7765,"totalTrials":285,"cells":7766},"Radiolabelled 14C-canagliflozin",{"EARLY_PHASE1":7767,"PHASE1":7769,"PHASE2":7777,"PHASE3":7779,"PHASE4":7781,"NA":7783},{"trials":7768,"activeCount":8},[],{"trials":7770,"activeCount":8},[7771],{"nctId":7772,"briefTitle":7773,"status":55,"phases":7774,"primaryCompletion":1016,"completion":564,"start":1041,"enrollment":98,"conditions":7775,"interventions":7776},"NCT01791231","A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers",[38],[17],[7765],{"trials":7778,"activeCount":8},[],{"trials":7780,"activeCount":8},[],{"trials":7782,"activeCount":8},[],{"trials":7784,"activeCount":8},[],{"intervention":7786,"totalTrials":285,"cells":7787},"31001074\u002Fparoxetine",{"EARLY_PHASE1":7788,"PHASE1":7790,"PHASE2":7798,"PHASE3":7800,"PHASE4":7802,"NA":7804},{"trials":7789,"activeCount":8},[],{"trials":7791,"activeCount":8},[7792],{"nctId":7793,"briefTitle":7794,"status":55,"phases":7795,"completion":4750,"start":2483,"enrollment":4195,"conditions":7796,"interventions":7797},"NCT01159821","A Drug Interaction Study of 31001074 and Paroxetine in Healthy Volunteers",[38],[17],[7786],{"trials":7799,"activeCount":8},[],{"trials":7801,"activeCount":8},[],{"trials":7803,"activeCount":8},[],{"trials":7805,"activeCount":8},[],{"intervention":7807,"totalTrials":285,"cells":7808},"Canagliflozin\u002FProbenecid",{"EARLY_PHASE1":7809,"PHASE1":7811,"PHASE2":7820,"PHASE3":7822,"PHASE4":7824,"NA":7826},{"trials":7810,"activeCount":8},[],{"trials":7812,"activeCount":8},[7813],{"nctId":7814,"briefTitle":7815,"status":55,"phases":7816,"primaryCompletion":7817,"completion":7817,"start":2040,"enrollment":4195,"conditions":7818,"interventions":7819},"NCT01428284","A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers",[38],"2011-10",[17],[7807],{"trials":7821,"activeCount":8},[],{"trials":7823,"activeCount":8},[],{"trials":7825,"activeCount":8},[],{"trials":7827,"activeCount":8},[],{"intervention":4267,"totalTrials":285,"cells":7829},{"EARLY_PHASE1":7830,"PHASE1":7832,"PHASE2":7838,"PHASE3":7840,"PHASE4":7842,"NA":7844},{"trials":7831,"activeCount":8},[],{"trials":7833,"activeCount":8},[7834],{"nctId":4262,"briefTitle":4263,"status":55,"phases":7835,"primaryCompletion":1822,"completion":1822,"start":1093,"enrollment":90,"conditions":7836,"interventions":7837},[38],[17],[4267,4177],{"trials":7839,"activeCount":8},[],{"trials":7841,"activeCount":8},[],{"trials":7843,"activeCount":8},[],{"trials":7845,"activeCount":8},[],{"intervention":7847,"totalTrials":285,"cells":7848},"JNJ-28431754\u002F Placebo",{"EARLY_PHASE1":7849,"PHASE1":7851,"PHASE2":7860,"PHASE3":7862,"PHASE4":7864,"NA":7866},{"trials":7850,"activeCount":8},[],{"trials":7852,"activeCount":8},[7853],{"nctId":7854,"briefTitle":7855,"status":55,"phases":7856,"primaryCompletion":1999,"completion":1999,"start":57,"enrollment":4578,"conditions":7857,"interventions":7858},"NCT01177150","A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers",[38],[17],[7847,7859],"JNJ-28431754",{"trials":7861,"activeCount":8},[],{"trials":7863,"activeCount":8},[],{"trials":7865,"activeCount":8},[],{"trials":7867,"activeCount":8},[],{"intervention":7859,"totalTrials":285,"cells":7869},{"EARLY_PHASE1":7870,"PHASE1":7872,"PHASE2":7878,"PHASE3":7880,"PHASE4":7882,"NA":7884},{"trials":7871,"activeCount":8},[],{"trials":7873,"activeCount":8},[7874],{"nctId":7854,"briefTitle":7855,"status":55,"phases":7875,"primaryCompletion":1999,"completion":1999,"start":57,"enrollment":4578,"conditions":7876,"interventions":7877},[38],[17],[7847,7859],{"trials":7879,"activeCount":8},[],{"trials":7881,"activeCount":8},[],{"trials":7883,"activeCount":8},[],{"trials":7885,"activeCount":8},[],{"intervention":7887,"totalTrials":285,"cells":7888},"divalproex sodium ER\u002Fpaliperidone ER",{"EARLY_PHASE1":7889,"PHASE1":7891,"PHASE2":7899,"PHASE3":7901,"PHASE4":7903,"NA":7905},{"trials":7890,"activeCount":8},[],{"trials":7892,"activeCount":8},[7893],{"nctId":7894,"briefTitle":7895,"status":55,"phases":7896,"primaryCompletion":6027,"completion":6027,"start":985,"enrollment":218,"conditions":7897,"interventions":7898},"NCT01094249","A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder",[38],[14,26,1137],[7887],{"trials":7900,"activeCount":8},[],{"trials":7902,"activeCount":8},[],{"trials":7904,"activeCount":8},[],{"trials":7906,"activeCount":8},[],{"intervention":7908,"totalTrials":285,"cells":7909},"JNJ-26483327",{"EARLY_PHASE1":7910,"PHASE1":7912,"PHASE2":7926,"PHASE3":7928,"PHASE4":7930,"NA":7932},{"trials":7911,"activeCount":8},[],{"trials":7913,"activeCount":8},[7914],{"nctId":7915,"briefTitle":7916,"status":55,"phases":7917,"completion":1093,"start":517,"enrollment":24,"conditions":7918,"interventions":7925},"NCT00676299","A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and\u002For Refractory Solid Malignancies.",[38],[7919,7920,7921,7922,4319,7923,7924],"Protein Kinase Inhibitors","Antineoplastic Protocols","Clinical Trial, Phase 1","Maximum Tolerated Dose","Advanced Malignancies","Solid Malignancies",[7908],{"trials":7927,"activeCount":8},[],{"trials":7929,"activeCount":8},[],{"trials":7931,"activeCount":8},[],{"trials":7933,"activeCount":8},[],{"intervention":7935,"totalTrials":285,"cells":7936},"norelgestromin\u002Fethinyl estradiol (NGMN\u002FEE) transdermal contraceptive system.",{"EARLY_PHASE1":7937,"PHASE1":7939,"PHASE2":7948,"PHASE3":7950,"PHASE4":7952,"NA":7954},{"trials":7938,"activeCount":8},[],{"trials":7940,"activeCount":8},[7941],{"nctId":7942,"briefTitle":7943,"status":55,"phases":7944,"completion":1064,"start":203,"enrollment":7945,"conditions":7946,"interventions":7947},"NCT00775086","Bioequivalence Study of Patches With Different Equilibration Profiles",[38],42,[3109],[7935],{"trials":7949,"activeCount":8},[],{"trials":7951,"activeCount":8},[],{"trials":7953,"activeCount":8},[],{"trials":7955,"activeCount":8},[],{"intervention":7957,"totalTrials":285,"cells":7958},"JNJ-38518168 \u002F MTX",{"EARLY_PHASE1":7959,"PHASE1":7961,"PHASE2":7969,"PHASE3":7971,"PHASE4":7973,"NA":7975},{"trials":7960,"activeCount":8},[],{"trials":7962,"activeCount":8},[7963],{"nctId":7964,"briefTitle":7965,"status":55,"phases":7966,"completion":7817,"start":1700,"enrollment":1107,"conditions":7967,"interventions":7968},"NCT01450982","A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants",[38],[92],[7957],{"trials":7970,"activeCount":8},[],{"trials":7972,"activeCount":8},[],{"trials":7974,"activeCount":8},[],{"trials":7976,"activeCount":8},[],{"intervention":7978,"totalTrials":285,"cells":7979},"JNJ-38877605",{"EARLY_PHASE1":7980,"PHASE1":7982,"PHASE2":7990,"PHASE3":7992,"PHASE4":7994,"NA":7996},{"trials":7981,"activeCount":8},[],{"trials":7983,"activeCount":8},[7984],{"nctId":7985,"briefTitle":7986,"status":68,"phases":7987,"primaryCompletion":4436,"completion":4436,"start":516,"enrollment":4195,"conditions":7988,"interventions":7989},"NCT00651365","A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.",[38],[137],[7978],{"trials":7991,"activeCount":8},[],{"trials":7993,"activeCount":8},[],{"trials":7995,"activeCount":8},[],{"trials":7997,"activeCount":8},[],{"intervention":7999,"totalTrials":285,"cells":8000},"Pancrelipase in combination with Ensure Plus",{"EARLY_PHASE1":8001,"PHASE1":8003,"PHASE2":8012,"PHASE3":8014,"PHASE4":8016,"NA":8018},{"trials":8002,"activeCount":8},[],{"trials":8004,"activeCount":8},[8005],{"nctId":8006,"briefTitle":8007,"status":55,"phases":8008,"primaryCompletion":986,"completion":986,"start":1093,"enrollment":785,"conditions":8009,"interventions":8011},"NCT00676702","A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI)",[38],[2849,8010,2850,2231],"Pancreatitis, Chronic",[7999],{"trials":8013,"activeCount":8},[],{"trials":8015,"activeCount":8},[],{"trials":8017,"activeCount":8},[],{"trials":8019,"activeCount":8},[],{"intervention":8021,"totalTrials":285,"cells":8022},"Extended release OROS paliperidone",{"EARLY_PHASE1":8023,"PHASE1":8025,"PHASE2":8033,"PHASE3":8035,"PHASE4":8037,"NA":8039},{"trials":8024,"activeCount":8},[],{"trials":8026,"activeCount":8},[8027],{"nctId":8028,"briefTitle":8029,"status":55,"phases":8030,"completion":385,"start":527,"enrollment":4427,"conditions":8031,"interventions":8032},"NCT00838669","A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone",[38],[14],[8021],{"trials":8034,"activeCount":8},[],{"trials":8036,"activeCount":8},[],{"trials":8038,"activeCount":8},[],{"trials":8040,"activeCount":8},[],{"intervention":8042,"totalTrials":285,"cells":8043},"JNJ-39439335; Placebo; Naproxen",{"EARLY_PHASE1":8044,"PHASE1":8046,"PHASE2":8054,"PHASE3":8056,"PHASE4":8058,"NA":8060},{"trials":8045,"activeCount":8},[],{"trials":8047,"activeCount":8},[8048],{"nctId":8049,"briefTitle":8050,"status":55,"phases":8051,"primaryCompletion":2498,"completion":2498,"start":252,"enrollment":4524,"conditions":8052,"interventions":8053},"NCT00933582","A Clinical Study to Investigate the Effect on Pain Relief of a Single Dose of JNJ-39439335 in Patients With Chronic Osteoarthritis Pain of the Knee",[38],[2322],[8042],{"trials":8055,"activeCount":8},[],{"trials":8057,"activeCount":8},[],{"trials":8059,"activeCount":8},[],{"trials":8061,"activeCount":8},[],{"intervention":991,"totalTrials":285,"cells":8063},{"EARLY_PHASE1":8064,"PHASE1":8066,"PHASE2":8072,"PHASE3":8074,"PHASE4":8076,"NA":8078},{"trials":8065,"activeCount":8},[],{"trials":8067,"activeCount":8},[8068],{"nctId":982,"briefTitle":983,"status":55,"phases":8069,"completion":985,"start":986,"enrollment":987,"conditions":8070,"interventions":8071},[38],[14,23],[990,991],{"trials":8073,"activeCount":8},[],{"trials":8075,"activeCount":8},[],{"trials":8077,"activeCount":8},[],{"trials":8079,"activeCount":8},[],{"intervention":8081,"totalTrials":285,"cells":8082},"JNJ-40411813 50 mg",{"EARLY_PHASE1":8083,"PHASE1":8085,"PHASE2":8094,"PHASE3":8096,"PHASE4":8098,"NA":8100},{"trials":8084,"activeCount":8},[],{"trials":8086,"activeCount":8},[8087],{"nctId":8088,"briefTitle":8089,"status":55,"phases":8090,"primaryCompletion":2483,"completion":2483,"start":3328,"enrollment":5906,"conditions":8091,"interventions":8092},"NCT01932333","A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients",[38],[17],[8081,8093],"JNJ-40411813 100 mg",{"trials":8095,"activeCount":8},[],{"trials":8097,"activeCount":8},[],{"trials":8099,"activeCount":8},[],{"trials":8101,"activeCount":8},[],{"intervention":8093,"totalTrials":285,"cells":8103},{"EARLY_PHASE1":8104,"PHASE1":8106,"PHASE2":8112,"PHASE3":8114,"PHASE4":8116,"NA":8118},{"trials":8105,"activeCount":8},[],{"trials":8107,"activeCount":8},[8108],{"nctId":8088,"briefTitle":8089,"status":55,"phases":8109,"primaryCompletion":2483,"completion":2483,"start":3328,"enrollment":5906,"conditions":8110,"interventions":8111},[38],[17],[8081,8093],{"trials":8113,"activeCount":8},[],{"trials":8115,"activeCount":8},[],{"trials":8117,"activeCount":8},[],{"trials":8119,"activeCount":8},[],{"intervention":8121,"totalTrials":285,"cells":8122},"Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay",{"EARLY_PHASE1":8123,"PHASE1":8125,"PHASE2":8134,"PHASE3":8136,"PHASE4":8138,"NA":8140},{"trials":8124,"activeCount":8},[],{"trials":8126,"activeCount":8},[8127],{"nctId":8128,"briefTitle":8129,"status":55,"phases":8130,"primaryCompletion":1269,"completion":1269,"start":2508,"enrollment":21,"conditions":8131,"interventions":8132},"NCT01535820","The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women",[38],[3199],[8121,8133],"Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay",{"trials":8135,"activeCount":8},[],{"trials":8137,"activeCount":8},[],{"trials":8139,"activeCount":8},[],{"trials":8141,"activeCount":8},[],{"intervention":8133,"totalTrials":285,"cells":8143},{"EARLY_PHASE1":8144,"PHASE1":8146,"PHASE2":8152,"PHASE3":8154,"PHASE4":8156,"NA":8158},{"trials":8145,"activeCount":8},[],{"trials":8147,"activeCount":8},[8148],{"nctId":8128,"briefTitle":8129,"status":55,"phases":8149,"primaryCompletion":1269,"completion":1269,"start":2508,"enrollment":21,"conditions":8150,"interventions":8151},[38],[3199],[8121,8133],{"trials":8153,"activeCount":8},[],{"trials":8155,"activeCount":8},[],{"trials":8157,"activeCount":8},[],{"trials":8159,"activeCount":8},[],{"intervention":8161,"totalTrials":285,"cells":8162},"Intermediate release (IR) Paliperidone",{"EARLY_PHASE1":8163,"PHASE1":8165,"PHASE2":8174,"PHASE3":8176,"PHASE4":8178,"NA":8180},{"trials":8164,"activeCount":8},[],{"trials":8166,"activeCount":8},[8167],{"nctId":8168,"briefTitle":8169,"status":55,"phases":8170,"completion":2146,"start":1064,"enrollment":1107,"conditions":8171,"interventions":8173},"NCT00791284","A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function",[38],[14,8172],"Hepatic Impairment",[8161],{"trials":8175,"activeCount":8},[],{"trials":8177,"activeCount":8},[],{"trials":8179,"activeCount":8},[],{"trials":8181,"activeCount":8},[],{"intervention":4274,"totalTrials":285,"cells":8183},{"EARLY_PHASE1":8184,"PHASE1":8186,"PHASE2":8192,"PHASE3":8194,"PHASE4":8196,"NA":8198},{"trials":8185,"activeCount":8},[],{"trials":8187,"activeCount":8},[8188],{"nctId":4269,"briefTitle":4270,"status":55,"phases":8189,"primaryCompletion":1822,"completion":1822,"start":2847,"enrollment":926,"conditions":8190,"interventions":8191},[38],[17],[4274,4177],{"trials":8193,"activeCount":8},[],{"trials":8195,"activeCount":8},[],{"trials":8197,"activeCount":8},[],{"trials":8199,"activeCount":8},[],{"intervention":8201,"totalTrials":285,"cells":8202},"JNJ 28431754 300 mg\u002Fplacebo",{"EARLY_PHASE1":8203,"PHASE1":8205,"PHASE2":8213,"PHASE3":8215,"PHASE4":8217,"NA":8219},{"trials":8204,"activeCount":8},[],{"trials":8206,"activeCount":8},[8207],{"nctId":8208,"briefTitle":7188,"status":55,"phases":8209,"completion":312,"start":172,"enrollment":90,"conditions":8210,"interventions":8211},"NCT01177163",[38],[29],[8201,8212],"JNJ 28431754 100 mg\u002Fplacebo",{"trials":8214,"activeCount":8},[],{"trials":8216,"activeCount":8},[],{"trials":8218,"activeCount":8},[],{"trials":8220,"activeCount":8},[],{"intervention":8212,"totalTrials":285,"cells":8222},{"EARLY_PHASE1":8223,"PHASE1":8225,"PHASE2":8231,"PHASE3":8233,"PHASE4":8235,"NA":8237},{"trials":8224,"activeCount":8},[],{"trials":8226,"activeCount":8},[8227],{"nctId":8208,"briefTitle":7188,"status":55,"phases":8228,"completion":312,"start":172,"enrollment":90,"conditions":8229,"interventions":8230},[38],[29],[8201,8212],{"trials":8232,"activeCount":8},[],{"trials":8234,"activeCount":8},[],{"trials":8236,"activeCount":8},[],{"trials":8238,"activeCount":8},[],{"intervention":8240,"totalTrials":285,"cells":8241},"Immediate release (IR) Paliperidone",{"EARLY_PHASE1":8242,"PHASE1":8244,"PHASE2":8252,"PHASE3":8254,"PHASE4":8256,"NA":8258},{"trials":8243,"activeCount":8},[],{"trials":8245,"activeCount":8},[8246],{"nctId":8247,"briefTitle":8248,"status":55,"phases":8249,"completion":749,"start":242,"enrollment":1260,"conditions":8250,"interventions":8251},"NCT00791349","A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone",[38],[14,938],[8240],{"trials":8253,"activeCount":8},[],{"trials":8255,"activeCount":8},[],{"trials":8257,"activeCount":8},[],{"trials":8259,"activeCount":8},[],{"intervention":8261,"totalTrials":285,"cells":8262},"R306465",{"EARLY_PHASE1":8263,"PHASE1":8265,"PHASE2":8274,"PHASE3":8276,"PHASE4":8278,"NA":8280},{"trials":8264,"activeCount":8},[],{"trials":8266,"activeCount":8},[8267],{"nctId":8268,"briefTitle":8269,"status":55,"phases":8270,"completion":609,"start":80,"enrollment":8271,"conditions":8272,"interventions":8273},"NCT00677001","A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies.",[38],15,[137],[8261],{"trials":8275,"activeCount":8},[],{"trials":8277,"activeCount":8},[],{"trials":8279,"activeCount":8},[],{"trials":8281,"activeCount":8},[],{"intervention":5737,"totalTrials":285,"cells":8283},{"EARLY_PHASE1":8284,"PHASE1":8286,"PHASE2":8292,"PHASE3":8294,"PHASE4":8296,"NA":8298},{"trials":8285,"activeCount":8},[],{"trials":8287,"activeCount":8},[8288],{"nctId":5730,"briefTitle":5731,"status":55,"phases":8289,"completion":2484,"start":2562,"enrollment":59,"conditions":8290,"interventions":8291},[38],[5734,5735,14],[5710,5737,5738],{"trials":8293,"activeCount":8},[],{"trials":8295,"activeCount":8},[],{"trials":8297,"activeCount":8},[],{"trials":8299,"activeCount":8},[],{"intervention":8301,"totalTrials":285,"cells":8302},"EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).",{"EARLY_PHASE1":8303,"PHASE1":8305,"PHASE2":8313,"PHASE3":8315,"PHASE4":8317,"NA":8319},{"trials":8304,"activeCount":8},[],{"trials":8306,"activeCount":8},[8307],{"nctId":8308,"briefTitle":8309,"status":55,"phases":8310,"completion":893,"start":203,"enrollment":268,"conditions":8311,"interventions":8312},"NCT00258063","A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)",[38],[3108,3109],[8301],{"trials":8314,"activeCount":8},[],{"trials":8316,"activeCount":8},[],{"trials":8318,"activeCount":8},[],{"trials":8320,"activeCount":8},[],{"intervention":4281,"totalTrials":285,"cells":8322},{"EARLY_PHASE1":8323,"PHASE1":8325,"PHASE2":8331,"PHASE3":8333,"PHASE4":8335,"NA":8337},{"trials":8324,"activeCount":8},[],{"trials":8326,"activeCount":8},[8327],{"nctId":4276,"briefTitle":4277,"status":55,"phases":8328,"primaryCompletion":1445,"completion":1445,"start":2191,"enrollment":1709,"conditions":8329,"interventions":8330},[38],[17],[4281,4282,4177],{"trials":8332,"activeCount":8},[],{"trials":8334,"activeCount":8},[],{"trials":8336,"activeCount":8},[],{"trials":8338,"activeCount":8},[],{"intervention":4282,"totalTrials":285,"cells":8340},{"EARLY_PHASE1":8341,"PHASE1":8343,"PHASE2":8349,"PHASE3":8351,"PHASE4":8353,"NA":8355},{"trials":8342,"activeCount":8},[],{"trials":8344,"activeCount":8},[8345],{"nctId":4276,"briefTitle":4277,"status":55,"phases":8346,"primaryCompletion":1445,"completion":1445,"start":2191,"enrollment":1709,"conditions":8347,"interventions":8348},[38],[17],[4281,4282,4177],{"trials":8350,"activeCount":8},[],{"trials":8352,"activeCount":8},[],{"trials":8354,"activeCount":8},[],{"trials":8356,"activeCount":8},[],{"intervention":8358,"totalTrials":285,"cells":8359},"Treatment A: Hydromorphone 8 mg",{"EARLY_PHASE1":8360,"PHASE1":8362,"PHASE2":8373,"PHASE3":8375,"PHASE4":8377,"NA":8379},{"trials":8361,"activeCount":8},[],{"trials":8363,"activeCount":8},[8364],{"nctId":8365,"briefTitle":8366,"status":55,"phases":8367,"primaryCompletion":1269,"completion":1269,"start":2508,"enrollment":90,"conditions":8368,"interventions":8369},"NCT01487512","Effect of Dose on the Pharmacokinetics of OROS Hydromorphone Under Fasted Conditions in Healthy Taiwanese Participants",[38],[3199],[8358,8370,8371,8372],"Treatment B: Hydromorphone 16 mg","Treatment C: Hydromorphone 32 mg","Treatment D: Hydromorphone 64 mg",{"trials":8374,"activeCount":8},[],{"trials":8376,"activeCount":8},[],{"trials":8378,"activeCount":8},[],{"trials":8380,"activeCount":8},[],{"intervention":8370,"totalTrials":285,"cells":8382},{"EARLY_PHASE1":8383,"PHASE1":8385,"PHASE2":8391,"PHASE3":8393,"PHASE4":8395,"NA":8397},{"trials":8384,"activeCount":8},[],{"trials":8386,"activeCount":8},[8387],{"nctId":8365,"briefTitle":8366,"status":55,"phases":8388,"primaryCompletion":1269,"completion":1269,"start":2508,"enrollment":90,"conditions":8389,"interventions":8390},[38],[3199],[8358,8370,8371,8372],{"trials":8392,"activeCount":8},[],{"trials":8394,"activeCount":8},[],{"trials":8396,"activeCount":8},[],{"trials":8398,"activeCount":8},[],{"intervention":8371,"totalTrials":285,"cells":8400},{"EARLY_PHASE1":8401,"PHASE1":8403,"PHASE2":8409,"PHASE3":8411,"PHASE4":8413,"NA":8415},{"trials":8402,"activeCount":8},[],{"trials":8404,"activeCount":8},[8405],{"nctId":8365,"briefTitle":8366,"status":55,"phases":8406,"primaryCompletion":1269,"completion":1269,"start":2508,"enrollment":90,"conditions":8407,"interventions":8408},[38],[3199],[8358,8370,8371,8372],{"trials":8410,"activeCount":8},[],{"trials":8412,"activeCount":8},[],{"trials":8414,"activeCount":8},[],{"trials":8416,"activeCount":8},[],{"intervention":8372,"totalTrials":285,"cells":8418},{"EARLY_PHASE1":8419,"PHASE1":8421,"PHASE2":8427,"PHASE3":8429,"PHASE4":8431,"NA":8433},{"trials":8420,"activeCount":8},[],{"trials":8422,"activeCount":8},[8423],{"nctId":8365,"briefTitle":8366,"status":55,"phases":8424,"primaryCompletion":1269,"completion":1269,"start":2508,"enrollment":90,"conditions":8425,"interventions":8426},[38],[3199],[8358,8370,8371,8372],{"trials":8428,"activeCount":8},[],{"trials":8430,"activeCount":8},[],{"trials":8432,"activeCount":8},[],{"trials":8434,"activeCount":8},[],{"intervention":8436,"totalTrials":285,"cells":8437},"JNJ-38431055; Placebo",{"EARLY_PHASE1":8438,"PHASE1":8440,"PHASE2":8448,"PHASE3":8450,"PHASE4":8452,"NA":8454},{"trials":8439,"activeCount":8},[],{"trials":8441,"activeCount":8},[8442],{"nctId":8443,"briefTitle":8444,"status":68,"phases":8445,"completion":3571,"start":153,"enrollment":4524,"conditions":8446,"interventions":8447},"NCT00946972","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus",[38],[29],[8436],{"trials":8449,"activeCount":8},[],{"trials":8451,"activeCount":8},[],{"trials":8453,"activeCount":8},[],{"trials":8455,"activeCount":8},[],{"intervention":8457,"totalTrials":285,"cells":8458},"OROS paliperidone",{"EARLY_PHASE1":8459,"PHASE1":8461,"PHASE2":8469,"PHASE3":8471,"PHASE4":8473,"NA":8475},{"trials":8460,"activeCount":8},[],{"trials":8462,"activeCount":8},[8463],{"nctId":8464,"briefTitle":8465,"status":55,"phases":8466,"completion":392,"start":115,"enrollment":1281,"conditions":8467,"interventions":8468},"NCT00796432","A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone",[38],[14],[8457],{"trials":8470,"activeCount":8},[],{"trials":8472,"activeCount":8},[],{"trials":8474,"activeCount":8},[],{"trials":8476,"activeCount":8},[],{"intervention":8478,"totalTrials":285,"cells":8479},"Erdafitinib",{"EARLY_PHASE1":8480,"PHASE1":8482,"PHASE2":8493,"PHASE3":8495,"PHASE4":8497,"NA":8499},{"trials":8481,"activeCount":8},[],{"trials":8483,"activeCount":8},[8484],{"nctId":8485,"briefTitle":8486,"status":55,"phases":8487,"primaryCompletion":8488,"completion":8488,"start":8489,"enrollment":8271,"conditions":8490,"interventions":8491},"NCT04330248","A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants",[38],"2022-06-14","2020-03-31",[17],[8478,8492],"Carbamazepine",{"trials":8494,"activeCount":8},[],{"trials":8496,"activeCount":8},[],{"trials":8498,"activeCount":8},[],{"trials":8500,"activeCount":8},[],{"intervention":8492,"totalTrials":285,"cells":8502},{"EARLY_PHASE1":8503,"PHASE1":8505,"PHASE2":8511,"PHASE3":8513,"PHASE4":8515,"NA":8517},{"trials":8504,"activeCount":8},[],{"trials":8506,"activeCount":8},[8507],{"nctId":8485,"briefTitle":8486,"status":55,"phases":8508,"primaryCompletion":8488,"completion":8488,"start":8489,"enrollment":8271,"conditions":8509,"interventions":8510},[38],[17],[8478,8492],{"trials":8512,"activeCount":8},[],{"trials":8514,"activeCount":8},[],{"trials":8516,"activeCount":8},[],{"trials":8518,"activeCount":8},[],{"intervention":2378,"totalTrials":2442,"cells":8520},{"EARLY_PHASE1":8521,"PHASE1":8523,"PHASE2":8525,"PHASE3":8527,"PHASE4":8537,"NA":8539},{"trials":8522,"activeCount":8},[],{"trials":8524,"activeCount":8},[],{"trials":8526,"activeCount":8},[],{"trials":8528,"activeCount":8},[8529,8533],{"nctId":2368,"briefTitle":2369,"status":55,"phases":8530,"primaryCompletion":153,"completion":153,"start":2031,"enrollment":2371,"conditions":8531,"interventions":8532},[40],[2373,2374,2330],[2337,2376,2377,2378,2378],{"nctId":3819,"briefTitle":3820,"status":68,"phases":8534,"primaryCompletion":1447,"completion":1447,"start":609,"enrollment":1798,"conditions":8535,"interventions":8536},[40],[3823],[2378,3808,2378],{"trials":8538,"activeCount":8},[],{"trials":8540,"activeCount":8},[8541],{"nctId":8542,"briefTitle":8543,"status":55,"phases":8544,"primaryCompletion":8545,"completion":8545,"start":2562,"enrollment":8546,"conditions":8547,"interventions":8549},"NCT01545778","Risk of Shopping Behavior of Tapentadol Immediate-Release (IR) Compared to Oxycodone Immediate-Release (IR)",[],"2012-02",646620,[8548],"Substance Abuse Detection",[2378,8550],"Oxycodone IR",{"intervention":8552,"totalTrials":2442,"cells":8553},"No intervention",{"EARLY_PHASE1":8554,"PHASE1":8556,"PHASE2":8558,"PHASE3":8560,"PHASE4":8562,"NA":8564},{"trials":8555,"activeCount":8},[],{"trials":8557,"activeCount":8},[],{"trials":8559,"activeCount":8},[],{"trials":8561,"activeCount":8},[],{"trials":8563,"activeCount":8},[],{"trials":8565,"activeCount":8},[8566,8574,8582],{"nctId":8567,"briefTitle":8568,"status":55,"phases":8569,"completion":234,"start":591,"enrollment":8570,"conditions":8571,"interventions":8573},"NCT00211068","A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa",[],124,[8572],"Pure Red-cell Aplasia",[8552],{"nctId":8575,"briefTitle":8576,"status":55,"phases":8577,"primaryCompletion":1008,"completion":3328,"start":702,"enrollment":8578,"conditions":8579,"interventions":8581},"NCT00210639","A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection",[],2233,[8580],"Musculoskeletal Diseases",[8552],{"nctId":8583,"briefTitle":8584,"status":250,"phases":8585,"primaryCompletion":332,"completion":332,"start":385,"enrollment":8,"conditions":8586,"interventions":8587},"NCT00210977","A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies",[],[20],[8552],{"intervention":8589,"totalTrials":482,"cells":8590},"Abiraterone Acetate",{"EARLY_PHASE1":8591,"PHASE1":8593,"PHASE2":8604,"PHASE3":8606,"PHASE4":8608,"NA":8610},{"trials":8592,"activeCount":8},[],{"trials":8594,"activeCount":8},[8595],{"nctId":8596,"briefTitle":8597,"status":55,"phases":8598,"primaryCompletion":8599,"completion":8599,"start":6962,"enrollment":98,"conditions":8600,"interventions":8602},"NCT01495910","A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency",[38],"2013-02",[8601],"21-hydroxylase Deficiency",[8603],"Abiraterone acetate",{"trials":8605,"activeCount":8},[],{"trials":8607,"activeCount":8},[],{"trials":8609,"activeCount":8},[],{"trials":8611,"activeCount":8},[8612],{"nctId":8613,"briefTitle":8614,"status":8615,"phases":8616,"conditions":8617,"interventions":8622},"NCT01217697","Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer","APPROVED_FOR_MARKETING",[],[8618,8619,8620,8621],"Prostate Neoplasms","Genital Neoplasms, Male","Urogenital Neoplasms","Genital Diseases, Male",[8589,8623],"Prednisone\\Prednisolone",{"intervention":2376,"totalTrials":482,"cells":8625},{"EARLY_PHASE1":8626,"PHASE1":8628,"PHASE2":8630,"PHASE3":8632,"PHASE4":8638,"NA":8640},{"trials":8627,"activeCount":8},[],{"trials":8629,"activeCount":8},[],{"trials":8631,"activeCount":8},[],{"trials":8633,"activeCount":8},[8634],{"nctId":2368,"briefTitle":2369,"status":55,"phases":8635,"primaryCompletion":153,"completion":153,"start":2031,"enrollment":2371,"conditions":8636,"interventions":8637},[40],[2373,2374,2330],[2337,2376,2377,2378,2378],{"trials":8639,"activeCount":8},[],{"trials":8641,"activeCount":8},[8642],{"nctId":8542,"briefTitle":8543,"status":55,"phases":8643,"primaryCompletion":8545,"completion":8545,"start":2562,"enrollment":8546,"conditions":8644,"interventions":8645},[],[8548],[2378,8550],{"intervention":8647,"totalTrials":285,"cells":8648},"Becaplermin users",{"EARLY_PHASE1":8649,"PHASE1":8651,"PHASE2":8653,"PHASE3":8655,"PHASE4":8657,"NA":8659},{"trials":8650,"activeCount":8},[],{"trials":8652,"activeCount":8},[],{"trials":8654,"activeCount":8},[],{"trials":8656,"activeCount":8},[],{"trials":8658,"activeCount":8},[],{"trials":8660,"activeCount":8},[8661],{"nctId":8662,"briefTitle":8663,"status":55,"phases":8664,"primaryCompletion":2508,"completion":2508,"start":1446,"conditions":8665,"interventions":8666},"NCT01235260","Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes",[],[1307,3354,3355,651],[8647],{"intervention":8668,"totalTrials":285,"cells":8669},"Current Domperidone",{"EARLY_PHASE1":8670,"PHASE1":8672,"PHASE2":8674,"PHASE3":8676,"PHASE4":8678,"NA":8680},{"trials":8671,"activeCount":8},[],{"trials":8673,"activeCount":8},[],{"trials":8675,"activeCount":8},[],{"trials":8677,"activeCount":8},[],{"trials":8679,"activeCount":8},[],{"trials":8681,"activeCount":8},[8682],{"nctId":8683,"briefTitle":8684,"status":55,"phases":8685,"primaryCompletion":312,"completion":312,"start":957,"enrollment":8686,"conditions":8687,"interventions":8689},"NCT00925457","Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone",[],1608,[8688],"Arrhythmias, Cardiac",[8668,8690],"Current proton pump inhibitor",{"intervention":8690,"totalTrials":285,"cells":8692},{"EARLY_PHASE1":8693,"PHASE1":8695,"PHASE2":8697,"PHASE3":8699,"PHASE4":8701,"NA":8703},{"trials":8694,"activeCount":8},[],{"trials":8696,"activeCount":8},[],{"trials":8698,"activeCount":8},[],{"trials":8700,"activeCount":8},[],{"trials":8702,"activeCount":8},[],{"trials":8704,"activeCount":8},[8705],{"nctId":8683,"briefTitle":8684,"status":55,"phases":8706,"primaryCompletion":312,"completion":312,"start":957,"enrollment":8686,"conditions":8707,"interventions":8708},[],[8688],[8668,8690],{"intervention":8623,"totalTrials":285,"cells":8710},{"EARLY_PHASE1":8711,"PHASE1":8713,"PHASE2":8715,"PHASE3":8717,"PHASE4":8719,"NA":8721},{"trials":8712,"activeCount":8},[],{"trials":8714,"activeCount":8},[],{"trials":8716,"activeCount":8},[],{"trials":8718,"activeCount":8},[],{"trials":8720,"activeCount":8},[],{"trials":8722,"activeCount":8},[8723],{"nctId":8613,"briefTitle":8614,"status":8615,"phases":8724,"conditions":8725,"interventions":8726},[],[8618,8619,8620,8621],[8589,8623],{"intervention":8728,"totalTrials":285,"cells":8729},"Sterile becaplermin gel vs. sterile placebo gel treatment 1",{"EARLY_PHASE1":8730,"PHASE1":8732,"PHASE2":8734,"PHASE3":8736,"PHASE4":8738,"NA":8740},{"trials":8731,"activeCount":8},[],{"trials":8733,"activeCount":8},[],{"trials":8735,"activeCount":8},[],{"trials":8737,"activeCount":8},[],{"trials":8739,"activeCount":8},[],{"trials":8741,"activeCount":8},[8742],{"nctId":8743,"briefTitle":8744,"status":55,"phases":8745,"completion":1165,"start":862,"enrollment":8746,"conditions":8747,"interventions":8749},"NCT00740922","Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers",[],563,[8748,3355,137],"Platelet-Derived Growth Factor",[8728],{"intervention":8751,"totalTrials":285,"cells":8752},"Transdermal Contraceptive System",{"EARLY_PHASE1":8753,"PHASE1":8755,"PHASE2":8757,"PHASE3":8759,"PHASE4":8761,"NA":8763},{"trials":8754,"activeCount":8},[],{"trials":8756,"activeCount":8},[],{"trials":8758,"activeCount":8},[],{"trials":8760,"activeCount":8},[],{"trials":8762,"activeCount":8},[],{"trials":8764,"activeCount":8},[8765],{"nctId":8766,"briefTitle":8767,"status":55,"phases":8768,"primaryCompletion":2031,"completion":2031,"start":784,"enrollment":8769,"conditions":8770,"interventions":8771},"NCT00377988","A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control",[],423,[3108,3109],[8751,8772],"Norgestimate-containing oral contraceptives with EE",{"intervention":8772,"totalTrials":285,"cells":8774},{"EARLY_PHASE1":8775,"PHASE1":8777,"PHASE2":8779,"PHASE3":8781,"PHASE4":8783,"NA":8785},{"trials":8776,"activeCount":8},[],{"trials":8778,"activeCount":8},[],{"trials":8780,"activeCount":8},[],{"trials":8782,"activeCount":8},[],{"trials":8784,"activeCount":8},[],{"trials":8786,"activeCount":8},[8787],{"nctId":8766,"briefTitle":8767,"status":55,"phases":8788,"primaryCompletion":2031,"completion":2031,"start":784,"enrollment":8769,"conditions":8789,"interventions":8790},[],[3108,3109],[8751,8772],{"intervention":8792,"totalTrials":285,"cells":8793},"Monophasic or triphasic Oral contraceptive",{"EARLY_PHASE1":8794,"PHASE1":8796,"PHASE2":8798,"PHASE3":8800,"PHASE4":8802,"NA":8804},{"trials":8795,"activeCount":8},[],{"trials":8797,"activeCount":8},[],{"trials":8799,"activeCount":8},[],{"trials":8801,"activeCount":8},[],{"trials":8803,"activeCount":8},[],{"trials":8805,"activeCount":8},[8806],{"nctId":8807,"briefTitle":8808,"status":55,"phases":8809,"primaryCompletion":234,"completion":234,"start":784,"enrollment":8810,"conditions":8811,"interventions":8812},"NCT00331071","Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks",[],334,[3108,3109],[8792,8813],"Ortho Evra transdermal patch containing 6 mg NGMN\u002F0.75 mg EE",{"intervention":8813,"totalTrials":285,"cells":8815},{"EARLY_PHASE1":8816,"PHASE1":8818,"PHASE2":8820,"PHASE3":8822,"PHASE4":8824,"NA":8826},{"trials":8817,"activeCount":8},[],{"trials":8819,"activeCount":8},[],{"trials":8821,"activeCount":8},[],{"trials":8823,"activeCount":8},[],{"trials":8825,"activeCount":8},[],{"trials":8827,"activeCount":8},[8828],{"nctId":8807,"briefTitle":8808,"status":55,"phases":8829,"primaryCompletion":234,"completion":234,"start":784,"enrollment":8810,"conditions":8830,"interventions":8831},[],[3108,3109],[8792,8813]]